0001185185-11-001794.txt : 20111031 0001185185-11-001794.hdr.sgml : 20111031 20111031171952 ACCESSION NUMBER: 0001185185-11-001794 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20110930 FILED AS OF DATE: 20111031 DATE AS OF CHANGE: 20111031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIZONE INTERNATIONAL INC CENTRAL INDEX KEY: 0000753772 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870412648 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 002-93277-D FILM NUMBER: 111169018 BUSINESS ADDRESS: STREET 1: 2330 MARINSHIP WAY STREET 2: SUITE 300 CITY: SAUSALITO STATE: CA ZIP: 94965 BUSINESS PHONE: (415) 331-0303 MAIL ADDRESS: STREET 1: 2330 MARINSHIP WAY STREET 2: SUITE 300 CITY: SAUSALITO STATE: CA ZIP: 94965 FORMER COMPANY: FORMER CONFORMED NAME: MADISON FUNDING INC DATE OF NAME CHANGE: 19860413 10-Q 1 medizone10q093011.htm medizone10q093011.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
 
FORM 10-Q
 
                                                                                                                                                      
 
(Mark One)
 
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
 
For the quarterly period ended September 30, 2011
   
 
Or
   
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
 
For the transition period from __________ to ____________
 
Commission File Number: 2-93277-D
MEDIZONE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
87-0412648
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
 
2330 Marinship Way, Suite 300, Sausalito, California 94965
(Address of principal executive offices, Zip Code)
 
(415) 331-0303
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ  No ¨
 
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes þ   No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)
 
Smaller reporting company þ
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨  No þ
 
At October 31, 2011, the registrant had 270,491,949 shares of common stock issued and outstanding.
 
 
MEDIZONE INTERNATIONAL, INC.
FORM 10-Q
 
TABLE OF CONTENTS
September 30, 2011
 
 
   
Page No.
Part I — Financial Information
  
     
Item 1.
3
     
 
3
     
 
4
     
 
5
     
 
7
     
Item 2.
15
     
Item 3.
21
     
Item 4.
21
     
Part II — Other Information
  
     
Item 1.
22
     
Item 2.
22
     
Item 6.
23
     
24
 
 
 
 
PART I — FINANCIAL INFORMATION
 
Item 1.  Financial Statements
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Balance Sheets
 
             
 
  
September 30, 2011
    
December 31, 2010
  
   
   (Unaudited)    
(Audited)
  
ASSETS
            
 
            
CURRENT ASSETS
            
Cash
   $ 357,432     $ 435,894  
Prepaid expenses
     78,736       8,800  
Deferred consulting fees
     4,500       63,923  
Total Current Assets
     440,668       508,617  
                 
PROPERTY AND EQUIPMENT (NET)
     4,428       1,344  
                 
OTHER ASSETS
                
Trademark and patents, net
     151,733       117,771  
Lease deposit
     1,122       1,122  
Total Other Assets
     152,855       118,893  
                 
TOTAL ASSETS
   $ 597,951     $ 628,854  
                 
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
                
 
                
CURRENT LIABILITIES
                
Accounts payable
   $ 497,440     $ 451,412  
Accounts payable – related parties
     229,204       228,269  
Accrued expenses
     445,270       427,529  
Accrued expenses – related parties
     1,963,000       1,964,316  
Due to stockholders
     -       6,000  
Customer deposits
     40,000       -  
Notes payable
     287,430       283,266  
Total Current Liabilities
     3,462,344       3,360,792  
                 
CONTINGENT LIABILITIES
     224,852       224,852  
                 
TOTAL LIABILITIES
     3,687,196       3,585,644  
                 
STOCKHOLDERS' EQUITY (DEFICIT)
                
                 
Preferred stock, 50,000,000 shares authorized of $0.00001par value, no shares issued or outstanding
     -       -  
Common stock, 395,000,000 shares authorized of $0.001par value, 270,491,949 and 259,362,171 shares issued and
outstanding, respectively
     270,492       259,362  
Additional paid-in capital
     22,991,809       21,593,448  
Other comprehensive loss
     (23,946 )     (8,519 )
Deficit accumulated during the development stage
     (26,327,600 )     (24,801,081 )
Total Stockholders’ Deficit
     (3,089,245 )     (2,956,790 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
   $ 597,951     $ 628,854  
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
MEDIZONE INTERNATIONAL, INC., AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Operations and Other Comprehensive Loss
(Unaudited)
 
                           
From Inception
  
   
For the
    
For the
    
on January 31, 1986
  
   
Three Months Ended
    
Nine Months Ended
    
Through
  
   
September 30,
    
September 30,
    
September 30,
  
   
2011
    
2010
    
2011
    
2010
    
2011
  
REVENUES
  
$
-
    
$
-
    
$
-
    
$
-
    
$
133,349
  
                                         
EXPENSES
                                        
Cost of sales
    
-
      
-
      
-
      
-
      
103,790
  
General and administrative
    
283,730
      
1,187,936
      
712,831
      
1,580,634
      
19,125,649
  
Research and development
    
189,688
      
485,011
      
778,982
      
776,034
      
4,939,062
  
Expense on extension of warrants
    
-
      
-
      
-
      
-
      
2,092,315
  
Depreciation and amortization
    
5,390
      
2,884
      
15,796
      
5,252
      
76,310
  
Bad debt expense
    
-
      
-
      
-
      
-
      
48,947
  
Total Expenses
    
478,808
      
1,675,831
      
1,507,609
      
2,361,920
      
26,386,073
  
Loss from Operations
    
(478,808
)
    
(1,675,831
)
    
(1,507,609
)
    
(2,361,920
)
    
(26,252,724
)
                                         
OTHER INCOME (EXPENSES)
                                        
Gain on sale of subsidiaries
    
-
      
-
      
-
      
-
      
208,417
  
Debt forgiveness
    
-
      
-
      
-
      
-
      
61,514
  
Non-controlling interest in loss
    
-
      
-
      
-
      
-
      
26,091
  
Other income
    
-
      
-
      
-
      
-
      
19,780
  
Interest expense
    
(6,232
)
    
(5,995
)
    
(18,910
)
    
(17,867
)
    
(1,160,416
)
Loss on termination of license agreement
    
-
      
-
      
-
      
-
      
(125,000
)
Total Other Expenses
    
(6,232
)
    
(5,995
)
    
(18,910
)
    
(17,867
)
    
(969,614
)
                                         
LOSS BEFORE EXTRAORDINARY ITEMS
    
(485,040
)
    
(1,681,826
)
    
(1,526,519
)
    
(2,379,787
)
    
(27,222,338
)
                                         
EXTRAORDINARY ITEMS
                                        
Debt forgiveness
    
-
      
-
      
-
      
-
      
479,738
  
Lawsuit settlement
    
-
      
-
      
-
      
-
      
415,000
  
Total Extraordinary Items
    
-
      
-
      
-
      
-
      
894,738
  
                                         
NET LOSS
  
$
(485,040
)
  
$
(1,681,826
)
  
$
(1,526,519
)
  
$
(2,379,787
)
  
$
(26,327,600
)
                                         
OTHER COMPREHENSIVE LOSS
                                        
(Loss) gain on foreign currency translation
    
(10,466
)
    
63
      
(15,427
)
    
(6,236
)
    
(23,946
)
                                         
TOTAL COMPREHENSIVE LOSS
  
$ 
(495,506
)
    
(1,681,763
)
  
$
(1,541,946
)
  
$
(2,386,023
)
  
$ 
(26,351,546
 ) 
                                         
BASIC LOSS PER SHARE
  
$
(0.00
)
  
$
(0.01
)
  
$
(0.01
)
  
$
(0.01
)
        
                                         
WEIGHTED AVERAGE NUMBER OF  COMMON SHARES OUTSTANDING
    
269,632,672
      
250,143,347
      
264,562,692
      
246,780,162
          
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)
 
               
From Inception
  
               
on January 31, 1986
  
   
For the Nine Months Ended
    
Through
  
   
September 30,
    
September 30,
  
   
2011
    
2010
    
2011
  
CASH FLOWS FROM OPERATING ACTIVITIES:
                  
Net loss
  
$
(1,526,519
)
  
$
(2,379,787
)
  
$
(26,327,600
)
Adjustments to reconcile net loss to net cash used in operating activities:
                        
Depreciation and amortization
    
15,735
      
5,197
      
76,166
  
Stock issued for services
    
-
      
1,268,213
      
4,714,741
  
Stock issued for early termination of a license agreement
    
-
      
-
      
125,000
  
Amortization of deferred consulting fees
    
59,423
      
21,211
      
196,811
  
Expense on extension of warrants below market value
    
-
      
-
      
2,092,315
  
Value of stock options granted
    
22,886
      
249,115
      
418,098
  
Bad debt expense
    
-
      
-
      
48,947
  
Non-controlling interest in loss
    
-
      
-
      
(26,091
)
Loss on disposal of equipment
    
-
      
-
      
693,752
  
Gain on settlement of debt and lawsuit settlements
    
-
      
-
      
(603,510
)
Changes in assets and liabilities:
                        
Prepaid expenses and lease deposit
    
(62,997
)
    
882
      
(113,067
)
Accounts payable and accounts payable-related parties
    
46,963
      
(61,169
)
    
1,347,521
  
Accrued expenses and accrued expenses-related parties
    
16,425
      
20,900
      
3,056,293
  
Customer deposits
    
40,000
      
-
      
40,000
  
Net Cash Used in Operating Activities
    
(1,388,084
)
    
(875,438
)
    
(14,260,624
)
CASH FLOWS FROM INVESTING ACTIVITIES:
                        
Trademark and patent costs
    
(48,377
)
    
(27,710
)
    
(101,519
)
Purchase of property and equipment
    
(4,404
)
    
-
      
(48,586
)
Net Cash Used in Investing Activities
    
(52,781
)
    
(27,710
)
    
(150,105
)
CASH FLOWS FROM FINANCING ACTIVITIES:
                        
Proceeds from lawsuit settlement
    
-
      
-
      
415,000
  
Principal payments on notes payable
    
(2,775
)
    
(4,055
)
    
(201,573
)
Cash received from notes payable
    
-
      
-
      
1,129,518
  
Advances from stockholders
    
-
      
-
      
44,658
  
Payment on stockholder advances
    
(6,000
)
    
-
      
(31,191
)
Capital contributions
    
-
      
-
      
439,870
  
Stock issuance costs
    
(4,300
)
    
(10,000
)
    
(119,612
)
Increase in non-controlling interest
    
-
      
-
      
14,470
  
Issuance of common stock and subscribed for cash
    
1,390,905
      
1,198,400
      
13,100,967
  
Net Cash Provided by Financing Activities
    
1,377,830
      
1,184,345
      
14,792,107
  
EFFECT ON CURRENCY EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS
    
(15,427
)
    
(6,236
)
    
(23,946
)
NET INCREASE (DECREASE) IN CASH
    
(78,462
)
    
274,961
      
357,432
  
CASH AT BEGINNING OF PERIOD
    
435,894
      
359,891
      
-
  
CASH AT END OF PERIOD
  
$
357,432
    
$
634,852
    
$
357,432
  
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Consolidated Statements of Cash Flows (Continued)
(Unaudited)
 
               
From Inception
  
 
For the
    
on January 31, 1986
  
   
Nine Months Ended
    
Through
  
   
September 30,
    
September 30,
  
   
2011
    
2010
    
2011
  
SUPPLEMENTAL CASH FLOW INFORMATION
                  
CASH PAID FOR:
                  
Interest
  
$
1,212
    
$
125
    
$
31,230
  
NON-CASH FINANCING ACTIVITIES
                        
Financing of insurance policy
  
$
6,939
    
$
-
    
$
6,939
  
Stock issued for prepaid consulting fees
  
$
-
    
$
70,303
    
$
301,811
  
Stock issued for stock offering cost
  
$
-
    
$
100,000
    
$
100,000
  
Stock issued for conversion of debt
  
$
-
    
$
-
    
$
4,373,912
  
Stock issued for license agreement
  
$
-
    
$
-
    
$
693,752
  
Stock issued for patent costs
  
$
-
    
$
67,465
    
$
82,215
  
 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 1  BASIS OF PRESENTATION
 
The financial information included herein is unaudited and has been prepared consistent with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, these consolidated financial statements do not include all information and footnotes required by GAAP for complete consolidated financial statements.  These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2010.  In the opinion of management, these consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of results for the interim period presented.  The results of operations for the three and nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for the full year.
 
Recent Accounting Pronouncements
 
 
The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2010-06, Fair Value Measurements and Disclosures about Fair Value Measurements (“ASU 2010-06).  ASU 2010-06 affects all entities that are required to make disclosures about recurring and nonrecurring fair value measurements under FASB ASC Topic 820, originally issued as FASB Statement No. 157, Fair Value Measurements.  This ASU requires certain new disclosures and clarifies two existing disclosure requirements.  The new disclosures and clarifications of existing disclosures are effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements.  Those disclosures are effective for fiscal years beginning after December 15, 2010 and for interim periods within those fiscal years.  The adoption of this new standard had no impact on the Company’s consolidated financial statements.
 
NOTE 2  CANADIAN FOUNDATION FOR GLOBAL HEALTH
 
In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada.  The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.
 
Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity.  In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties.  If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it.  The Company determined that CFGH meets the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009.  Accordingly, the financial condition and operations of CFGH are being consolidated with the Company as of September 30, 2011 and December 31, 2010 and for the three and nine months ended September 30, 2011 and 2010.
 
NOTE 3  BASIC LOSS PER SHARE
 
The computations of basic loss per share of common stock are based on the weighted average number of common shares outstanding during the periods of the consolidated financial statements as follows:
 
   
For the Three Months Ended
September 30,
  
   
2011
    
2010
  
Numerator
            
 - Loss before extraordinary items
  
$
(485,040
)
  
$
(1,681,826
)
 - Extraordinary items
    
-
      
-
  
 Denominator (weighted average number of common shares outstanding)
    
269,632,672
      
250,143,347
  
Basic loss per share
                
 - Before extraordinary items
  
$
(0.00
)
  
$
(0.01
)
 - Extraordinary items
  
$
(0.00
)
  
$ 
0.00
  
Basic Loss Per Share
  
$
(0.00
)
  
$
(0.01
)
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 3  BASIC LOSS PER SHARE (Continued)
 
   
For the Nine Months Ended
September 30,
  
   
2011
    
2010
  
Numerator
            
 - Loss before extraordinary items
  
$
(1,526,519
)
  
$
(2,379,787
)
 - Extraordinary items
    
-
      
-
  
                 
Denominator (weighted average number of common shares outstanding)
    
264,562,692
      
246,780,162
  
                 
Basic loss per share
                
 - Before extraordinary items
  
$
(0.01
)
  
$
(0.01
)
 - Extraordinary items
  
$
(0.00
)
  
$
(0.00
)
Basic Loss Per Share
  
$
(0.01
)
  
$
(0.01
)
 
Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.
 
NOTE 4  GOING CONCERN
 
The Company’s consolidated financial statements are prepared using GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through September 30, 2011, which have resulted in a deficit accumulated during the development stage of $26,327,600 as of September 30, 2011.  The Company has funds sufficient to cover its operating costs for the next few months, has a working capital deficit of $3,021,676, and has relied exclusively on debt and equity financing.  Accordingly, there is substantial doubt about its ability to continue as a going concern.  
 
Continuation of the Company as a going concern is dependent upon obtaining additional funds and ultimately, upon the Company’s attaining profitable operations.  The Company will require a substantial amount of additional funds to complete the development of its products, hospital beta testing, commercialization, and to fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company were unsuccessful in any of the additional funding noted below, it would most likely be forced to substantially reduce or cease operations.
 
As discussed in Note 7, the Company entered into a Common Stock Purchase Agreement (“Stock Purchase Agreement”) and established an equity line financing facility (or “Equity Line”).  Management does not anticipate needing to draw the full amount of the Equity Line to implement our business plan and to develop and market its disinfection technologies.  The Company believes that it will need approximately $3 million during the year ending December 31, 2011 for research, development, marketing, and related activities, as well as for general corporate purposes, including final product development and initiation of sales.  Pursuant to the Stock Purchase Agreement with Mammoth Corporation (“Mammoth”), the frequency and amounts of draws are within the Company’s control.  The Company is not obligated to make any draws, and the Company may draw any amount up to the full amount of the Equity Line, in its discretion.  The Company does not plan to draw more funds (and correspondingly put more shares to Mammoth) under the Equity Line than is necessary to implement its business plan.  During the nine months ended September 30, 2011, the Company drew $886,606 (net of a one-time administrative fee of $4,300 as discussed in Note 7) of the Equity Line through the issuance of 5,379,778 shares of common stock at prices ranging from $0.10875 to $0.192 per share (after consideration of the 25% discount as discussed in Note 7).  
 
Also, during the nine months ended September 30, 2011, the Company raised a total of $500,000 through the sale of 5,750,000 shares of common stock as of September 30, 2011, at prices ranging from $0.08 to $0.12 per share.  These funds, as well as the Equity Line funds, have been used to keep the Company current in its reporting obligations under the SEC Exchange Act of 1934 (“Exchange Act”) and to pay certain other corporate obligations including the final costs of development for the production version of its AsepticSure™ hospital disinfection system.  In addition, if the Company were to need additional resources outside the Equity Line, the Company believes the Company would be able to continue to raise additional funds from some of the same investors who have purchased shares previously, although the Company has no current agreements with these investors and there is no assurance given that these investors will in fact purchase additional shares.
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 4  GOING CONCERN (Continued)
 
The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties.  
 
NOTE 5  COMMITMENTS AND CONTINGENCIES
 
The Company is subject to certain claims and lawsuits arising in the normal course of business.  In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.
 
Litigation
Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000. The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002. On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of September 30, 2011 and December 31, 2010. The Company intends to contest the judgment if and when it is able to in the future.
 
Contingent Liabilities
As of September 30, 2011 and December 31, 2010, the Company has recorded contingent liabilities totaling $224,852 related to certain past due payables for which the Company has not received invoices or demands for over ten years.  Although management of the Company does not believe that the amounts will ever be paid, the amounts are being recorded as contingent liabilities until such time as the Company is certain that no liability exists and until the statute of limitations has expired.  
 
Operating Leases
In 2009, the Company entered into a lease agreement and established its own certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which will provide a primary research and development platform for the Company as it proceeds towards commercialization of its products.  The initial lease term expired on June 30, 2011, but has been extended to June 30, 2012, with a monthly lease payment increasing from $1,300 to $1,350 Canadian Dollars plus the applicable Goods and Services Tax (“GST”).  A second laboratory space for full scale room testing also expired on June 30, 2011, but was extended to June 30, 2012, with a monthly lease payment increasing from $1,200 to $1,250 Canadian Dollars, plus the applicable GST.  In March 2011, the Company also entered into a lease agreement and established its own corporate offices in California that includes a monthly lease payment of $2,500 U.S. Dollars and is renewable on a month to month basis following the initial lease term that ended in May 2011.  This arrangement should allow the Company to expand its commercial offices even further, should that become necessary sooner than currently envisioned.  
 
NOTE 6  COMMON STOCK WARRANTS AND OPTIONS
 
Warrants
All outstanding warrants were either exercised or expired unexercised prior to December 31, 2009, thus there are no warrants outstanding as of September 30, 2011 or December 31, 2010.  
 
Options
In March 2011, the Company granted options for the purchase of 150,000 shares of common stock to an individual for accounting related services to be performed through December 30, 2011, which do not vest until such date.  The options have an exercise price of $0.14 per share, and are exercisable for up to five years.  The grant date fair value of these options was $20,042, in connection with which the Company recognized $6,380 and $13,731 of expense during the three and nine months ended September 30, 2011, respectively.  The remaining $6,311 will be recognized between October 1, and December 30, 2011.
 
In March 2011, the Company granted options for the purchase of 100,000 shares of common stock to an individual for web and press support services to be performed through December 30, 2011, which do not vest until such date. The options have an exercise price of $0.14 per share, and are exercisable for up to five years.  The grant date fair value of these options was $13,361, in connection with which the Company recognized $4,254 and $9,155 of expense during the three and nine months ended September 30, 2011, respectively.  The remaining $4,206 will be recognized between October 1, and December 30, 2011. 
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 6  COMMON STOCK WARRANTS AND OPTIONS (Continued)
 
In March, 2010, the Company granted options for the purchase of 250,000 shares of common stock to an individual for research and development consulting services to be performed for the period of April 1, 2010 through September 30, 2010.  The options have an exercise price of $0.19 per share, and are exercisable for up to five years.  The grant date fair value of these options was $46,094, in connection with which the Company recognized $46,094 of expense during the nine months ended September 30, 2010.  
 
In July 2010, the Company granted options for the purchase of a total of 3,500,000 shares of common stock to certain board members and employees of the Company as additional compensation for work performed.  These options have an exercise price of $0.20 per share, are exercisable for up to five years, but do not vest until the Company has achieved commercial sales.  As of September 30, 2011, none of these options had vested.  The grant date fair value of these options was $710,577, and will be recorded in the future once the Company has achieved commercial sales.
 
Also, in July 2010, the Company granted options for the purchase of 1,000,000 shares of common stock to a director of the Company in lieu of an actual stock grant for his services as a board member (see Note 7 for additional discussion on common shares issued to other board members for board service).  These options have an exercise price of $0.20 per share, are exercisable for up to five years, and became fully vested on the date of the grant.  The grant date fair value of these options was $203,021 and has been recorded as board compensation for the nine months ended September 30, 2010.
 
In August 2010, the Company granted options for the purchase of 250,000 shares of common stock to an outside consultant for patent work performed on behalf of the Company.  These options have an exercise price of $0.27 per share, are exercisable for up to five years, and had no vesting provisions.  The grant date fair value of these options was 67,465 and has been capitalized to patent costs as of September 30, 2010, which costs are being amortized over the expected life of the patent.
 
In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to an outside consultant in connection with extending his consulting agreement with the Company through September 1, 2011.  These options have an exercise price of $0.275 per share, are exercisable for up to five years, but do not vest until the Company has achieved commercialization and sales of the AsepticSure™ product.  As of September 30, 2011, none of these options had vested.  The grant date fair value of these options was $65,067, and will be recorded in the future once the Company has achieved the required commercial sales.
 
For the nine months ended September 30, 2011, the Company estimated the fair value of the stock options at the date of the grant, based on the following weighted average assumptions:
 
Risk-free interest rate
    
2.43
%
Expected life
  
5 years
  
Expected volatility
    
176.45
%
Dividend yield
    
0.00
%

A summary of the status of the Company’s outstanding options as of September 30, 2011 and changes during the nine months ended is presented below:

   
Shares
    
Weighted Average Exercise Price
  
Outstanding, beginning of period
    
7,750,000
    
$
0.17
  
Granted
    
250,000
    
$
0.14
  
Expired/Canceled
    
-
      
n/a
  
Exercised
    
-
      
n/a
  
Outstanding, end of period
    
8,000,000
    
$
0.17
  
Exercisable
    
3,000,000
    
$
0.16
  
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 6  COMMON STOCK WARRANTS AND OPTIONS (Continued)
 
The Company estimates the fair value of each stock award by using the Black-Scholes option pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes model is zero.  Under the provisions of this accounting standard, additional expense of $22,886 and $249,115 was recorded for the nine months ended September 30, 2011 and 2010, respectively, using the Black-Scholes option pricing model.  An additional amount of $67,465 has been capitalized as patent costs as of September 30, 2010, as previously mentioned, which costs are being amortized over the expected useful life of the patents.    
 
NOTE 7  STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS
 
Common Stock for Cash – For the Nine Months Ended September 30, 2011
During February 2011, the Company issued 582,065 shares of common stock to Mammoth, an accredited investor (as part of the Equity Line), for cash proceeds of $59,000 (net of $4,300 of stock issuance costs) at a price of $0.10875 per share.  There were no underwriters involved.  
 
During March 2011, the Company sold an aggregate of 1,000,000 restricted shares of common stock that were subscribed for as of March 31, 2011 and issued in April 2011.  The purchasers of these shares were two accredited investors, not otherwise affiliated with the Company.  The Company received cash proceeds of $120,000, or $0.12 per share in connection with these sales.  There were no underwriters involved.  
 
During April and May 2011, the Company issued 3,649,867 shares of common stock to Mammoth (as part of the Equity Line) for cash proceeds of $658,012.  The sales were made pursuant to two separate “Draw Down Notices” issued by the Company under the Stock Purchase Agreement. The first notice was effective May 18, 2011, for 1,583,771 shares and proceeds of $261,322, or approximately $0.165 per share.  The second notice was effective June 16, 2011, for 2,066,096 shares and proceeds of $396,690, or approximately $0.192 per share.  There were no underwriters involved.
 
During April, May and June 2011, the Company sold an aggregate of 4,625,000 restricted shares of common stock, to accredited investors, not otherwise affiliated with the Company, for cash proceeds of $370,000 at a price of $0.08 per share.  There were no underwriters involved.
 
During June 2011, the Company entered into a transaction, with an accredited investor not otherwise affiliated with the Company, for 125,000 restricted shares of common stock that were subscribed for as of June 30, 2011 and issued in July 2011, for cash proceeds of $10,000 at a price of $0.08 per share.  There were no underwriters involved.
 
During September 2011, the Company issued 1,147,846 shares of common stock to Mammoth (as part of the Equity Line) for cash proceeds of $169,594, at a price of $0.14775 per share.  There were no underwriters involved.
 
Common Stock for Cash – For the Nine Months Ended September 30, 2010
In January and February 2010, the Company issued an aggregate of 500,000 shares of common stock, for cash proceeds totaling $125,000, or $0.25 per share.  The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.  There were no underwriters involved.
 
In April, May and June 2010, the Company issued an aggregate of 3,622,777 shares of common stock for cash proceeds totaling $441,400, at prices ranging from $0.12 to $0.18 per share.  The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.  The Company also paid stock offering costs to an investment firm of $10,000 who assisted the Company in raising these funds.  
 
In July, August and September 2010, the Company issued an aggregate of 5,266,666 shares of common stock for cash proceeds totaling $632,000, at prices ranging from $0.12 to $0.18 per share.  The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.  There were no underwriters involved.
 
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 7  STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Continued)
 
Restricted Stock for Services –For the Nine Months Ended September 30, 2010
In February 2010, the Company issued a total of 137,000 restricted shares of common stock to two consultants for consulting, marketing, and web support services valued at $39,730, or $0.29 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  Both consulting agreements were based on a term through June 30, 2010, the shares vested in equal increments, and the consulting expense was recognized over the same period during 2010 ($15,891 as stock issued for services and $23,839 as amortization of deferred consulting expense).
 
In March 2010, the Company issued 250,000 restricted shares of common stock to a consulting firm for investor relation services valued at $47,500, or $0.19 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The consulting agreement was based on a term through June 30, 2010, the shares vested in equal increments, and the consulting expense was recognized over the same period during 2010.
 
In April 2010, the Company issued 120,000 restricted shares of common stock in lieu of outstanding consulting fees valued at $22,800, or $0.19 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  These shares had no vesting requirements.
 
Also, in April 2010, the Company issued 588,235 restricted shares of common stock in satisfaction of a one-year contract with an investment firm to assist the Company in raising required capital, valued at $100,000, or $0.17 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The Company recognized this as a stock issuance cost at the date of issuance and such shares had no vesting requirements.
 
In July 2010, the Company issued 135,000 shares of restricted common stock to an investor relations company pursuant to a one-year agreement through July 15, 2011 valued at $25,650, or $0.19 per share, which represents the market value of the shares on the date that the Board authorized the issuance of the shares.  The shares vest in equal increments and the expense is to be recorded over the period of the agreement.  The Company recognized consulting expense of $13,894 and $5,343 during the nine months ended September 30, 2011 and 2010, respectively.
 
Also, in July 2010, the Company issued a total of 4,000,000 shares of restricted common stock to certain directors and officers for board service and performance bonuses valued at a total of $840,000, or $0.21 per share, which represents the market value of the shares on the date that the disinterested members of the Board authorized the issuance of the shares.  The value of the shares, or $840,000, was recorded as director compensation and bonus expense for the nine months ended September 30, 2010.
 
In August 2010, the Company issued a total of 225,000 shares of restricted common stock to two consultants for consulting, marketing, and web support services valued at a total of $60,750, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The first agreement was for the period of July 15, 2010 through March 31, 2011.  The second agreement was for the period of August 26, 2010 through August 26, 2011.  For both agreements, the shares vest in equal increments and the consulting expense is recognized over the period of the contracts.  The Company recognized consulting expense of $32,029 and $10,754 during the nine months ended September 30, 2011 and 2010, respectively.
 
Also, in August 2010, the Company issued 118,839 shares of restricted common stock to a consultant in lieu of outstanding consulting fees valued at $32,087, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  An additional 1,000,000 shares of restricted common stock were issued to this same consultant on September 1, 2010, as bonus compensation for extending his consulting agreement through September 1, 2011, valued at $270,000, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The entire amount was recorded as bonus compensation during the nine months ended September 30, 2010.
 
In December 2010, the Company issued 100,000 shares of restricted common stock to an individual, as part of a web services and media representation consulting agreement, valued at $18,000, or $0.18 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The consulting agreement is for the year of 2011.  The Company recognized consulting expense of $13,500 during the nine months ended September 30, 2011.
        
 
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 7  STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Continued)
 
Stock Purchase Agreement
In November 2010, the Company entered into the Stock Purchase Agreement with Mammoth providing for the Equity Line.  The Stock Purchase Agreement provides that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth is committed to purchase up to $10,000,000 of shares of our common stock over the 24-month term of the Stock Purchase Agreement under certain specified conditions and limitations.  Furthermore, in no event may Mammoth purchase any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9 percent of the then outstanding shares of the Company’s common stock.  These maximum share and beneficial ownership limitations may not be waived by the parties.
 
Under the terms of the Stock Purchase Agreement, the Company has the opportunity for a 24-month period, commencing on the date on which the SEC first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock.  For each share of common stock purchased under the Stock Purchase Agreement, Mammoth will pay to the Company a purchase price equal to 75 percent of the lowest closing bid price during the five consecutive trading day period (the “Draw Down Pricing Period”) preceding the date a draw down notice (the “Draw Down Notice”) is delivered by the Company to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement.  Subject to the limitations outlined below, the Company may, at its sole discretion, issue a Draw Down Notice to Mammoth, and Mammoth will then be irrevocably bound to purchase such shares.
 
Each Draw Down Notice must specify the lowest purchase price during the Draw Down Pricing Period at which the Company will sell the shares to Mammoth, which shall not be less than 75 percent of the lowest closing bid price during the Draw Down Pricing Period. Furthermore, the number of shares to be issued is limited by multiplying by five the average daily trading volume for the 30 trading days immediately preceding the delivery of the Draw Down Notice.  The Draw Down Notice will also include the aggregate dollar amount of the Draw Down, which will not be less than $25,000 and not more than $500,000 in any Draw Down Notice.  There must be a minimum of 15 trading days between each Draw Down Notice.
 
The Company agreed to pay up to $5,000 (of which the Company paid $4,300 during the nine months ended September 30, 2011 to fully satisfy this obligation) of reasonable attorneys’ fees and expenses (exclusive of disbursements and out-of-pocket expenses) incurred by Mammoth in connection with the preparation, negotiation, execution and delivery of the Stock Purchase Agreement and related transaction documentation.  Further, if the Company issues a Draw Down Notice and fails to deliver the shares to Mammoth on the applicable settlement date, and such failure continues for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery is late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery is late.  
 
In connection with the Stock Purchase Agreement, the Company granted registration rights to Mammoth, and agreed to register the resale of shares issued to Mammoth in connection with Draw Downs made in connection with the Stock Purchase Agreement.  In January 2011, the Company filed a registration statement to cover the resale by Mammoth of up to 66,666,667 shares of our common stock under the Stock Purchase Agreement.  The Company is not permitted to make Draw Downs under the Stock Purchase Agreement at any time there is not an effective registration statement registering the resale of shares of common stock by Mammoth.  On January 25, 2011, the registration statement was declared effective by the SEC.  The Company has agreed to file all necessary post-effective amendments to the registration statement under applicable SEC rules and regulations in order to keep the registration statement currently effective.  As previously mentioned, the Company has made four Draw Down request under the Stock purchase Agreement during the nine months ended September 30, 2011.  
 
The Stock Purchase Agreement may be terminated at any time by the mutual written consent of the parties.  Unless earlier terminated, the Stock Purchase Agreement will terminate automatically on the 24-month anniversary of the effective date of the registration statement (which term may not be extended by the parties).
 
ADA Innovations
In December 2010, the Company reached an agreement with ADA Innovations (“ADA”) for final development and production manufacturing of portable versions of the Company’s AsepticSure™ disinfection systems.  A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011.
 

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES
(A Development Stage Company)
Notes to the Consolidated Financial Statements (Unaudited)
September 30, 2011 and December 31, 2010
 
NOTE 7  STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Continued)
 
In addition, BiOzone Corporation will remain involved as a development support partner and manufacturer of laboratory equipment, and will assist, as requested, in construction of permanent installations for large-scale industrial applications.  Any and all notes, reports, information, inventions, sketches, plans concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company.  The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement.  Deliverables will include: (1) the pre-production prototype designed and manufactured to our specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties.  The Company will pay ADA as services are provided.  During the three and nine months ended September 30, 2011, the Company incurred expenses totaling approximately $156,000 and $482,000, respectively, for services provided under the Services Agreement.  Of these amounts, approximately $138,000 and $466,000 were recorded as research and development costs in the three and nine months ended September 30, 2011, respectively.
 
NOTE 8  DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE – RELATED PARTIES
 
In previous years, certain directors had advanced a total of $7,000 to the Company to cover operating expenses.  During 2010, the Company repaid $1,000 leaving $6,000 outstanding as of December 31, 2010 which was non-interest bearing, unsecured and due on demand.  During the nine months ended September 30, 2011, the remaining $6,000 was repaid.
 
As of September 30, 2011 and December 31, 2010, the Company had outstanding $229,204 and $228,269, respectively, owed to certain employees for unpaid services in previous years. These employees are shareholders of the Company and therefore have been classified as related parties.
 
NOTE 9  CUSTOMER DEPOSITS
 
As of September 30, 2011, the Company received two purchase orders and related customer deposits totaling $40,000 to purchase the AsepticSure™ disinfection systems.  The company anticipates deliveries of its first disinfection systems early in 2012.  As of September 30, 2011, these customer deposits have been reflected as current liabilities in the accompanying consolidated balance sheet.
 
NOTE 10  SUBSEQUENT EVENTS
 
The Company has evaluated subsequent events per the requirements of ASC Topic 855 and has concluded that there are no events to be reported.
 
 
Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
General
 
Medizone International, Inc. (“Medizone,” the “Company,” “we,” “us,” “our”), prior to 2008, had been dedicated to (i) seeking regulatory approval of a precise mixture of ozone and oxygen, and the process of inactivating lipid-enveloped viruses for the intended purpose of decontaminating blood and blood products and assisting in the treatment of certain diseases; (ii) developing or acquiring the related technology and equipment for the medical application of our products, including a drug production and delivery system; and, (iii) applying our novel technology to the problem of nosocomial infections world-wide.  
 
Ozone is a gas composed of three oxygen atoms in an unstable and highly reactive form.  Ozone naturally tends to seek its normal state, exhibiting a short half-life as it reverts to oxygen fairly rapidly.  There are many uses of ozone as a disinfecting agent.  Although Ozone does react with organic matter it leaves no residue in water or on the treated product.  Ozone also does not form any toxic byproducts and when used in water which means that no change in color or flavor results from ozone treatment, unlike chlorine treatment.  Ozone can be generated onsite from ambient air or from oxygen.  Each method has its advantages and unique challenges.  It has been demonstrated that ozone can be economically produced and is effectively used as an agent in food processing, equipment sanitizing, and in water treatment facilities globally.  Ozone technology is replacing conventional sanitation techniques such as chlorine, steam, or hot water.
 
Corporate Operations
 
Early in 2008, we began to consider other applications of our core technologies and new technologies with lower development costs with the objective of moving us to revenue production in the shortest period of time.
 
Beginning in 2008, management re-positioned the Company to pursue an initiative in the field of hospital disinfection. Following laboratory results with Bacillus subtilis, an internationally recognized surrogate for anthrax, that produced 7 log reductions (sterilization), we have expanded our research and business plan to include bio-terrorism countermeasures as well as hospital disinfection and critical infrastructure de-contamination.
 
By way of explanation, “log reduction” is a mathematical term (as is “log increase”) used to show the relative number of live microbes eliminated from a surface by disinfecting or cleaning.  For example, a “5-log reduction” means lowering the number of microorganisms by 100,000-fold, that is, if a surface has 100,000 pathogenic microbes on it, a 5-log reduction would reduce the number of microorganisms to one, as indicated in the following table:  
 
·  
1 log reduction means the number of germs is 10 times smaller
·  
2 log reduction means the number of germs is 100 times smaller
·  
3 log reduction means the number of germs is 1000 times smaller
·  
4 log reduction means the number of germs is 10,000 times smaller
·  
5 log reduction means the number of germs is 100,000 times smaller
·  
6 log reduction means the number of germs is 1,000,000 times smaller
·  
7 log reduction means the number of germs is 10,000,000 times smaller
 
This change in focus was based, in part, on a review of published data on hospital-derived infections, an area of rapidly growing concern in the medical community.  We identified an opportunity to build on our experience with ozone technologies and its bio-oxidative qualities in pursuing this initiative and shifted our near term efforts towards one of our founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing biological fluids (blood, serum, and plasma and plasma fractionates) as well as biologically contaminated equipment and spaces.
 
We expect our unique ozone generating technologies will play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as “the silent epidemic” (American Academy of Orthopedic Surgeons, May 2008, copy on file with the Company (“AAOS Study”)), a reference to MRSA (Methicillin-resistant Staphylococcus aureus) infection.  This is a strain of Staphylococcus aureus bacteria (“staph”) that is resistant to the broad-spectrum antibiotics commonly used to treat it. MRSA can be fatal.  According to the AAOS Study, “the number of hospital admissions for MRSA has exploded in the past decade. By 2005, admissions were triple the number in 2000 and 10-fold higher than in 1995.
 
 
In 2005, in the United States, 368,600 hospital admissions for MRSA — including 94,000 invasive infections — resulted in 18,650 deaths.  The number of MRSA fatalities in 2005 surpassed the number of fatalities from hurricane Katrina and AIDS combined and is substantially higher than fatalities at the peak of the U.S. polio epidemic.”  Indeed, biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control or “CDC” (CDC Report, 17 Oct, 2007, copy on file with the Company), as one of the greatest threats to public health and safety in the industrial world. This concern was reflected in an article published in the journal Science (18 July 2008, Vol 321, pp 356-361, copy on file with the Company) which estimated that hospital-based infections in 2006 accounted for almost 100,000 deaths in the United States.  We expect that current data, if available, would indicate that deaths in the United States from hospital-acquired MRSA infections now exceed 100,000 per year.
 
In response to this situation, we are developing a highly portable, low-cost, ozone-based technology (“AsepticSure™”) specifically for the purpose of decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units. Since this technology is not considered a medical treatment or a diagnostic, its development pathway is not subject to a stringent and expensive regulatory review process.  We anticipate that the development pathway will be based on independent peer-reviewed science and engineering excellence.  A government variant of AsepticSure™ is being developed for bio-terrorism countermeasures.
 
During May 2009, we commenced the first of a series of trials designed to confirm that our AsepticSure™ Hospital Disinfection System can rapidly eliminate hospital-based bacterial pathogens known to be responsible for the growing number of deaths and serious infections currently plaguing the healthcare system worldwide.  We engaged an internationally recognized expert in medical microbiology and hospital infections to lead these trials.
 
We commenced a second series of laboratory trials in early June 2009, after the first series produced results that our researchers deemed to have demonstrated significant bactericidal effects against C. difficile, E. coli, Pseudomonas aeruginosa, MRSA and Vanocomycin-resistant Enterococci (“VRE”), the main causative agents of hospital derived nosocomial infections. This second series of laboratory trials resulted in what are estimated to be levels of bactericidal action necessary to achieve our commercial objectives.
 
In October 2009, we began a third series of laboratory trials to establish the precise protocols necessary to obtain maximum bactericidal action in combination with minimum turn-around times in keeping with normal hospital flow patterns. This third series of laboratory trials was completed during January 2010 and demonstrated predictably greater than 6 logs (99.9999%) of bacterial “kill” across the full spectrum of hospital contaminants including MRSA, C difficile, E coli, Pseudomonas aeruginosa and VRE in addition to the internationally accepted surrogate for anthrax, Bacillus subtilis.  Our research has shown that the technology can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means.  We expect that this development will significantly expand the utility and acceptance or our AsepticSure™ technology.
 
In connection with our trials described above, we also designed and produced a development prototype which has demonstrated that it can reach both the charge time and saturation requirements of its design criteria.  In January 2010, we started mock-up trials for both public (hospital) and government (bio-terrorism countermeasures) applications of our system. Results obtained during early February 2010 demonstrated that every full-scale test run completed in our hospital room mock-up facility had resulted in the total elimination of all bacteria present in the room. Additional testing was designed to confirm in a more realistic hospital setting these laboratory findings indicating extremely high antibacterial efficacy for our novel technology (6-7.2 log reductions) against the primary causative agents of hospital acquired infections (HAIs), sometimes referred to as “Super Bugs.”  We completed multiple runs with very high concentrations of MRSA, VRE and E. coli samples that were distributed throughout the test room.  In every instance, the AsepticSure™ system produced greater than 6 log (99.9999%) reductions, which by definition, is sterilization.  We have now systematically collected empirically verifiable scientific data on all of the remaining causative agents of HAIs.  We have also disinfected Bacillus subtilis, the recognized surrogate for anthrax in full-sized room settings to a sterilization standard of >6 log, which we interpret as a positive indicator that AsepticSure™ could play a vital role in the government arena of bio-terrorism countermeasures.  
 
We started hospital beta-testing of a prototype system utilizing the original technology during the summer of 2010, with the initial phases successfully completed during early October 2010.  The first round of in-hospital beta-testing for this AsepticSure™ hospital disinfection system was completed on October 9, 2010, at a Hotel Dieu hospital in Kingston, Ontario, Canada.  The targeted hospital space was artificially contaminated with high concentrations of MRSA and C. difficile, using both regulatory compliant stainless steel discs and carpet samples typically found in many health care facilities. One hundred percent of the MRSA and C. difficile was eliminated from the discs (7.1 logs for MRSA and 6.2 logs for C difficile).  The pathogens were also completely eliminated from all contaminated carpet samples, something we believe to be unachievable with any other technology.  Testing further indicated that beyond the test samples artificially introduced, all pre-occurring pathogens present before testing were also eliminated on all surfaces by the AsepticSure™ hospital disinfection system.
 
 
Our goal is to demonstrate an actual and significant reduction in the rate of re-infection for hospital acquired infections by institutions utilizing our system.  We expect to conduct the majority of the remaining hospital beta testing using production equipment.
 
In addition to the hospital disinfection initiative, we have developed an ozone-destruct unit which is used following disinfection of the treated infrastructure to reverse the ozone gas (O3) in the space, and turn it back into O2 in a short period of time.  We have initially targeted the treatment of a typically sized surgical suite including disinfection followed by ozone destruct to habitable standards in ninety minutes or less.  This short turn-around period is considered of great importance relative to commercialization of the technology.  
 
In addition, work completed by the Company at Queen’s University demonstrated that the AsepticSure™ system can reliably eliminate in excess of 7 logs (99.99999%) reductions of Listeria monocytogenes and Salmonella typhium with 30-minute exposure to our unique and patented gas mixture, which provides an additional application of the AsepticSure™ technology, beyond that of hospital acquired infections for the food processing industry.
 
We anticipate that in the future we will enter into one or more relationships with larger established companies that are already fully embedded in our sector of business as suppliers, such as medical device manufacturers or service companies, for distribution and support. We have not entered into any agreements at this time and it is too early to predict whether these relationships might be in the form of licensing agreements, partnerships, technology transfers or the sale or combination of the Company.  
 
Additionally, we possibly may partner with several such companies, perhaps covering different geographical markets such as North America, Asia, and Europe.  The same may prove to be true for the outsourcing of additional manufacturing capacity, as required. By developing relationships with multiple corporate partners, management believes that we will be able to better maintain control over our products and obtain more competitive returns.  We have held preliminary talks with potential corporate partners in the hospital sector, but have not committed to any corporate relationship at the present time.  At this time, we intend to maintain sales of the government variant of AsepticSure™ in-house, as we have full-time staff and consultants that are very experienced in dealing with government affairs and government contracts.
 
Recent Developments
 
International Recognition of AsepticSure™
 
A prestigious peer review medical journal, The American Journal of Infection Control, recently published a peer-reviewed article on the science of AsepticSure™ and its unprecedented micro microbial disinfection ability. (> 6 log kill for all pathogens tested), titled: “Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces,” authored by Dick Zoutman, MD, FRCPC, Michael Shannon, MD, MSc,b,c, and Arkady Mandel, MD, PhD, DScc, Kingston, and Ottawa, Ontario, Canada.  The review was based on the work completed at our laboratories located at Innovation Park, Queen’s University, in Kingston, Ontario, Canada.
 
In July 2011, canadaNOW, a bi-annual national magazine of the Canadian university research parks, featured AsepticSure™ in an article titled, “Taking on the ‘silent epidemic.”
 
Also in July 2011, AsepticSure™ was awarded one of three Awards for Innovation at the First International Conference on Prevention and Infection Control (ICPICP) sponsored by the World Health Organization in Geneva, Switzerland.
 
Canadian Foundation for Global Health – Consolidated Variable Interest Entity
 
In 2008, we assisted in the formation of CFGH, a not-for-profit foundation based in Ottawa, Canada.  We helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with us for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit, and (2) to provide a means for us to use a tiered pricing structure for services and products in emerging economies and extend the reach of our technology to as many in need as possible.
 
The CFGH may not contract for research or other services on our behalf without our prior approval.  In addition, our understanding with the CFGH provides that all intellectual property, including but not limited to, scientific results, patents and trademarks that are derived from work done on our behalf or at our request by CFGH or parties contracted by CFGH with our prior approval will be our sole and exclusive property.
 
 
The CFGH is registered as a not-for-profit corporation under Canadian Federal Charter.  Dr. Shannon M.A., M.Sc., M.D. is President of CFGH and maintains offices at CFGH.  Mr. Brad Goble, President of TDVGlobal, Inc., is also a board member of CFGH and serves as the Secretary-Treasurer for that organization. According to its website, TDVGlobal, Inc. “is a strategic management consulting company” focusing on the public sector.  It is based in Ottawa, Ontario, Canada.  Other members of the CFGH board are Edwin G. Marshall (our Chief Executive Officer and Chairman), Daniel D. Hoyt (one of our directors), Dr. Jill C. Marshall, NMD, (Mr. Marshall’s wife and a former corporate officer of the Company), and Dr. Ron St. John.
 
We follow the accounting standard which requires a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties.  If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it.  We have determined that CFGH meets the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009.  Accordingly, the financial position and operations of CFGH are being consolidated with our financial results and in our consolidated financial statements included within this quarterly report.  
 
Employees
 
As of September 30, 2011, we had four employees (of which three are full-time employees) and a number of outside consultants and experts engaged in product development, government relations and science.  The total number of people now involved in the AsepticSure™ research, development and manufacturing program as either employees, consultants, contractors or business support on either a full time or part time basis now exceeds 20.
 
Results of Operations
 
Three Months Ended September 30, 2011 and 2010
 
We were incorporated in January 1986.  We are a development stage company engaged in research into the use of an ozone based fogging mixture as a disinfectant.  Our current work is in the field of hospital disinfection, and other industrial applications requiring disinfectant, rather than human therapies.  We are now developing production equipment with the intention of initiating sales later this year.  We have not generated, and cannot predict when or if we will generate, revenues or sufficient cash flow to fund continuing or planned operations.   If we fail to obtain additional funding, we will be forced to suspend or permanently cease operations, and may need to seek protection under United States bankruptcy laws.
 
For the three months ended September 30, 2011, we had a net loss of $485,040, compared with a net loss for the three months ended September 30, 2010 of $1,681,826.  Our primary expenses are payroll and consulting fees, research and development costs, office expenses, together with interest expense and additional expense recorded as a result of options granted to consultants.  The reason for the significant decrease in the net loss for the three months ended September 30, 2011 as compared to the prior year is the result of certain issuances of restricted common stock and common stock options as discussed in the following paragraph.
 
During the three months ended September 30, 2010, we incurred additional expenses of: (1) $840,000 as a result of the issuance of a total of 4,000,000 restricted shares of common stock to certain directors and officers for board service and performance bonuses recorded as part of general and administration expense, (2) $203,022 as a result of the valuation of 1,000,000 common stock options granted to a board member in lieu of the share issuance described in the preceding sentence and recorded as part of general and administrative expense, and  (3) $270,000 as a result of the issuance of 1,000,000 restricted shares of common stock to a consultant as bonus compensation for extending his consulting agreement through September 1, 2011 recorded as part of research and development expense.
 
For the three months ended September 30, 2011 and 2010, we incurred $283,730 and $1,187,936, respectively, in general and administrative expenses.  The primary decrease for the three months ended September 30, 2011 compared to 2010 was a result of restricted common stock and common stock option issuances as part of director fees and performance bonuses as described above.  The remaining general and administrative expenses include payroll and consulting fees, professional fees, rent, office expenses and travel expenses. 
 
For the three months ended September 30, 2011 and 2010, we incurred, $189,688 and $485,011, respectively, in research and development costs.  The primary decrease for the three months ended September 30, 2011 compared to 2010 was a result of the restricted common stock issuance as part of a consultant extending his consulting agreement as described above.  The remaining costs include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development and final development and production manufacturing of portable versions of our AsepticSure™ disinfection system. Since inception, we have spent a total of $4,939,062 for research and development related to our ozone technology and related apparatus.
 
Principal amounts owed on notes payable totaled $287,430 and $283,266 as of September 30, 2011 and December 31, 2010, respectively.  Interest expense on these obligations during the three months ended September 30, 2011 and 2010 was $6,232 and $5,995, respectively.  The applicable interest rates on this debt ranged from 7.75 percent to 10 percent per annum.
 
 
Nine Months Ended September 30, 2011 and 2010
 
For the nine months ended September 30, 2011, we had a net loss of $1,526,519, compared with a net loss for the nine months ended September 30, 2010 of $2,379,787.  The reason for the significant decrease in the net loss for the nine months ended September 30, 2011 compared to the prior year is the result of certain issuances of restricted common stock and common stock options as previously discussed.  Our primary expenses are payroll and consulting fees, research and development costs, office expenses, together with interest expense and additional expense recorded as a result of options granted to consultants.
 
For the nine months ended September 30, 2011 and 2010, we incurred $712,831 and $1,580,634, respectively, in general and administrative expenses.  The primary decrease for the nine months ended September 30, 2011 compared to 2010 was a result of restricted common stock and common stock option issuances as part of director fees and performance bonuses as described above.  The remaining general and administrative expenses include payroll and consulting fees, professional fees, rent, office expenses and travel expenses.
 
For the nine months ended September 30, 2011 and 2010, we incurred $778,982 and $776,034, respectively, in research and development costs.  The primary factor that the amounts remained fairly consistent for the nine months ended September 30, 2011 compared to 2010 was a result of approximately $466,000 in services performed by ADA Innovations in connection with the final development and production manufacturing of portable versions of our AsepticSure™ disinfection system.  The remaining costs include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development.  Since inception, we have spent a total of $4,939,062 for research and development of our ozone technology and related apparatus.  
 
Principal amounts owed on notes payable totaled $287,430 and $283,266 as of September 30, 2011 and December 31, 2010, respectively.  Interest expense on these obligations during the nine months ended September 30, 2011 and 2010 was $18,910 and $17,867, respectively.  The applicable interest rates on this debt ranged from 7.75 percent to 10 percent per annum.
 
Liquidity and Capital Resources
 
As of September 30, 2011, our working capital deficiency was $3,021,676, compared to a working capital deficiency of $2,852,175 as of December 31, 2010.  The stockholders’ deficit as of September 30, 2011 was $3,089,245, compared to $2,956,790 as of December 31, 2010.   
 
As a development stage company, we have had no revenues.  We will continue to require additional financing to fund operations and to continue to fund the research necessary to undertake our new business plans, to further the ongoing testing as previously described, and then to market a system for hospital and medical sterilization.  The Company entered into the Common Stock Purchase Agreement (“Stock Purchase Agreement”) with Mammoth Corporation (“Mammoth”), in November 2010, and established the equity line financing facility (or “Equity Line”).  We do not anticipate needing to draw the full amount of the Equity Line to implement our business plan and to develop and market our disinfection technologies.  We believe that we will need approximately $3 million during the year ending December 31, 2011 for continued research, development, marketing, and related activities, as well as for general corporate purposes, including final product development and initiation of sales.  Pursuant to the Stock Purchase Agreement, the frequency and amounts of draws are within our control.  We are not obligated to make any draws, and we may draw any amount up to the full amount of the Equity Line, in our discretion.  We do not plan to draw more funds (and correspondingly put more shares to Mammoth) under the Equity Line than is necessary to implement our business plan.
 
During the nine months ended September 30, 2011, we drew $886,606 (net of a one-time administrative fee of $4,300) on the Equity Line through the sale of 5,379,778 shares of common stock at prices ranging from $0.10875 to $0.192 per share (after consideration of the 25 percent discount required under the Stock Purchase Agreement).  During the nine months ended September 30, 2011, we also raised cash proceeds of $500,000 through the sale of 5,750,000 shares of common stock at prices ranging from $0.08 to $0.12 per share.  Of this amount, 125,000 shares were subscribed for at June 30, 2011 and were issued in July 2011.
 
We expect that additional funding during the next 12 months will come primarily from the Equity Line to continue our research and development activities and to sustain operations.  Also, we anticipate that we will be able to raise additional funds, if needed, from some of the same accredited investors who have purchased shares during previous years, although we have no agreements at this time with any of these investors and there is no assurance that these investors will purchase additional shares.
 
Our unaudited financial statements included in this report have been prepared on the assumption that the Company will continue as a going concern.  Through the date of this report, it has been necessary to rely upon financing from the sale of our equity securities to sustain operations as indicated above.  Additional financing will be required if we are to continue as a going concern.  If additional financing is not obtained in the near future, we will be required to curtail or discontinue operations, or seek protection under the bankruptcy laws.  Even if additional financing becomes available, there can be no assurance that it will be on terms favorable to the Company.  In any event, this additional financing will likely result in immediate and possibly substantial dilution to existing shareholders.
 
 
Critical Accounting Policies and Estimates
 
This Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  The preparation of such statements requires our management to make significant estimates and judgments that affect the reported amounts of assets, liabilities, and expenses.  By their nature, these judgments are subject to an inherent degree of uncertainty.  On an on-going basis, we evaluate these estimates, including those related to intangible assets, expenses, and income taxes.  We base our estimates on historical experience and other facts and circumstances that are believed to be reasonable, and the results form the basis for making judgments about the carrying value of assets and liabilities.  The actual results may differ from these estimates under different assumptions or conditions.
 
We account for equity securities issued for services rendered at the fair value of the securities on the date of grant.
 
Forward-Looking Statements and Risks Affecting the Company
 
The statements contained in this report on Form 10-Q that are not purely historical are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  These statements regard our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future.  They may be identified by the use of the words or phrases “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others. Forward-looking statements include, but are not limited to, statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs.  Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our Annual Report on Form 10-K for the year ended December 31, 2010. 
 
We believe that many of the risks previously discussed in our SEC filings are part of doing business in the industry in which we operate and compete and will likely be present in all periods reported.  The fact that certain risks are endemic to the industry does not lessen their significance.  The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements.  Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:
 
·  
Rigorous government scrutiny and regulation of our products and planned products;
·  
Potential effects of adverse publicity regarding ozone and related technologies or industries;
·  
Failure to sustain or manage growth including the failure to continue to develop new products; and
·  
The ability to obtain needed financing.
 
Outlook
 
The following discussion is intended to provide a brief overview of management’s plan moving forward with our AsepticSure™ product line as we transition our operations from research and development to production and sales.  The achievement of these plans is subject to risks and the following statements are subject to the cautionary statement under the caption “Forward-Looking Statements and Risks Affecting the Company” above.  Those risks include, but are not limited to the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, the existence of competitive products, an increasingly competitive environment for our technologies, successful testing and government regulatory issues as well as the outcome of various relationships with other companies that are still in the development stage at the time of this filing.
 
Final performance verification of the AsepticSure™ modular design, production-prototype disinfection system was recently achieved in testing at Medizone’s laboratories located in Innovation Park, Queens University, Kingston, Ontario, Canada.  As a result, we have determined that the system is now at a point that we are ready to pursue technology transfer and production ramp-up.
 
In anticipation of production ramp-up, Medizone representatives have met recently with several established electronic and medical device manufacturing firms that we believe would be capable of establishing manufacturing and supply lines for the AsepticSure™ system, and producing high quality production and support services for our products.  ADA Innovations, our current development partner, will continue to provide support with technology transfer into full production with partnering firms.  It is anticipated that our future production partner or partners will have the capacity to scale and ramp up production from small and modest levels to higher capacities over short periods of time if required.  High quality product service and support for our customers, following delivery, will also be expected of these partners.
 
We anticipate that we will be in a position to finalize an agreement for manufacturing during the fourth quarter of 2011; in which case we anticipate that the first “soft launch” of AsepticSure™ machines would take place by the end of the year.  The “soft launch” has now been expanded in terms of the number of units intended to be produced, and will include units suitable for additional in-hospital beta testing for both the United States and Canadian hospital market.  Another unit will be dedicated for bedbug testing in the United States with a major hotel chain after definitive agreements for such testing have been executed.  Early adopter units will also be produced to fill the pre-orders received for our system from the FIME Medical Purchasing Show which took place in August 2011.
 
 
The AsepticSure™ production design targets a lead-free, high level green content and system design intended to be globally acceptable to the most stringent regulatory and import licensing bodies.  Our original market penetration plan, initially targeted North America exclusively.  However, at the FIME Medical Purchasing Show in Miami, we received a very high level of interest in our system from many other parts of the world, particularly South America.  Hospital Acquired Infections (HAIs) such as Methicillin resistant Staphylococcus aureus (MRSA) appears to be of special concern in the region.
 
We have also received applications from potential distributors for our system from regions as varied as Malaysia, Indonesia, and the Middle East, as well as Central and South America.  In light of this expanded and strong interest from markets outside North America, we have revised our marketing plans and have identified qualified and experienced medical distribution companies to represent our product into certain sectors of South America, in addition to our originally planned markets in North America.  Each country and region has its own import and licensing regulations.  In this regard, management feels the prudent approach is to establish sales in regions of demonstrated interest where we believe demand may lead to increased sales in a reasonable period of time.  Pre-sales have also played a role in identifying our initial markets from a regulatory perspective.  We also have added New Zealand to our list as we have received initial pre-sale orders with deposits from New Zealand, as well as the United States.  Production units for these orders are scheduled for delivery during the first quarter of 2012.
 
While we anticipate achieving additional sales through a modest distribution system in 2012, our primary goal continues to be that of partnering with a much larger corporation that is globally established in the disinfection market for the sales and marketing of AsepticSure™.  We will negotiate our distribution arrangements with that primary objective in view and believe that our ability to achieve this primary objective will be enhanced by establishing increased production capability with established electronic and medical device manufacturers.  There is no assurance that we will accomplish our objective of partnering with a major multinational corporation as we intend or that we will be successful in establishing successful distribution arrangements.
 
Item 3.  Quantitative and Qualitative Disclosures About Market Risk
 
We are exposed to changes in prevailing market interest rates affecting the return on its investments but do not consider this interest rate market risk exposure to be material to our financial condition or results of operations.  We invest primarily in United States Treasury instruments with short-term (less than one year) maturities.  The carrying amount of these investments approximates fair value due to the short-term maturities.  Under current policies, we do not use derivative financial instruments, derivative commodity instruments or other financial instruments to manage our exposure to changes in interest rates or commodity prices.
 
Item 4.  Controls and Procedures
 
Evaluation of Disclosure Controls and Procedures
 
As of September 30, 2011, we updated our evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for purposes of filing reports under the Exchange Act.  This controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and our chief financial officer.  Our chief executive officer and our chief financial officer concluded that at September 30, 2011, our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) are effective to provide reasonable assurance that information that we are required to disclose in the reports that we file or submit to the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.  Our disclosure controls and procedures are designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
 
Changes in Internal Controls
 
We maintain a system of internal control over financial reporting that is designed to provide reasonable assurance that our books and records accurately reflect our transactions and that our established policies and procedures are followed.  There were no changes to our internal control over financial reporting during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 
PART II — OTHER INFORMATION
 
Item 1.  Legal Proceedings
 
There were no material developments during the quarter ended September 30, 2011 relative to the legal matters previously disclosed by the Company.
 
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds
 
Sales Under the Equity Line
 
During the nine months ended September 30, 2011, we sold a total of 5,379,778 shares of common stock pursuant to the Stock Purchase Agreement to Mammoth, for net cash proceeds totaling approximately $886,606 (after payment of one-time administrative fee of $4,300).  The sales to Mammoth were made pursuant to four separate “Draw Down Notices” issued by us under the Stock Purchase Agreement.  The first notice was effective February 11, 2011, for 582,065 shares and proceeds of $59,000, or approximately $0.10875 per share.  The second notice was effective May 18, 2011, for 1,583,771 shares and proceeds of $261,322, or approximately $0.165 per share.  The third notice was effective June 16, 2011, for 2,066,096 shares and proceeds of $396,690, or approximately $0.192 per share.  The fourth notice was effective September 6, 2011, for 1,147,846 shares and proceeds of $169,594, or approximately $0.14775 per share.
 
There were no underwriters involved in these purchases.  The proceeds of these transactions are used for general operating expenses and for the continuing development of the AsepticSure™ hospital disinfection system.  The sales to Mammoth were made without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(2) of the Securities Act for private and limited offers and sales of securities made to accredited investors, and the exemptions provided under Regulation D and Rule 506 under the Securities Act for private and limited offers and sales of securities made to accredited investors.
 
The resale of shares issued to Mammoth is registered under an effective registration statement filed by the Company under the Securities Act (File No. 333-171524).
 
Private Placements
 
During the three months ended March 31, 2011, we sold an aggregate of 1,000,000 restricted shares of common stock to two accredited investors for cash proceeds totaling $120,000, or $0.12 per share.  The purchasers of the shares were current shareholders of, but not otherwise affiliated with the Company.  There were no underwriters or public solicitation involved in the offer or sale of these securities.  The proceeds were used for general operating expenses and the continuing development of the AsepticSure™ hospital disinfection system.  The offer and sale of these securities was made without registration under the Securities Act in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(2) of the Securities Act for private and limited offers and sales of securities made solely to accredited investors.
 
During the three months ended June 30, 2011, we sold an aggregate of 4,625,000 restricted shares of common stock to a total of 14 accredited investors for cash proceeds totaling $370,000, or $0.08 per share.  The purchasers of the shares were current shareholders of, but not otherwise affiliated with the Company.  These common shares were sold on various dates beginning April 21, 2011 through June 3, 2011.  There were no underwriters or public solicitation involved in the offer or sale of these securities.  The proceeds were used for general operating expenses and the continuing development of the AsepticSure™ hospital disinfection system.  The offer and sale of these securities was made without registration under the Securities Act in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(2) of the Securities Act for private and limited offers and sales of securities made solely to accredited investors.
 
In June 2011, we sold 125,000 restricted shares of common stock to a single accredited investor for cash proceeds totaling $10,000, or $0.08 per share.  As of June 30, 2011, these shares were subscribed for, and were issued in July 2011.  The purchaser of the shares was a current shareholder of, but not otherwise affiliated with the Company.  There were no underwriters or public solicitation involved in the offer or sale of these securities.  The proceeds were used for general operating expenses and the continuing development of the AsepticSure™ hospital disinfection system.  The offer and sale of these securities was made without registration under the Securities Act in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(2) of the Securities Act for private and limited offers and sales of securities made solely to accredited investors.
 
 
Item 6.  Exhibits
 
Exhibit 31.1
Exhibit 31.2
Exhibit 32.1
Exhibit 32.2
101.INS**
XBRL Instance Document
101.SCH**
XBRL Taxonomy Extension Schema
101.CAL**
XBRL Taxonomy Extension Calculation Linkbase
101.DEF**
XBRL Taxonomy Extension Definition Linkbase
101.LAB**
XBRL Taxonomy Extension Label Linkbase
101.PRE**
XBRL Taxonomy Extension Presentation Linkbase

 
 

** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.
 
 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MEDIZONE INTERNATIONAL, INC.
(Registrant)
  
       
October 31, 2011
By:
/s/ Edwin G. Marshall
  
   
Edwin G. Marshall
  
   
Chairman and Chief Executive Officer
(Principal Executive Officer)
       
 
By:
/s/ Thomas (Tommy) E. Auger
  
   
Thomas (Tommy) E. Auger
  
   
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)
       
 
 


 EX-31.1 2 ex31-1.htm ex31-1.htm
Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Edwin G. Marshall, certify that:

(1)           I have reviewed this quarterly report on Form 10-Q of Medizone International, Inc. for the quarter ended September 30, 2011;
 
(2)           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
(4)           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5)           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2011

 
/s Edwin G. Marshall           
Edwin G. Marshall
Chief Executive Officer (Principal Executive Officer)
 EX-31.2 3 ex31-2.htm ex31-2.htm
Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Tommy E. Auger, certify that:

(1)           I have reviewed this quarterly report on Form 10-Q of Medizone International, Inc. for the quarter ended September 30, 2011;

(2)           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5)           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2011


/s/ Tommy E. Auger                    
Tommy E. Auger
Chief Financial Officer (Principal Accounting Officer)
 EX-32.1 4 ex32-1.htm ex32-1.htm
Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

I, Edwin G. Marshall, the Chief Executive Officer of Medizone International, Inc. (“Medizone”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i)           the accompanying Form 10-Q of Medizone for the quarter ended September 30, 2011 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)           the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Medizone.


/s/ Edwin G. Marshall               
Edwin G. Marshall
Chief Executive Officer (Principal Executive Officer)
Medizone International, Inc.

October 31, 2011
 EX-32.2 5 ex32-2.htm ex32-2.htm
Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

I, Tommy E. Auger, the Chief Financial Officer of Medizone International, Inc. (“Medizone”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i)           the accompanying Form 10-Q of Medizone for the quarter ended September 30, 2011 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)           the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Medizone.


/s/ Tommy E. Auger                   
Tommy E. Auger
Chief Financial Officer
(Principal Financial and Accounting Officer)

October 31, 2011
 EX-101.INS 6 mzei-20110930.xml 0000753772 2011-09-30 0000753772 2010-12-31 0000753772 1986-01-31 2011-09-30 0000753772 2011-07-01 2011-09-30 0000753772 2010-07-01 2010-09-30 0000753772 2011-01-01 2011-09-30 0000753772 2010-01-01 2010-09-30 0000753772 2009-12-31 0000753772 2010-09-30 0000753772 2011-10-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares 357432 435894 78736 8800 4500 63923 440668 508617 4428 1344 151733 117771 1122 1122 152855 118893 597951 628854 497440 451412 229204 228269 445270 427529 1963000 1964316 6000 40000 287430 283266 3462344 3360792 224852 224852 3687196 3585644 0 0 0.00001 0.00001 50000000 50000000 0 0 0 0 270492 259362 0.001 0.001 395000000 395000000 270491949 259362171 270491949 259362171 22991809 21593448 -23946 -8519 26327600 24801081 -3089245 -2956790 597951 628854 133349 103790 283730 1187936 712831 1580634 19125649 189688 485011 778982 776034 4939062 2092315 5390 2884 15796 5252 76310 48947 478808 1675831 1507609 2361920 26386073 -478808 -1675831 -1507609 -2361920 -26252724 208417 61514 -26091 19780 6232 5995 18910 17867 1160416 -125000 -6232 -5995 -18910 -17867 -969614 -485040 -1681826 -1526519 -2379787 -27222338 -479738 -415000 894738 -485040 -1681826 -1526519 -2379787 -26327600 -10466 63 -15427 -6236 -23946 -495506 -1681763 -1541946 -2386023 -26351546 0.00 -0.01 -0.01 -0.01 269632672 250143347 264562692 246780162 15735 5197 76166 1268213 4714741 59423 21211 196811 22886 249115 418098 693752 -603510 -62997 882 -113067 46963 -61169 1347521 16425 20900 3056293 40000 40000 -1388084 -875438 -14260624 48377 27710 101519 4404 48586 -52781 -27710 -150105 415000 2775 4055 201573 1129518 44658 6000 31191 439870 4300 10000 119612 14470 1390905 1198400 13100967 1377830 1184345 14792107 -15427 -6236 -23946 -78462 274961 357432 359891 634852 1212 125 31230 6939 6939 70303 301811 100000 100000 4373912 693752 67465 82215 Medizone International Inc 10-Q --12-31 270491949 false 0000753772 Yes No Smaller Reporting Company No 2011 Q3 2011-09-30 <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 1&#160; BASIS OF PRESENTATION</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The financial information included herein is unaudited and has been prepared consistent with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.&#160;&#160;Accordingly, these consolidated financial statements do not include all information and footnotes required by GAAP for complete consolidated financial statements.&#160;&#160;These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2010. &#160;In the opinion of management, these consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of results for the interim period presented.&#160;&#160;The results of operations for the three and nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for the full year.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Recent Accounting Pronouncements</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2010-06, <font style="FONT-STYLE: italic; DISPLAY: inline">Fair Value Measurements and Disclosures about Fair Value Measurements</font> (&#8220;ASU 2010-06).&#160;&#160;ASU 2010-06 affects all entities that are required to make disclosures about recurring and nonrecurring fair value measurements under FASB ASC Topic 820, originally issued as FASB Statement No. 157, <font style="FONT-STYLE: italic; DISPLAY: inline">Fair Value Measurements</font>. &#160;This ASU requires certain new disclosures and clarifies two existing disclosure requirements.&#160;&#160;The new disclosures and clarifications of existing disclosures are effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements. &#160;Those disclosures are effective for fiscal years beginning after December 15, 2010 and for interim periods within those fiscal years. &#160;The adoption of this new standard had no impact on the Company&#8217;s consolidated financial statements.</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 2&#160; CANADIAN FOUNDATION FOR GLOBAL HEALTH</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (&#8220;CFGH&#8221;), a not-for-profit foundation based in Ottawa, Canada. &#160;The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company&#8217;s technology to as many in need as possible.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accounting standards require a variable interest entity (&#8220;VIE&#8221;) to be consolidated by a company if that company absorbs a majority of the VIE&#8217;s expected losses and/or receives a majority of the entity&#8217;s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. &#160;In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. &#160;If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it. &#160;The Company determined that CFGH meets the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009.&#160;&#160;Accordingly, the financial condition and operations of CFGH are being consolidated with the Company as of September 30, 2011 and December 31, 2010 and for the three and nine months ended September 30, 2011 and 2010.</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 3&#160; BASIC LOSS PER SHARE</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The computations of basic loss per share of common stock are based on the weighted average number of common shares outstanding during the periods of the consolidated financial statements as follows:</font> </div><br/><table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="6" valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended</font> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2010</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td align="left" valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Numerator</font> </div> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Loss before extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(485,040</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,681,826</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Denominator (weighted average number of common shares outstanding)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,632,672</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250,143,347</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic loss per share</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Before extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.00</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.00</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$&#160;</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic Loss Per Share</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.00</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> </table><br/><table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="6" valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nine Months Ended</font> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2010</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr> <td align="left" valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Numerator</font> </div> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" colspan="2" valign="bottom" width="12%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Loss before extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,526,519</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,379,787</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Denominator (weighted average number of common shares outstanding)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">264,562,692</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">246,780,162</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic loss per share</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Before extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;- Extraordinary items</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.00</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.00</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic Loss Per Share</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font> </div> </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font> </div> </div> </td> </tr> </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 4&#160; GOING CONCERN</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s consolidated financial statements are prepared using GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. &#160;The Company has incurred significant losses from its inception through September 30, 2011, which have resulted in a deficit accumulated during the development stage of $26,327,600 as of September 30, 2011. &#160;The Company has funds sufficient to cover its operating costs for the next few months, has a working capital deficit of $3,021,676, and has relied exclusively on debt and equity financing.&#160;&#160;Accordingly, there is substantial doubt about its ability to continue as a going concern.&#160;&#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Continuation of the Company as a going concern is dependent upon obtaining additional funds and ultimately, upon the Company&#8217;s attaining profitable operations.&#160;&#160;The Company will require a substantial amount of additional funds to complete the development of its products, hospital beta testing, commercialization, and to fund additional losses, until revenues are sufficient to cover the Company&#8217;s operating expenses. If the Company were unsuccessful in any of the additional funding noted below, it would most likely be forced to substantially reduce or cease operations.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As discussed in Note 7, the Company entered into a Common Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) and established an equity line financing facility (or &#8220;Equity Line&#8221;). &#160;Management does not anticipate needing to draw the full amount of the Equity Line to implement our business plan and to develop and market its disinfection technologies.&#160;&#160;The Company believes that it will need approximately $3 million during the year ending December 31, 2011 for research, development, marketing, and related activities, as well as for general corporate purposes, including final product development and initiation of sales.&#160;&#160;Pursuant to the Stock Purchase Agreement with Mammoth Corporation (&#8220;Mammoth&#8221;), the frequency and amounts of draws are within the Company&#8217;s control.&#160;&#160;The Company is not obligated to make any draws, and the Company may draw any amount up to the full amount of the Equity Line, in its discretion.&#160;&#160;The Company does not plan to draw more funds (and correspondingly put more shares to Mammoth) under the Equity Line than is necessary to implement its business plan.&#160;&#160;During the nine months ended September 30, 2011, the Company drew $886,606 (net of a one-time administrative fee of $4,300 as discussed in Note 7) of the Equity Line through the issuance of 5,379,778 shares of common stock at prices ranging from $0.10875 to $0.192 per share (after consideration of the 25% discount as discussed in Note 7).&#160;&#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, during the nine months ended September 30, 2011, the Company raised a total of $500,000 through the sale of 5,750,000 shares of common stock as of September 30, 2011, at prices ranging from $0.08 to $0.12 per share.&#160;&#160;These funds, as well as the Equity Line funds, have been used to keep the Company current in its reporting obligations under the SEC Exchange Act of 1934 (&#8220;Exchange Act&#8221;) and to pay certain other corporate obligations including the final costs of development for the production version of its AsepticSure&#8482; hospital disinfection system.&#160;&#160;In addition, if the Company were to need additional resources outside the Equity Line, the Company believes the Company would be able to continue to raise additional funds from some of the same investors who have purchased shares previously, although the Company has no current agreements with these investors and there is no assurance given that these investors will in fact purchase additional shares.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.&#160;&#160;The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties.&#160;&#160;</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 5&#160; COMMITMENTS AND CONTINGENCIES</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is subject to certain claims and lawsuits arising in the normal course of business. &#160;In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company&#8217;s consolidated financial position, results of operations, or cash flows.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Litigation</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement. &#160;In September 2001, the parties agreed to settle the matter for $25,000. The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002. On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties. &#160;The Company has been unable to post the required bond amount as of the date of this report.&#160;&#160;Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of September 30, 2011 and December 31, 2010. The Company intends to contest the judgment if and when it is able to in the future.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Contingent Liabilities</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of September 30, 2011 and December 31, 2010, the Company has recorded contingent liabilities totaling $224,852 related to certain past due payables for which the Company has not received invoices or demands for over ten years.&#160;&#160;Although management of the Company does not believe that the amounts will ever be paid, the amounts are being recorded as contingent liabilities until such time as the Company is certain that no liability exists and until the statute of limitations has expired. &#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Operating Leases</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2009, the Company entered into a lease agreement and established its own certified laboratory located at Innovation Park, Queen&#8217;s University in Kingston, Ontario, Canada, which will provide a primary research and development platform for the Company as it proceeds towards commercialization of its products.&#160;&#160;The initial lease term expired on June 30, 2011, but has been extended to June 30, 2012, with a monthly lease payment increasing from $1,300 to $1,350 Canadian Dollars plus the applicable Goods and Services Tax (&#8220;GST&#8221;).&#160;&#160;A second laboratory space for full scale room testing also expired on June 30, 2011, but was extended to June 30, 2012, with a monthly lease payment increasing from $1,200 to $1,250 Canadian Dollars, plus the applicable GST.&#160;&#160;In March 2011, the Company also entered into a lease agreement and established its own corporate offices in California that includes a monthly lease payment of $2,500 U.S. Dollars and is renewable on a month to month basis following the initial lease term that ended in May 2011. &#160;This arrangement should allow the Company to expand its commercial offices even further, should that become necessary sooner than currently envisioned. &#160;</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 6&#160; COMMON STOCK WARRANTS AND OPTIONS</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrants</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All outstanding warrants were either exercised or expired unexercised prior to December 31, 2009, thus there are no warrants outstanding as of September 30, 2011 or December 31, 2010. &#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Options</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2011, the Company granted options for the purchase of 150,000 shares of common stock to an individual for accounting related services to be performed through December 30, 2011, which do not vest until such date.&#160;&#160;The options have an exercise price of $0.14 per share, and are exercisable for up to five years.&#160;&#160;The grant date fair value of these options was $20,042, in connection with which the Company recognized $6,380 and $13,731 of expense during the three and nine months ended September 30, 2011, respectively.&#160;&#160;The remaining $6,311 will be recognized between October 1, and December 30, 2011.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">In March 2011, the Company granted options for the purchase of 100,000 shares of common stock to an individual for web and press support services to be performed through December 30, 2011, which do not vest until such date. The options have an exercise price of $0.14 per share, and are exercisable for up to five years. &#160;The grant date fair value of these options was $13,361, in connection with which the Company recognized $4,254 and $9,155 of expense during the three and nine months ended September 30, 2011, respectively.&#160;&#160;The remaining $4,206 will be recognized between October 1, and December 30, 2011.</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March, 2010, the Company granted options for the purchase of 250,000 shares of common stock to an individual for research and development consulting services to be performed for the period of April 1, 2010 through September 30, 2010.&#160;&#160;The options have an exercise price of $0.19 per share, and are exercisable for up to five years.&#160;&#160;The grant date fair value of these options was $46,094, in connection with which the Company recognized $46,094 of expense during the nine months ended September 30, 2010.&#160;&#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2010, the Company granted options for the purchase of a total of 3,500,000 shares of common stock to certain board members and employees of the Company as additional compensation for work performed.&#160;&#160;These options have an exercise price of $0.20 per share, are exercisable for up to five years, but do not vest until the Company has achieved commercial sales.&#160;&#160;As of September 30, 2011, none of these options had vested.&#160;&#160;The grant date fair value of these options was $710,577, and will be recorded in the future once the Company has achieved commercial sales.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, in July 2010, the Company granted options for the purchase of 1,000,000 shares of common stock to a director of the Company in lieu of an actual stock grant for his services as a board member (see Note 7 for additional discussion on common shares issued to other board members for board service).&#160;&#160;These options have an exercise price of $0.20 per share, are exercisable for up to five years, and became fully vested on the date of the grant.&#160;&#160;The grant date fair value of these options was $203,021 and has been recorded as board compensation for the nine months ended September 30, 2010.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2010, the Company granted options for the purchase of 250,000 shares of common stock to an outside consultant for patent work performed on behalf of the Company.&#160;&#160;These options have an exercise price of $0.27 per share, are exercisable for up to five years, and had no vesting provisions.&#160;&#160;The grant date fair value of these options was 67,465 and has been capitalized to patent costs as of September 30, 2010, which costs are being amortized over the expected life of the patent.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to an outside consultant in connection with extending his consulting agreement with the Company through September 1, 2011.&#160;&#160;These options have an exercise price of $0.275 per share, are exercisable for up to five years, but do not vest until the Company has achieved commercialization and sales of the AsepticSure&#8482; product.&#160;&#160;As of September 30, 2011, none of these options had vested.&#160;&#160;The grant date fair value of these options was $65,067, and will be recorded in the future once the Company has achieved the required commercial sales.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the nine months ended September 30, 2011, the Company estimated the fair value of the stock options at the date of the grant, based on the following weighted average assumptions:</font> </div><br/><table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="61%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk-free interest rate</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.43</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="61%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected life</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5 years</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="61%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176.45</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font> </div> </div> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="61%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dividend yield</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.00</font> </div> </div> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font> </div> </div> </td> </tr> </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A summary of the status of the Company&#8217;s outstanding options as of September 30, 2011 and changes during the nine months ended is presented below:</font> </div><br/><table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="47%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted Average Exercise Price</font> </div> </td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, beginning of period</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,750,000</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.17</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250,000</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.14</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired/Canceled</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">n/a</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">n/a</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: #CCEEFF;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, end of period</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,000,000</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.17</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> <tr style="background-color: white;"> <td valign="bottom" width="47%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,000,000</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> <td valign="bottom" width="1%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font> </div> </div> </td> <td valign="bottom" width="11%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.16</font> </div> </div> </td> <td valign="bottom" width="1%"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font> </td> </tr> </table><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company estimates the fair value of each stock award by using the Black-Scholes option pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company&#8217;s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes model is zero. &#160;Under the provisions of this accounting standard, additional expense of $22,886 and $249,115 was recorded for the nine months ended September 30, 2011 and 2010, respectively, using the Black-Scholes option pricing model.&#160;&#160;An additional amount of $67,465 has been capitalized as patent costs as of September 30, 2010, as previously mentioned, which costs are being amortized over the expected useful life of the patents.&#160;&#160;&#160;&#160;</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 7&#160; STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock for Cash &#8211; For the Nine Months Ended September 30, 2011</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During February 2011, the Company issued 582,065 shares of common stock to Mammoth, an accredited investor (as part of the Equity Line), for cash proceeds of $59,000 (net of $4,300 of stock issuance costs) at a price of $0.10875 per share.&#160;&#160;There were no underwriters involved. &#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During March 2011, the Company sold an aggregate of 1,000,000 restricted shares of common stock that were subscribed for as of March 31, 2011 and issued in April 2011.&#160;&#160;The purchasers of these shares were two accredited investors, not otherwise affiliated with the Company.&#160;&#160;The Company received cash proceeds of $120,000, or $0.12 per share in connection with these sales.&#160;&#160;There were no underwriters involved.&#160;&#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During April and May 2011, the Company issued 3,649,867 shares of common stock to Mammoth (as part of the Equity Line) for cash proceeds of $658,012.&#160;&#160;The sales were made pursuant to two separate &#8220;Draw Down Notices&#8221; issued by the Company under the Stock Purchase Agreement. The first notice was effective May 18, 2011, for 1,583,771 shares and proceeds of $261,322, or approximately $0.165 per share. &#160;The second notice was effective June 16, 2011, for 2,066,096 shares and proceeds of $396,690, or approximately $0.192 per share.&#160;&#160;There were no underwriters involved.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During April, May and June 2011, the Company sold an aggregate of 4,625,000 restricted shares of common stock, to accredited investors, not otherwise affiliated with the Company, for cash proceeds of $370,000 at a price of $0.08 per share.&#160;&#160;There were no underwriters involved.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During June 2011, the Company entered into a transaction, with an accredited investor not otherwise affiliated with the Company, for 125,000 restricted shares of common stock that were subscribed for as of June 30, 2011 and issued in July 2011, for cash proceeds of $10,000 at a price of $0.08 per share.&#160;&#160;There were no underwriters involved.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During September 2011, the Company issued 1,147,846 shares of common stock to Mammoth (as part of the Equity Line) for cash proceeds of $169,594, at a price of $0.14775 per share.&#160;&#160;There were no underwriters involved.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Common Stock for Cash &#8211; For the Nine Months Ended September 30, 2010</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In January and February 2010, the Company issued an aggregate of 500,000 shares of common stock, for cash proceeds totaling $125,000, or $0.25 per share. &#160;The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company. &#160;There were no underwriters involved.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April, May and June 2010, the Company issued an aggregate of 3,622,777 shares of common stock for cash proceeds totaling $441,400, at prices ranging from $0.12 to $0.18 per share. &#160;The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company. &#160;The Company also paid stock offering costs to an investment firm of $10,000 who assisted the Company in raising these funds. &#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July, August and September 2010, the Company issued an aggregate of 5,266,666 shares of common stock for cash proceeds totaling $632,000, at prices ranging from $0.12 to $0.18 per share. &#160;The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.&#160;&#160;There were no underwriters involved.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Restricted Stock for Services &#8211;For the Nine Months Ended September 30, 2010</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, the Company issued a total of 137,000 restricted shares of common stock to two consultants for consulting, marketing, and web support services valued at $39,730, or $0.29 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares. &#160;Both consulting agreements were based on a term through June 30, 2010, the shares vested in equal increments, and the consulting expense was recognized over the same period during 2010 ($15,891 as stock issued for services and $23,839 as amortization of deferred consulting expense).</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2010, the Company issued 250,000 restricted shares of common stock to a consulting firm for investor relation services valued at $47,500, or $0.19 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares. &#160;The consulting agreement was based on a term through June 30, 2010, the shares vested in equal increments, and the consulting expense was recognized over the same period during 2010.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In April 2010, the Company issued 120,000 restricted shares of common stock in lieu of outstanding consulting fees valued at $22,800, or $0.19 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;These shares had no vesting requirements.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, in April 2010, the Company issued 588,235 restricted shares of common stock in satisfaction of a one-year contract with an investment firm to assist the Company in raising required capital, valued at $100,000, or $0.17 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;The Company recognized this as a stock issuance cost at the date of issuance and such shares had no vesting requirements.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In July 2010, the Company issued 135,000 shares of restricted common stock to an investor relations company pursuant to a one-year agreement through July 15, 2011 valued at $25,650, or $0.19 per share, which represents the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;The shares vest in equal increments and the expense is to be recorded over the period of the agreement.&#160;&#160;The Company recognized consulting expense of $13,894 and $5,343 during the nine months ended September 30, 2011 and 2010, respectively.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, in July 2010, the Company issued a total of 4,000,000 shares of restricted common stock to certain directors and officers for board service and performance bonuses valued at a total of $840,000, or $0.21 per share, which represents the market value of the shares on the date that the disinterested members of the Board authorized the issuance of the shares.&#160;&#160;The value of the shares, or $840,000, was recorded as director compensation and bonus expense for the nine months ended September 30, 2010.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In August 2010, the Company issued a total of 225,000 shares of restricted common stock to two consultants for consulting, marketing, and web support services valued at a total of $60,750, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;The first agreement was for the period of July 15, 2010 through March 31, 2011.&#160;&#160;The second agreement was for the period of August 26, 2010 through August 26, 2011.&#160;&#160;For both agreements, the shares vest in equal increments and the consulting expense is recognized over the period of the contracts.&#160;&#160;The Company recognized consulting expense of $32,029 and $10,754 during the nine months ended September 30, 2011 and 2010, respectively.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Also, in August 2010, the Company issued 118,839 shares of restricted common stock to a consultant in lieu of outstanding consulting fees valued at $32,087, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;An additional 1,000,000 shares of restricted common stock were issued to this same consultant on September 1, 2010, as bonus compensation for extending his consulting agreement through September 1, 2011, valued at $270,000, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;The entire amount was recorded as bonus compensation during the nine months ended September 30, 2010.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2010, the Company issued 100,000 shares of restricted common stock to an individual, as part of a web services and media representation consulting agreement, valued at $18,000, or $0.18 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.&#160;&#160;The consulting agreement is for the year of 2011.&#160;&#160;The Company recognized consulting expense of $13,500 during the nine months ended September 30, 2011.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Stock Purchase Agreement</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In November 2010, the Company entered into the Stock Purchase Agreement with Mammoth providing for the Equity Line.&#160;&#160;The Stock Purchase Agreement provides that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth is committed to purchase up to $10,000,000 of shares of our common stock over the 24-month term of the Stock Purchase Agreement under certain specified conditions and limitations.&#160;&#160;Furthermore, in no event may Mammoth purchase any shares of the Company&#8217;s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9 percent of the then outstanding shares of the Company&#8217;s common stock.&#160;&#160;These maximum share and beneficial ownership limitations may not be waived by the parties.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the Stock Purchase Agreement, the Company has the opportunity for a 24-month period, commencing on the date on which the SEC first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock.&#160;&#160;For each share of common stock purchased under the Stock Purchase Agreement, Mammoth will pay to the Company a purchase price equal to 75 percent of the lowest closing bid price during the five consecutive trading day period (the &#8220;Draw Down Pricing Period&#8221;) preceding the date a draw down notice (the &#8220;Draw Down Notice&#8221;) is delivered by the Company to Mammoth (the &#8220;Draw Down Date&#8221;) in a manner provided by the Stock Purchase Agreement. &#160;Subject to the limitations outlined below, the Company may, at its sole discretion, issue a Draw Down Notice to Mammoth, and Mammoth will then be irrevocably bound to purchase such shares.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each Draw Down Notice must specify the lowest purchase price during the Draw Down Pricing Period at which the Company will sell the shares to Mammoth, which shall not be less than 75 percent of the lowest closing bid price during the Draw Down Pricing Period. Furthermore, the number of shares to be issued is limited by multiplying by five the average daily trading volume for the 30 trading days immediately preceding the delivery of the Draw Down Notice.&#160;&#160;The Draw Down Notice will also include the aggregate dollar amount of the Draw Down, which will not be less than $25,000 and not more than $500,000 in any Draw Down Notice. &#160;There must be a minimum of 15 trading days between each Draw Down Notice.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company agreed to pay up to $5,000 (of which the Company paid $4,300 during the nine months ended September 30, 2011 to fully satisfy this obligation) of reasonable attorneys&#8217; fees and expenses (exclusive of disbursements and out-of-pocket expenses) incurred by Mammoth in connection with the preparation, negotiation, execution and delivery of the Stock Purchase Agreement and related transaction documentation.&#160;&#160;Further, if the Company issues a Draw Down Notice and fails to deliver the shares to Mammoth on the applicable settlement date, and such failure continues for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery is late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery is late. &#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the Stock Purchase Agreement, the Company granted registration rights to Mammoth, and agreed to register the resale of shares issued to Mammoth in connection with Draw Downs made in connection with the Stock Purchase Agreement.&#160;&#160;In January 2011, the Company filed a registration statement to cover the resale by Mammoth of up to 66,666,667 shares of our common stock under the Stock Purchase Agreement. &#160;The Company is not permitted to make Draw Downs under the Stock Purchase Agreement at any time there is not an effective registration statement registering the resale of shares of common stock by Mammoth. &#160;On January 25, 2011, the registration statement was declared effective by the SEC. &#160;The Company has agreed to file all necessary post-effective amendments to the registration statement under applicable SEC rules and regulations in order to keep the registration statement currently effective. &#160;As previously mentioned, the Company has made four Draw Down request under the Stock purchase Agreement during the nine months ended September 30, 2011.&#160;&#160;</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Stock Purchase Agreement may be terminated at any time by the mutual written consent of the parties.&#160;&#160;Unless earlier terminated, the Stock Purchase Agreement will terminate automatically on the 24-month anniversary of the effective date of the registration statement (which term may not be extended by the parties).</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">ADA Innovations</font></font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2010, the Company reached an agreement with ADA Innovations (&#8220;ADA&#8221;) for final development and production manufacturing of portable versions of the Company&#8217;s AsepticSure&#8482; disinfection systems. &#160;A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, BiOzone Corporation will remain involved as a development support partner and manufacturer of laboratory equipment, and will assist, as requested, in construction of permanent installations for large-scale industrial applications. &#160;Any and all notes, reports, information, inventions, sketches, plans concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company. &#160;The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement. &#160;Deliverables will include: (1) the pre-production prototype designed and manufactured to our specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties.&#160;&#160;The Company will pay ADA as services are provided.&#160;&#160;During the three and nine months ended September 30, 2011, the Company incurred expenses totaling approximately $156,000 and $482,000, respectively, for services provided under the Services Agreement.&#160;&#160;Of these amounts, approximately $138,000 and $466,000 were recorded as research and development costs in the three and nine months ended September 30, 2011, respectively.</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 8&#160; DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE &#8211; RELATED PARTIES</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In previous years, certain directors had advanced a total of $7,000 to the Company to cover operating expenses. &#160;During 2010, the Company repaid $1,000 leaving $6,000 outstanding as of December 31, 2010 which was non-interest bearing, unsecured and due on demand.&#160;&#160;During the nine months ended September 30, 2011, the remaining $6,000 was repaid.</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of September 30, 2011 and December 31, 2010, the Company had outstanding $229,204 and $228,269, respectively, owed to certain employees for unpaid services in previous years. These employees are shareholders of the Company and therefore have been classified as related parties.</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 9&#160; CUSTOMER DEPOSITS</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of September 30, 2011, the Company received two purchase orders and related customer deposits totaling $40,000 to purchase the AsepticSure&#8482; disinfection systems.&#160;&#160;The company anticipates deliveries of its first disinfection systems early in 2012.&#160;&#160;As of September 30, 2011, these customer deposits have been reflected as current liabilities in the accompanying consolidated balance sheet.</font> </div><br/> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NOTE 10&#160; SUBSEQUENT EVENTS</font> </div><br/><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has evaluated subsequent events per the requirements of ASC Topic 855 and has concluded that there are no events to be reported.</font> </div><br/> EX-101.SCH 7 mzei-20110930.xsd 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - NOTE 1 BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - NOTE 3 BASIC LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - NOTE 4 GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - NOTE 5 COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - NOTE 6 COMMON STOCK WARRANTS AND OPTIONS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - NOTE 8 DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE - RELATED PARTIES link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - NOTE 9 CUSTOMER DEPOSITS link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - NOTE 10 SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 mzei-20110930_cal.xml EX-101.DEF 9 mzei-20110930_def.xml EX-101.LAB 10 mzei-20110930_lab.xml EX-101.PRE 11 mzei-20110930_pre.xml XML 12 R3.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Balance Sheets (Parentheticals) (USD $)
Sep. 30, 2011
Dec. 31, 2010
Preferred stock par value (in Dollars per share)$ 0.00001$ 0.00001
Preferred stock, shares authorized50,000,00050,000,000
Preferred stock, shares issued00
Preferred stock, shares outstanding00
Common stock par value (in Dollars per share)$ 0.001$ 0.001
Common stock, shares authorized395,000,000395,000,000
Common stock, shares issued270,491,949259,362,171
Common stock, shares outstanding270,491,949259,362,171
 XML 13 R4.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) (USD $)
3 Months Ended9 Months Ended312 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
REVENUES    $ 133,349
EXPENSES     
Cost of sales    103,790
General and administrative283,7301,187,936712,8311,580,63419,125,649
Research and development189,688485,011778,982776,0344,939,062
Expense on extension of warrants    2,092,315
Depreciation and amortization5,3902,88415,7965,25276,310
Bad debt expense    48,947
Total Expenses478,8081,675,8311,507,6092,361,92026,386,073
Loss from Operations(478,808)(1,675,831)(1,507,609)(2,361,920)(26,252,724)
OTHER INCOME (EXPENSES)     
Gain on sale of subsidiaries    208,417
Debt forgiveness    61,514
Non-controlling interest in loss    26,091
Other income    19,780
Interest expense(6,232)(5,995)(18,910)(17,867)(1,160,416)
Loss on termination of license agreement    (125,000)
Total Other Expenses(6,232)(5,995)(18,910)(17,867)(969,614)
LOSS BEFORE EXTRAORDINARY ITEMS(485,040)(1,681,826)(1,526,519)(2,379,787)(27,222,338)
EXTRAORDINARY ITEMS     
Debt forgiveness    479,738
Lawsuit settlement    415,000
Total Extraordinary Items    894,738
NET LOSS(485,040)(1,681,826)(1,526,519)(2,379,787)(26,327,600)
OTHER COMPREHENSIVE LOSS     
(Loss) gain on foreign currency translation(10,466)63(15,427)(6,236)(23,946)
TOTAL COMPREHENSIVE LOSS$ (495,506)$ (1,681,763)$ (1,541,946)$ (2,386,023)$ (26,351,546)
BASIC LOSS PER SHARE (in Dollars per share)$ 0.00$ (0.01)$ (0.01)$ (0.01) 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (in Shares)269,632,672250,143,347264,562,692246,780,162 
 XML 14 R1.htm IDEA: XBRL DOCUMENT v2.3.0.15
Document And Entity Information
9 Months Ended
Sep. 30, 2011
Oct. 31, 2011
Document and Entity Information [Abstract]  
Entity Registrant NameMedizone International Inc 
Document Type10-Q 
Current Fiscal Year End Date--12-31 
Entity Common Stock, Shares Outstanding 270,491,949
Amendment Flagfalse 
Entity Central Index Key0000753772 
Entity Current Reporting StatusYes 
Entity Voluntary FilersNo 
Entity Filer CategorySmaller Reporting Company 
Entity Well-known Seasoned IssuerNo 
Document Period End DateSep. 30, 2011
Document Fiscal Year Focus2011 
Document Fiscal Period FocusQ3 
 XML 15 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 16 R12.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS
9 Months Ended
Sep. 30, 2011
Stockholders' Equity Note Disclosure [Text Block]
NOTE 7  STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

Common Stock for Cash – For the Nine Months Ended September 30, 2011

During February 2011, the Company issued 582,065 shares of common stock to Mammoth, an accredited investor (as part of the Equity Line), for cash proceeds of $59,000 (net of $4,300 of stock issuance costs) at a price of $0.10875 per share.  There were no underwriters involved.  

During March 2011, the Company sold an aggregate of 1,000,000 restricted shares of common stock that were subscribed for as of March 31, 2011 and issued in April 2011.  The purchasers of these shares were two accredited investors, not otherwise affiliated with the Company.  The Company received cash proceeds of $120,000, or $0.12 per share in connection with these sales.  There were no underwriters involved.  

During April and May 2011, the Company issued 3,649,867 shares of common stock to Mammoth (as part of the Equity Line) for cash proceeds of $658,012.  The sales were made pursuant to two separate “Draw Down Notices” issued by the Company under the Stock Purchase Agreement. The first notice was effective May 18, 2011, for 1,583,771 shares and proceeds of $261,322, or approximately $0.165 per share.  The second notice was effective June 16, 2011, for 2,066,096 shares and proceeds of $396,690, or approximately $0.192 per share.  There were no underwriters involved.

During April, May and June 2011, the Company sold an aggregate of 4,625,000 restricted shares of common stock, to accredited investors, not otherwise affiliated with the Company, for cash proceeds of $370,000 at a price of $0.08 per share.  There were no underwriters involved.

During June 2011, the Company entered into a transaction, with an accredited investor not otherwise affiliated with the Company, for 125,000 restricted shares of common stock that were subscribed for as of June 30, 2011 and issued in July 2011, for cash proceeds of $10,000 at a price of $0.08 per share.  There were no underwriters involved.

During September 2011, the Company issued 1,147,846 shares of common stock to Mammoth (as part of the Equity Line) for cash proceeds of $169,594, at a price of $0.14775 per share.  There were no underwriters involved.

Common Stock for Cash – For the Nine Months Ended September 30, 2010

In January and February 2010, the Company issued an aggregate of 500,000 shares of common stock, for cash proceeds totaling $125,000, or $0.25 per share.  The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.  There were no underwriters involved.

In April, May and June 2010, the Company issued an aggregate of 3,622,777 shares of common stock for cash proceeds totaling $441,400, at prices ranging from $0.12 to $0.18 per share.  The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.  The Company also paid stock offering costs to an investment firm of $10,000 who assisted the Company in raising these funds.  

In July, August and September 2010, the Company issued an aggregate of 5,266,666 shares of common stock for cash proceeds totaling $632,000, at prices ranging from $0.12 to $0.18 per share.  The shares were issued in private transactions to accredited investors not otherwise affiliated with the Company.  There were no underwriters involved.

Restricted Stock for Services –For the Nine Months Ended September 30, 2010

In February 2010, the Company issued a total of 137,000 restricted shares of common stock to two consultants for consulting, marketing, and web support services valued at $39,730, or $0.29 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  Both consulting agreements were based on a term through June 30, 2010, the shares vested in equal increments, and the consulting expense was recognized over the same period during 2010 ($15,891 as stock issued for services and $23,839 as amortization of deferred consulting expense).

In March 2010, the Company issued 250,000 restricted shares of common stock to a consulting firm for investor relation services valued at $47,500, or $0.19 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The consulting agreement was based on a term through June 30, 2010, the shares vested in equal increments, and the consulting expense was recognized over the same period during 2010.

In April 2010, the Company issued 120,000 restricted shares of common stock in lieu of outstanding consulting fees valued at $22,800, or $0.19 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  These shares had no vesting requirements.

Also, in April 2010, the Company issued 588,235 restricted shares of common stock in satisfaction of a one-year contract with an investment firm to assist the Company in raising required capital, valued at $100,000, or $0.17 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The Company recognized this as a stock issuance cost at the date of issuance and such shares had no vesting requirements.

In July 2010, the Company issued 135,000 shares of restricted common stock to an investor relations company pursuant to a one-year agreement through July 15, 2011 valued at $25,650, or $0.19 per share, which represents the market value of the shares on the date that the Board authorized the issuance of the shares.  The shares vest in equal increments and the expense is to be recorded over the period of the agreement.  The Company recognized consulting expense of $13,894 and $5,343 during the nine months ended September 30, 2011 and 2010, respectively.

Also, in July 2010, the Company issued a total of 4,000,000 shares of restricted common stock to certain directors and officers for board service and performance bonuses valued at a total of $840,000, or $0.21 per share, which represents the market value of the shares on the date that the disinterested members of the Board authorized the issuance of the shares.  The value of the shares, or $840,000, was recorded as director compensation and bonus expense for the nine months ended September 30, 2010.

In August 2010, the Company issued a total of 225,000 shares of restricted common stock to two consultants for consulting, marketing, and web support services valued at a total of $60,750, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The first agreement was for the period of July 15, 2010 through March 31, 2011.  The second agreement was for the period of August 26, 2010 through August 26, 2011.  For both agreements, the shares vest in equal increments and the consulting expense is recognized over the period of the contracts.  The Company recognized consulting expense of $32,029 and $10,754 during the nine months ended September 30, 2011 and 2010, respectively.

Also, in August 2010, the Company issued 118,839 shares of restricted common stock to a consultant in lieu of outstanding consulting fees valued at $32,087, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  An additional 1,000,000 shares of restricted common stock were issued to this same consultant on September 1, 2010, as bonus compensation for extending his consulting agreement through September 1, 2011, valued at $270,000, or $0.27 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The entire amount was recorded as bonus compensation during the nine months ended September 30, 2010.

In December 2010, the Company issued 100,000 shares of restricted common stock to an individual, as part of a web services and media representation consulting agreement, valued at $18,000, or $0.18 per share, which represented the market value of the shares on the date that the Board authorized the issuance of the shares.  The consulting agreement is for the year of 2011.  The Company recognized consulting expense of $13,500 during the nine months ended September 30, 2011.

Stock Purchase Agreement

In November 2010, the Company entered into the Stock Purchase Agreement with Mammoth providing for the Equity Line.  The Stock Purchase Agreement provides that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth is committed to purchase up to $10,000,000 of shares of our common stock over the 24-month term of the Stock Purchase Agreement under certain specified conditions and limitations.  Furthermore, in no event may Mammoth purchase any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9 percent of the then outstanding shares of the Company’s common stock.  These maximum share and beneficial ownership limitations may not be waived by the parties.

Under the terms of the Stock Purchase Agreement, the Company has the opportunity for a 24-month period, commencing on the date on which the SEC first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock.  For each share of common stock purchased under the Stock Purchase Agreement, Mammoth will pay to the Company a purchase price equal to 75 percent of the lowest closing bid price during the five consecutive trading day period (the “Draw Down Pricing Period”) preceding the date a draw down notice (the “Draw Down Notice”) is delivered by the Company to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement.  Subject to the limitations outlined below, the Company may, at its sole discretion, issue a Draw Down Notice to Mammoth, and Mammoth will then be irrevocably bound to purchase such shares.

Each Draw Down Notice must specify the lowest purchase price during the Draw Down Pricing Period at which the Company will sell the shares to Mammoth, which shall not be less than 75 percent of the lowest closing bid price during the Draw Down Pricing Period. Furthermore, the number of shares to be issued is limited by multiplying by five the average daily trading volume for the 30 trading days immediately preceding the delivery of the Draw Down Notice.  The Draw Down Notice will also include the aggregate dollar amount of the Draw Down, which will not be less than $25,000 and not more than $500,000 in any Draw Down Notice.  There must be a minimum of 15 trading days between each Draw Down Notice.

The Company agreed to pay up to $5,000 (of which the Company paid $4,300 during the nine months ended September 30, 2011 to fully satisfy this obligation) of reasonable attorneys’ fees and expenses (exclusive of disbursements and out-of-pocket expenses) incurred by Mammoth in connection with the preparation, negotiation, execution and delivery of the Stock Purchase Agreement and related transaction documentation.  Further, if the Company issues a Draw Down Notice and fails to deliver the shares to Mammoth on the applicable settlement date, and such failure continues for 10 trading days, the Company agreed to pay Mammoth, in addition to all other remedies available to Mammoth under the Stock Purchase Agreement, an amount in cash equal to $100 for each $5,000 of the Draw Down Amount for the first 10 days such delivery is late, and $350 for each $5,000 of the Draw Down Amount for each trading day beyond 10 trading days that such delivery is late.  

In connection with the Stock Purchase Agreement, the Company granted registration rights to Mammoth, and agreed to register the resale of shares issued to Mammoth in connection with Draw Downs made in connection with the Stock Purchase Agreement.  In January 2011, the Company filed a registration statement to cover the resale by Mammoth of up to 66,666,667 shares of our common stock under the Stock Purchase Agreement.  The Company is not permitted to make Draw Downs under the Stock Purchase Agreement at any time there is not an effective registration statement registering the resale of shares of common stock by Mammoth.  On January 25, 2011, the registration statement was declared effective by the SEC.  The Company has agreed to file all necessary post-effective amendments to the registration statement under applicable SEC rules and regulations in order to keep the registration statement currently effective.  As previously mentioned, the Company has made four Draw Down request under the Stock purchase Agreement during the nine months ended September 30, 2011.  

The Stock Purchase Agreement may be terminated at any time by the mutual written consent of the parties.  Unless earlier terminated, the Stock Purchase Agreement will terminate automatically on the 24-month anniversary of the effective date of the registration statement (which term may not be extended by the parties).

ADA Innovations

In December 2010, the Company reached an agreement with ADA Innovations (“ADA”) for final development and production manufacturing of portable versions of the Company’s AsepticSure™ disinfection systems.  A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011.

In addition, BiOzone Corporation will remain involved as a development support partner and manufacturer of laboratory equipment, and will assist, as requested, in construction of permanent installations for large-scale industrial applications.  Any and all notes, reports, information, inventions, sketches, plans concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company.  The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement.  Deliverables will include: (1) the pre-production prototype designed and manufactured to our specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties.  The Company will pay ADA as services are provided.  During the three and nine months ended September 30, 2011, the Company incurred expenses totaling approximately $156,000 and $482,000, respectively, for services provided under the Services Agreement.  Of these amounts, approximately $138,000 and $466,000 were recorded as research and development costs in the three and nine months ended September 30, 2011, respectively.

XML 17 R8.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 3 BASIC LOSS PER SHARE
9 Months Ended
Sep. 30, 2011
Earnings Per Share [Text Block]
NOTE 3  BASIC LOSS PER SHARE

The computations of basic loss per share of common stock are based on the weighted average number of common shares outstanding during the periods of the consolidated financial statements as follows:

   
For the Three Months Ended
September 30,
 
   
2011
   
2010
 
Numerator
           
 - Loss before extraordinary items
 
$
(485,040
)
 
$
(1,681,826
)
 - Extraordinary items
   
-
     
-
 
 Denominator (weighted average number of common shares outstanding)
   
269,632,672
     
250,143,347
 
Basic loss per share
               
 - Before extraordinary items
 
$
(0.00
)
 
$
(0.01
)
 - Extraordinary items
 
$
(0.00
)
 
$ 
0.00
 
Basic Loss Per Share
 
$
(0.00
)
 
$
(0.01
)

   
For the Nine Months Ended
September 30,
 
   
2011
   
2010
 
Numerator
           
 - Loss before extraordinary items
 
$
(1,526,519
)
 
$
(2,379,787
)
 - Extraordinary items
   
-
     
-
 
                 
Denominator (weighted average number of common shares outstanding)
   
264,562,692
     
246,780,162
 
                 
Basic loss per share
               
 - Before extraordinary items
 
$
(0.01
)
 
$
(0.01
)
 - Extraordinary items
 
$
(0.00
)
 
$
(0.00
)
Basic Loss Per Share
 
$
(0.01
)
 
$
(0.01
)

Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the periods presented.

XML 18 R14.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 9 CUSTOMER DEPOSITS
9 Months Ended
Sep. 30, 2011
Other Liabilities Disclosure [Text Block]
NOTE 9  CUSTOMER DEPOSITS

As of September 30, 2011, the Company received two purchase orders and related customer deposits totaling $40,000 to purchase the AsepticSure™ disinfection systems.  The company anticipates deliveries of its first disinfection systems early in 2012.  As of September 30, 2011, these customer deposits have been reflected as current liabilities in the accompanying consolidated balance sheet.

XML 19 R15.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 10 SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2011
Subsequent Events [Text Block]
NOTE 10  SUBSEQUENT EVENTS

The Company has evaluated subsequent events per the requirements of ASC Topic 855 and has concluded that there are no events to be reported.

XML 20 R13.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 8 DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE - RELATED PARTIES
9 Months Ended
Sep. 30, 2011
Related Party Transactions Disclosure [Text Block]
NOTE 8  DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE – RELATED PARTIES

In previous years, certain directors had advanced a total of $7,000 to the Company to cover operating expenses.  During 2010, the Company repaid $1,000 leaving $6,000 outstanding as of December 31, 2010 which was non-interest bearing, unsecured and due on demand.  During the nine months ended September 30, 2011, the remaining $6,000 was repaid.

As of September 30, 2011 and December 31, 2010, the Company had outstanding $229,204 and $228,269, respectively, owed to certain employees for unpaid services in previous years. These employees are shareholders of the Company and therefore have been classified as related parties.

XML 21 R6.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 1 BASIS OF PRESENTATION
9 Months Ended
Sep. 30, 2011
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
NOTE 1  BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, these consolidated financial statements do not include all information and footnotes required by GAAP for complete consolidated financial statements.  These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2010.  In the opinion of management, these consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of results for the interim period presented.  The results of operations for the three and nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for the full year.

Recent Accounting Pronouncements

The Financial Accounting Standards Board (“FASB”) has issued Accounting Standards Update (“ASU”) No. 2010-06, Fair Value Measurements and Disclosures about Fair Value Measurements (“ASU 2010-06).  ASU 2010-06 affects all entities that are required to make disclosures about recurring and nonrecurring fair value measurements under FASB ASC Topic 820, originally issued as FASB Statement No. 157, Fair Value Measurements.  This ASU requires certain new disclosures and clarifies two existing disclosure requirements.  The new disclosures and clarifications of existing disclosures are effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements.  Those disclosures are effective for fiscal years beginning after December 15, 2010 and for interim periods within those fiscal years.  The adoption of this new standard had no impact on the Company’s consolidated financial statements.

XML 22 R9.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 4 GOING CONCERN
9 Months Ended
Sep. 30, 2011
Liquidity Disclosure [Policy Text Block]
NOTE 4  GOING CONCERN

The Company’s consolidated financial statements are prepared using GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through September 30, 2011, which have resulted in a deficit accumulated during the development stage of $26,327,600 as of September 30, 2011.  The Company has funds sufficient to cover its operating costs for the next few months, has a working capital deficit of $3,021,676, and has relied exclusively on debt and equity financing.  Accordingly, there is substantial doubt about its ability to continue as a going concern.  

Continuation of the Company as a going concern is dependent upon obtaining additional funds and ultimately, upon the Company’s attaining profitable operations.  The Company will require a substantial amount of additional funds to complete the development of its products, hospital beta testing, commercialization, and to fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company were unsuccessful in any of the additional funding noted below, it would most likely be forced to substantially reduce or cease operations.

As discussed in Note 7, the Company entered into a Common Stock Purchase Agreement (“Stock Purchase Agreement”) and established an equity line financing facility (or “Equity Line”).  Management does not anticipate needing to draw the full amount of the Equity Line to implement our business plan and to develop and market its disinfection technologies.  The Company believes that it will need approximately $3 million during the year ending December 31, 2011 for research, development, marketing, and related activities, as well as for general corporate purposes, including final product development and initiation of sales.  Pursuant to the Stock Purchase Agreement with Mammoth Corporation (“Mammoth”), the frequency and amounts of draws are within the Company’s control.  The Company is not obligated to make any draws, and the Company may draw any amount up to the full amount of the Equity Line, in its discretion.  The Company does not plan to draw more funds (and correspondingly put more shares to Mammoth) under the Equity Line than is necessary to implement its business plan.  During the nine months ended September 30, 2011, the Company drew $886,606 (net of a one-time administrative fee of $4,300 as discussed in Note 7) of the Equity Line through the issuance of 5,379,778 shares of common stock at prices ranging from $0.10875 to $0.192 per share (after consideration of the 25% discount as discussed in Note 7).  

Also, during the nine months ended September 30, 2011, the Company raised a total of $500,000 through the sale of 5,750,000 shares of common stock as of September 30, 2011, at prices ranging from $0.08 to $0.12 per share.  These funds, as well as the Equity Line funds, have been used to keep the Company current in its reporting obligations under the SEC Exchange Act of 1934 (“Exchange Act”) and to pay certain other corporate obligations including the final costs of development for the production version of its AsepticSure™ hospital disinfection system.  In addition, if the Company were to need additional resources outside the Equity Line, the Company believes the Company would be able to continue to raise additional funds from some of the same investors who have purchased shares previously, although the Company has no current agreements with these investors and there is no assurance given that these investors will in fact purchase additional shares.

The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties.  

XML 23 R10.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 5 COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2011
Commitments and Contingencies Disclosure [Text Block]
NOTE 5  COMMITMENTS AND CONTINGENCIES

The Company is subject to certain claims and lawsuits arising in the normal course of business.  In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

Litigation

Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000. The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002. On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of September 30, 2011 and December 31, 2010. The Company intends to contest the judgment if and when it is able to in the future.

Contingent Liabilities

As of September 30, 2011 and December 31, 2010, the Company has recorded contingent liabilities totaling $224,852 related to certain past due payables for which the Company has not received invoices or demands for over ten years.  Although management of the Company does not believe that the amounts will ever be paid, the amounts are being recorded as contingent liabilities until such time as the Company is certain that no liability exists and until the statute of limitations has expired.  

Operating Leases

In 2009, the Company entered into a lease agreement and established its own certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which will provide a primary research and development platform for the Company as it proceeds towards commercialization of its products.  The initial lease term expired on June 30, 2011, but has been extended to June 30, 2012, with a monthly lease payment increasing from $1,300 to $1,350 Canadian Dollars plus the applicable Goods and Services Tax (“GST”).  A second laboratory space for full scale room testing also expired on June 30, 2011, but was extended to June 30, 2012, with a monthly lease payment increasing from $1,200 to $1,250 Canadian Dollars, plus the applicable GST.  In March 2011, the Company also entered into a lease agreement and established its own corporate offices in California that includes a monthly lease payment of $2,500 U.S. Dollars and is renewable on a month to month basis following the initial lease term that ended in May 2011.  This arrangement should allow the Company to expand its commercial offices even further, should that become necessary sooner than currently envisioned.  

XML 24 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 25 R11.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 6 COMMON STOCK WARRANTS AND OPTIONS
9 Months Ended
Sep. 30, 2011
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
NOTE 6  COMMON STOCK WARRANTS AND OPTIONS

Warrants

All outstanding warrants were either exercised or expired unexercised prior to December 31, 2009, thus there are no warrants outstanding as of September 30, 2011 or December 31, 2010.  

Options

In March 2011, the Company granted options for the purchase of 150,000 shares of common stock to an individual for accounting related services to be performed through December 30, 2011, which do not vest until such date.  The options have an exercise price of $0.14 per share, and are exercisable for up to five years.  The grant date fair value of these options was $20,042, in connection with which the Company recognized $6,380 and $13,731 of expense during the three and nine months ended September 30, 2011, respectively.  The remaining $6,311 will be recognized between October 1, and December 30, 2011.

In March 2011, the Company granted options for the purchase of 100,000 shares of common stock to an individual for web and press support services to be performed through December 30, 2011, which do not vest until such date. The options have an exercise price of $0.14 per share, and are exercisable for up to five years.  The grant date fair value of these options was $13,361, in connection with which the Company recognized $4,254 and $9,155 of expense during the three and nine months ended September 30, 2011, respectively.  The remaining $4,206 will be recognized between October 1, and December 30, 2011. 

In March, 2010, the Company granted options for the purchase of 250,000 shares of common stock to an individual for research and development consulting services to be performed for the period of April 1, 2010 through September 30, 2010.  The options have an exercise price of $0.19 per share, and are exercisable for up to five years.  The grant date fair value of these options was $46,094, in connection with which the Company recognized $46,094 of expense during the nine months ended September 30, 2010.  

In July 2010, the Company granted options for the purchase of a total of 3,500,000 shares of common stock to certain board members and employees of the Company as additional compensation for work performed.  These options have an exercise price of $0.20 per share, are exercisable for up to five years, but do not vest until the Company has achieved commercial sales.  As of September 30, 2011, none of these options had vested.  The grant date fair value of these options was $710,577, and will be recorded in the future once the Company has achieved commercial sales.

Also, in July 2010, the Company granted options for the purchase of 1,000,000 shares of common stock to a director of the Company in lieu of an actual stock grant for his services as a board member (see Note 7 for additional discussion on common shares issued to other board members for board service).  These options have an exercise price of $0.20 per share, are exercisable for up to five years, and became fully vested on the date of the grant.  The grant date fair value of these options was $203,021 and has been recorded as board compensation for the nine months ended September 30, 2010.

In August 2010, the Company granted options for the purchase of 250,000 shares of common stock to an outside consultant for patent work performed on behalf of the Company.  These options have an exercise price of $0.27 per share, are exercisable for up to five years, and had no vesting provisions.  The grant date fair value of these options was 67,465 and has been capitalized to patent costs as of September 30, 2010, which costs are being amortized over the expected life of the patent.

In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to an outside consultant in connection with extending his consulting agreement with the Company through September 1, 2011.  These options have an exercise price of $0.275 per share, are exercisable for up to five years, but do not vest until the Company has achieved commercialization and sales of the AsepticSure™ product.  As of September 30, 2011, none of these options had vested.  The grant date fair value of these options was $65,067, and will be recorded in the future once the Company has achieved the required commercial sales.

For the nine months ended September 30, 2011, the Company estimated the fair value of the stock options at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate
   
2.43
%
Expected life
 
5 years
 
Expected volatility
   
176.45
%
Dividend yield
   
0.00
%

A summary of the status of the Company’s outstanding options as of September 30, 2011 and changes during the nine months ended is presented below:

   
Shares
   
Weighted Average Exercise Price
 
Outstanding, beginning of period
   
7,750,000
   
$
0.17
 
Granted
   
250,000
   
$
0.14
 
Expired/Canceled
   
-
     
n/a
 
Exercised
   
-
     
n/a
 
Outstanding, end of period
   
8,000,000
   
$
0.17
 
Exercisable
   
3,000,000
   
$
0.16
 

The Company estimates the fair value of each stock award by using the Black-Scholes option pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes model is zero.  Under the provisions of this accounting standard, additional expense of $22,886 and $249,115 was recorded for the nine months ended September 30, 2011 and 2010, respectively, using the Black-Scholes option pricing model.  An additional amount of $67,465 has been capitalized as patent costs as of September 30, 2010, as previously mentioned, which costs are being amortized over the expected useful life of the patents.    

XML 26 R5.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Statements of Cash Flows (Unaudited) (USD $)
9 Months Ended312 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Sep. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:   
Net loss$ (1,526,519)$ (2,379,787)$ (26,327,600)
Adjustments to reconcile net loss to net cash used in operating activities:   
Depreciation and amortization15,7355,19776,166
Stock issued for services 1,268,2134,714,741
Stock issued for early termination of a license agreement  125,000
Amortization of deferred consulting fees59,42321,211196,811
Expense on extension of warrants below market value  2,092,315
Value of stock options granted22,886249,115418,098
Bad debt expense  48,947
Non-controlling interest in loss  (26,091)
Loss on disposal of equipment  693,752
Gain on settlement of debt and lawsuit settlements  (603,510)
Changes in assets and liabilities:   
Prepaid expenses and lease deposit(62,997)882(113,067)
Accounts payable and accounts payable-related parties46,963(61,169)1,347,521
Accrued expenses and accrued expenses-related parties16,42520,9003,056,293
Customer deposits40,000 40,000
Net Cash Used in Operating Activities(1,388,084)(875,438)(14,260,624)
CASH FLOWS FROM INVESTING ACTIVITIES:   
Trademark and patent costs(48,377)(27,710)(101,519)
Purchase of property and equipment(4,404) (48,586)
Net Cash Used in Investing Activities(52,781)(27,710)(150,105)
CASH FLOWS FROM FINANCING ACTIVITIES:   
Proceeds from lawsuit settlement  415,000
Principal payments on notes payable(2,775)(4,055)(201,573)
Cash received from notes payable  1,129,518
Advances from stockholders  44,658
Payment on stockholder advances(6,000) (31,191)
Capital contributions  439,870
Stock issuance costs(4,300)(10,000)(119,612)
Increase in non-controlling interest  14,470
Issuance of common stock and subscribed for cash1,390,9051,198,40013,100,967
Net Cash Provided by Financing Activities1,377,8301,184,34514,792,107
EFFECT ON CURRENCY EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS(15,427)(6,236)(23,946)
NET INCREASE (DECREASE) IN CASH(78,462)274,961357,432
CASH AT BEGINNING OF PERIOD435,894359,891 
CASH AT END OF PERIOD357,432634,852357,432
CASH PAID FOR:   
Interest1,21212531,230
NON-CASH FINANCING ACTIVITIES   
Financing of insurance policy6,939 6,939
Stock issued for prepaid consulting fees 70,303301,811
Stock issued for stock offering cost 100,000100,000
Stock issued for conversion of debt  4,373,912
Stock issued for license agreement  693,752
Stock issued for patent costs $ 67,465$ 82,215
 XML 27 R7.htm IDEA: XBRL DOCUMENT v2.3.0.15
NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH
9 Months Ended
Sep. 30, 2011
Consolidation, Variable Interest Entity, Policy [Policy Text Block]
NOTE 2  CANADIAN FOUNDATION FOR GLOBAL HEALTH

In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada.  The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

Accounting standards require a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity.  In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties.  If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate it.  The Company determined that CFGH meets the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009.  Accordingly, the financial condition and operations of CFGH are being consolidated with the Company as of September 30, 2011 and December 31, 2010 and for the three and nine months ended September 30, 2011 and 2010.

ZIP 28 0001185185-11-001794-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001185185-11-001794-xbrl.zip M4$L#!!0````(`(**7S^C:1&TA%0``(9F`P`1`!P`;7IE:2TR,#$Q,#DS,"YX M;6Q55`D``P,1KTX#$:].=7@+``$$)0X```0Y`0``[%WK<]LXDO]^5?<_\+)5 M4S-544SP32?C*L6/G'<2VVLY.S/W98LF(9D[%*DE*=N:O_X:("F!;Y""',_L MIBJ)S0?ZUXU^`6B`'_YG,I$^X1#'3HH]Z7XC^:??I\L?I(ET&BU7,]>7+L,4 M[KJI_XCA6OB(8_@=[C^DZ>KXZ.CIZ>F="X\FKA_C)%K'+D[(!6DR.9'(G__^ MKP^$R&F,"8ECZ4L42M=N*JE(0O:Q9ARKEO3U[E129(2RE^"-Y_LXD)Z709C\ M^(8A1"Z_B^+%D2++ZI$?)JD3NOA-]N0QN>L/?-[;O<`^;!QE-XM'U\DDW:SP M#LW<2>[IP\6=(X)_(J.)BHJ7EK_C,IPE]OS?HQ#[84I$1%^1;54N7@C\\+<. M_.3VO9/L\`<=#__R&9YFX"\<9]6(GMQH`.\GD:8@LTN>8^X*4SV7;N2:9TDO2! MM'&"[1-H])9_WX)O&7JX`(DEY[B/'\QS>DNR9%E[Q[3KPW1R=90VX$ M-O"<2K[WXQM7_LO`@#E,_W9QL+\`EWR,7YS[8#(6"2[P4 M,CJ]_.G-B0Q_3%TU3>7#T>XUMOVC'8'BT@K'?N2525)1I">9T.V)*G\X*JYM M6]J]E_%XE#-9M%1F&F5,HS/L0JORZV9:GB`%-&UOII5_7,314D5_=4)D6\9= M5.GTUR4`8#5.S\#'GA"PF;%].-I=91!3S!Z]RNI(<6VDN%0J+O37=4`:K4GK ME0HK$X`)\GI186FLL.2=L%ZC:96$)0\0EBQ(6'HN+"?\XVD6>FG-,EAA_<$T MBUM8HC3+9..:;+]"$>WB&G`L)JY9I0SF->I%*9B+R6#LO*=AZ/%*/40P.[:_[#$3K*.\4F>M1]_G9U]."HN2KOVR/O,[VQS-SB>/3@Q M2;'S1CW_$3@N<4%>N%HOR8`RBD]V-W@@;!LYJK92;O\,A]'2#XM[333H6/`X M(7"3!CYW5*IM;26]XZU',AF1G5!Z(#0WEHW#CD^=Y&$:>N2_\W^M_4J$V.I$\[/I+)X`A%!BZJIN:"FHZ MB-R)8(C5L409HJ;JEJWM!_$FQBO']\Z?5SA,\.DZCN&=\5(S+5,U=H@:6S^I M]N1@#-UBL2Q9[H=00G"=/N#X#,\QW/5.HR1-KO`>4M!T%D%CXWLCZ):!H=J* MV@^AC&&:)#A-]M8!39,-P]H1+S4[GF@WP[IL&8^^S[]S[@2]$>)JF*V99J9I)5#.\45AZ=$LQ=<4>@>5LC>\BP5J%;$.5 MV;RWG4C#:&X`;A&HJB&;MC(,P&FT7/KIDDXKA#"0#%-(@''HPCO[A"/-TMF9EG8B5>L8 M!ZMXEI)X0E\HIGU+@+9SP=QBT0'8.^*H41N\-L)5QRT. M;H<<#P67/I),U^E#%/N_8V\',Y]'YA;HY=4%F2+*_K2!K)*KN[^]X'4(\(#P M+I-DO;?D>C!E-`3BZ1.50#S7ZY0L&Y&)G,,*B2$D&MF>XNI$1J)?%(IP]#!J MTNQ*7&5;WH]V3TS7;=482_M`3E[-O"9J1-7A,`\#M$-^XH$*=NRJK5==9P$97\IBA@(H35 M#FSJ>9#41Z$3W#B^=QF>.BL_=?98S%$4VT:6S,Y!-9-H2*5'@.GQ\@B$HVG6 M*#"NNUZNZ\1!1%<@(7PL\#G9.[&*_02?X;GO^BE#XFP= M@RY7W]A#:PU5,8W27.7>:$Y>DKT>.]`LN&BA`[)'OH$##(/1HMV+KAFG+`R$PTR33T!,ID^K27!^E]IFHP<"&K>4- M!'8+:A6NN^>J.O825`L<5)6-T$7C37E4`HXHOR^&MJR6]*5$H0X@VS<6@(BF MWM(/_22-';)-+%_R[8+4OE>@-J=MLM/J/22%8FPOT:\M?)LV6R#&`U(8RO;: M^$H1&P)9HF\CR?:2]&JE@R4;JO:-),EO)C92=(,UTGZ<%8>18"=V25TC$Y($ MF@VR;,.R6"?20;!!BJ,!\MJ,9NF`^AL`Y#87T[(MY1L`Y+45$W(]UE1>#""W MF6BV:LO&`!E6!E+_7"=TA>IZ_K,3QTZ8)I_(O]B[B.(9CA]]5U#(561;49'. MCK!X:#?F_S!@<'V'#,_@YP"3'XA76$9QZO].KXNP;UVU2WE^/]5:L<2>2'D- M'3(K[=LBY;5XI)OL"B4G5+%8>8U?5W3EVTJ5V[A,0T7#=;5>VOSH)W`+S.\L M6M^G\W50%$^)\566K3&%UEWT:IU^O2+;5&!XF7NR3D2\%JZ9EB4S$;Q&Y&0/ M$-R9K6'JI:2Q`<4>,/@M4X9@9Q\*!J_1*:J!;$4^%`S^<&6HEB&;:C>0-BB[ M>2P1:CIIU=,=G39-Y4/"JZN3=F5EH>R%A5=A)^T:*PP+K]9.VM56&!9NU9TH M!D0N4]'ZT%1'=8X?7L?DWG4X3,I?A;'V?^)[OQ)VS/P,R04MC-]QP MT*V%`_).0E[!\-+Y,V%M[2'IZ,REHD:)AO M6M7:UCJIFF`+I`*'\X;";MJL$&@8A@R`P.M>==O6#P2!.PVP;#:3K&$82Y][ M=LJT#/,`]/D5$AFRQI9^-W5#S1=EWHN4>))3O.YP3'<[BTKO)TC12Z4`G23K M)=A5TEKL;,F23![/Y]B%\'WZX(0+ M?!GF`U"@O#X%E,"F_ILE9RK*)A5KOH904Q8`1A(4LQ#BR);RF*`0,8 MQ2C51OSI1#%@_&1"(FC^B44Q('LW%4515>O0PJA-5M[#,"%)XS49T)QA-\9. M@B^B>`%-AEC4X%2#CF9YZR7;6#V1^@N:Z\QPF@98]*+*1$/E?*N#8$VM:IW# M4T+%#8U,H;+B:Z76/18]2$PK4:A'9FX`XV-)'<%(".-]N#`(XWVG,`A#9ARJ M=7%5$/49A8;*/S![["_";!>AN[F+G3`AIR+3U0OZ6T"M<+=V6*C[#3VR"UJA M[J-P(T+4',D:N^/SI;"W;2S^QF+C-4ZC>HC0BXCLU8EK@"/1%/,_6C;4^1F* M^JUL\]4);8"[+E>2_WGLDZQOPXW2'/>-T[??G3_CL75=/JS@VCEXK=(;E*Z9 M!XX+7>)[I?(;$B+0H>WV#RB_`8FR94W*,O700F_H096Q]I.'/KA M(BGVCGYT$M_EV;3*Y?&5;/LJ,]AN(M>008V&Q>5*`=8$<*%>7&(P<;FG%\;$ M9?+C,/T,>ON08F_ZB&-G@:_6RWL<7\]K^R,K6!NW9')I6;8YT[!A!&V8S%+: M("`-2BB2$2Z]S'>9RDA35;;.[S4QPJ7,>8]HN@'=\DI[A,L",D8TP[1D9`AD M)#\4>%=D>IA*856O!)H.DH)1E@4/%]7Z3)G^=7P:./Y2R(0F4@Q+0>PYOT,0U)=Y1.'GKW,VD69J:`\& M&I2$[2%2;9:?R`TFNQ!3`*S;6BTW[B0J&BAWB3!2V%U-+P]T0'$;C'@'0BWO M5,ZS%'+T^I(L-PESKXIB68Q/:";4M'=Z,"+N;M5LQ.X/:H.T)QQ^*R:G4U@< M(FHI!LM*64N'IV]/3A=3G6JK)KM#A8_TSAC(I_BRXEMF53,K9`4/]=EY2M9^ MNKLC9@AIR#"$A"'50.(-Q2VEF<7+,#\)N["GQA.QA(?J]9 MC\3.G]SM!;Y63D,^G$6WLWK8^[CY"CGB9;C=9?Q5()9L!V>)H M;OI--6$"H'/'`LO4-;9X;1#R`P`?D%-HBB$;RFBI5[=:.QMZ+/A=-'4A,8]Q M]3-!0@S44DUVNW4?S=J1RON`Y';HILENBWA9D`/.;$*E(C\>F'U`6S^K):3O M-?8S+?RT#X5[P!D!.CLO,00YCX.X#!]Q<@"GK"NFA7J=0P/U@\#F7Q$O6]\W MACW`'>O`C#X.>/W4"Q=C+R&D/^.%$^PF'02E&I5:\BZ"=?.[A9%J9@+7<_9; M(T+F`$V3D6$;I9K$QD#BU4A-UE\*TH#]ZF0MB@=5JV()QX208NO(:M:JBJA: M43'CBHVP/?.:9N@MN*KT.KMQ"#A>A2]_1ZF+6NWPR7'`^,>#"-F(%UI'E]+M MP*1N!GL\!U*-TN2?OBAU'LIQNZ5I*?YBH&K*:UZ5\W M]0ZGO%V5C;/UDOX#;KDGVU1;MF6]&6\S6:$XN=43A*ZUY28O@'/`'"Q8DFV8 MPY#RS1E<^"&\+'Q(@&#P;:G]R74#><[)CH'`^97"TE2M/[E^,>`#G(1I*T@V M1T*O%G'FNVC/GUVZC_86HO!U2)HCFVWA/Z)FCZ!P/0.%L3N`AM!OJD$5!'_D M3IS!Z`\"?O2.F&'P2]B;'SK@SC'3TDI?*!I`OT%O1,'GGP#4(`]Y=?#Y,W?= MU-31XN?`/@47%L<;\%:]G[(RV0/X9;N&U+;L7DE7R(F&:)4^7E#?-%KY@N8( MB,5Y3>2[+4("N8(:S@4CK3CV',7(""4A,2\9NL8O]QQ[`W">4RZITBBC_[+BT"6\187+EC4:+) M04^,Z7TBA^8(<2R&J1G5_1IGZZN<4+ M^F42:,=98MX(>/(%>_[O48@E&FBS@QR=`'YS/QRU-H#2W6;%3Q3) MD[]ES;.O[RR:W,G+C2[\Q'6"7[$3GX?>&8R&N(E,)DB9D".CNUH[J8IQCP\A MVGD6?.VFS3N[=E]HY*/'.`[RPA0$Y1%A703.@EL,CAYY_PAIL"<=RFKIID$V%K:R=2G5[6)[=X138FA`OR3=9UPDWV5YR4Z#6V M5A%A]NC?HP#\LA-O+OR`3!3S4KR*6(*55AHIT5NGH&>+*.87Z`R4!MZ3MKQ( MI/+?"3D'%-:VOU+T_$"R?, M]^N0"!`%OE=LF[L!1P$-Y'MY\FE%)Z!?-::+$F?`3A`EZQC?`<*/`;@7;KC? M!>E[SW^4DG03X!^_^]^]S49`_!,P<@)?0;&G[8>"'^+UT<7UU-[F8?KG\#!?O_"5.I"O\)-U&2R?, M[\XN_^_\6$);&(38U?7=>4%P2Q%]YRQ7[_^"#/F]]'$ZNYQ)UQ?2S>WY#'B? MWEU>7Q%(1P13'2^]!;*C=^#G^_BH^/'?0Z)W#[A*;UYH)[0]C^)EME/*#]U@ M[6%/@AP(^_`[F4]UUIZ?PC4(?]*#DVR[9MO6/<:AM"*[*&)XS"5Y49*2I/G) M3Q\D9WO>)#R3'SB92(OL\VW!I@H,'L91D#Z)K__-)W>;']%[W_(&MWR&L70&B12_K*%;\(:!4LH^O3\29KJ)>6& MTDB"7'TID4R)OC.%0.`&6+((,$C'UMDY%CE/Q6NSR2_O=NJ[^XEL%"!G-2Z" MS5M".:'.*WHG4`U#!0=DCW5O``Q7^N0RKV75\4 MNM<-IT$PA/.,+LGG,?3<5K=SQ@)S&-]Q*@*OK^)RHJ MTL8&HJ`$Z1NT>H9=3#;.2RIZ6S<1,J1Z)^T$Y!*(GV?&R3H64U>48"##:$>$I4AO+J0L!%395KX M07IZ\%TPY!B_S857TX,61D(02I*03X40B3G2W/'C'69XNHH((N@Z`-"%@`NS M7=&@3)P,B;#8:].VLIR*U@!5?F`XB&+;=OH`@^U,4<"Y2I#PIP])UILU_F;$ M)V7=*[\EO8F(.*CM%3SZ($D?1@@N/767T$SK;K=`!/H(AH"?5]BE&IU#FJ^A M\XA2O6L(9W_P8)9%I[M?/T-X(G5!OLO@V3/`\45/*H^S\]/K6YHQ'$-L@_$[ MN;=KBU]71%?6FIP.OM::N\J>E<%25SW1#;>CM;J MG0@NB/NCTT>5V/<%AF\P*MB%KMU(`7Z_C]:IQ/5N2?^JC!:<_-"X"#0Z/#1PN M6>E0FY6((DC3V:ET!Y''E2P%O'*43_(2/YQI054YZ%O;X1CI;`GIYHOU;*EW MV&S@[@$2;=)#N30AF..8!O,0/U7UL213D*$;0.R9TTYYBB"D9*&>>:P:$RF) MSIR-D*W2J<+(R;IY4(5PUT`ZH3J"J0:1H`AQKMI.$>$)*Z6,BPX8:-A/(%9" MSX94:^;P^#;9JC:&=!*<9?LM@"'#B&U@K2OB:AV[X#UP\E9*'!B1O*UTG)^7 MD<%]`BUA]@'D"23Y3!8A\$2\%/#O9.5#FUUJNVWL,_GVKJ0R*EY2ZK(N1`FN MBK#E=`$G+))P+`4RE`KP!PO6J5Y M&I@2G29ZE.3^%WPU,7C)A[3;I?GT+C\J&FC(R5M2_]+(HRGJ_C][5]O4-K*L M_\J<]+P")_$ M@QT[#0*^X)J\.K^5K>)Q387EPLG@C."8IC]EV`\9.2"@ND"+F,!"O'"!#/TW M[&6[4%\"Z9.>S+&*9@@7\TB8L*5=+J<8R,%42H#VIAS8G1,AF':(?+YPO"O\ MWQ.RQN1/33>IDU0/#(?@12^`3_HOI9N)H<*'*(CWL)NX<@!7+97B`GJ9G)QL M0!C\WM=-U(`0]S6(8)CL6C)RZ]P0,U,O-H'#ANR8EB]]O)J/=\7B"'$\&`3@ M%Y>D+PU<^3:BS#BM#&2K%43\(V$+,.5O=-V7G5_P#%=NZ06+05C-I/BQ)#'+[S'"\$5C%"GX%\(QC/A3?!D`9/ES,SH M]T#C,)E2)P@.]J^N!U0%O$#H4]NQG`GV&[P.*RHH*B":9C1MULB16;\G$*X/ MS:4I806TDAPQDL>`C7D4J:4V0O!3]G.3G_XL?WT^'.:220GEG'X9W9!72U2: M8W+&TGS&Q_G(=[R1CZCFEW0O2X0BEKD2028I)%GT/MJRR'M-5$";GJK:BT96 MU61%!Z5]A2W(`8`\L2"[L.%U`PD`: ME\FQA?M8F5-*(#*Z-W2I'CT&<1B9QI6/@LF-6,XKC;0POF3<\<#@AU%"D^1= MT6\,$="+1&-3%,(>G!)'1TG*.KT5.L4HFX''9QT`!O^JT)U\XAD3=O;*&*\H M),\$/L%!]C1-8@OM82(FQY6F2:'K1)+%]*!#7#[%!<=$[58%XW=BY(4XFG9' MII3W6L$IHC2#*0D_B@V96C3TEKJ`;C`2:/H<72`P"N/+*S)LH*HV;><7)+*I M'RMG?W=4PRNN4-T6K7+\4#9V[UPIWMCQ^S\V-MA_OAQ_WOSO?_[2W?#Z;[N[ M8WSKSR=_W]B?]L+%?M_;Z7_H7'ZZN/&M_ES_UK+>!SOA_,Q_?_'7L3@6BZ.; M@YV##Y>]PYX[FNM[UY='@Z/QU[,#^]=.O^NU].'K\-.?7X[?>9_,8]]:'-L? M9GOZ^ZOQX&3_PU2<".?XQ+2__7W5_W1TQ;<7IY=?_SR8;T]W@LM?=_OO9Z]; M,_^O\_/W_QY\\`\VVY]WKT\'PM\Y>;]]]>'SHAM.IL:9M_W^X^Q0S+V;J?7M MTKE\;;6\;]WMC\'L\WQOZ^N7_1WQ96O1^WKMG)LSI^?N_\G%XG3DBLOSW<.= M]J]N__4!/_@OVST_V]@H[ATL/N=<[3U8,=W<+.P]V&5'I^?G[./PC)T?#,Z& M58A7HFM9T1_531BD_#>BYYNC<,'J$Z--?/B]3GOPH%>(U*0&EMEU0"E?1.R+ MZ!GFC,N'F#.;GF*>;8?V\95YR\GL)#1H3[,,;%$A+`IFJZ[+<\Q!+,M9^&^^ M"QWTI@NF"\MR4;G8DVA>6M$,XQ'?Y7KYR,(T@FGT7;_[K^C;4F$[GLJ`IA+K M=%[E5"[[8LGY19C%II&##;S*`E)RV,@AUQ+C&-#S[/'MZ<7%Z_(9UW.N*8E:N,]_E%'=9,G/15$G<$BO3CKP.C!)V'LYJ M[>\W6I-MICOH0+%U>BN9K-.KLMG;T[.]X5EBLI'%@;C`<(R8XWZ8>ZJH@(O< MPBOU*=^A1YG2Z(LO0]F]$:2+F66T='VHW!DLG^36-Y^Z=Q`G[%CJ9B' MM'^D$J,5\YW0O\+$,JLGR4Z<7\7NBFL:93/%-?7DFI;BFCKZS;V49&X$(X#_ MQ,.-%AO@:X[WAOW/[NYP^.[=;W=8Y$%EYU)P/Z6WI=V_S?\?&0DGX0S7NR"U M?YBL^.D\[+9\LO:.=1;@%"8`Q\RL06F74 M@G1Z%&WUO9[=;)I[R%$KIWL*"+RX3T9?.[>I0M!:0LC#+3UW>=.C@^CEUG97 M:VU558=J#B3%1+5AHE\:R40J@"NW40%\90"I`%ZO`-[6>MMM;;O3JT13S<&D MV*@V;%2/(/[TZV&JWM0\K-ZCWC2\5XWIZ0&N5*H:M9)6C9!6&XHP&N,Z:M3K M,VI%DXHFE>MDCJFE^7KZ9[U2I3V!#W"R::OBDJ3IY:HWFI>;R-QP7EE14+10 MPXBZGJ-6.J)6.J+3V]%ZFQVMU^\H1=$8)U*C7I]1*\*L%V%V6UI[:U/;W.HK MPFQT"J96K)Y[&O86'P-6[5+R7_X)8;;4@H)3H#^^=>JMNTZN96S_*J)6_/04$U"[_1D.H'J6^EZU7K>HG.-4< M1XJ(:D-$]=C@K^*WL3OVB]WKOS< M4(7GVA:BGME-?*M"U=\L0IF:NB42G$T6G$L$QPU1]WZA():;WE2U:B&1)D[ M-^C3`\P_"H^=-WV#_AIP@I*':^.XJ@RU5I"KARA49:CGC[0ZD)LJ0RF=H71& M+5Q1Z8RU@EQ]=$:3]XTIG=$,QQ_I>Z8+RW*Y M@<^>B^S3BNR-1WR7Z^4C6=3VNU6P7>TNB++T/9O9%C M94SS+GZ<9]DZC`73?*7ZR7MW`NTMDRS'T(^ISX:V(8QJA*X<710BH!OGP@T$ M/K:U>EOM9DNKL/:CB$5%L@^[BJFD@)("];#9@[PC7DF!AR7^3JM=72Q0[%X7 MOU$V4USS7+BF>@%4<8U2DA4/_/IY#E197RU-[2-/[DDX$QZ]>N-A$MVG;LF6]':6K?3T[KMG4HTU1Q,BHUJPT;UV&NF@KAR MFT:YC0KBC89038)X1]OL[VC][>HW!M8<3(J-:L-&]0CB#U%S4F^[>8NS]?>P.L)*S5J]4YE M-=MJU.LZ:N7939YM53^N<])2A_KQGK"=F6G3G1M+ZLGPAF MAWCW/7/&3'=F,\=F/CXRV%^>=3EAX`?EI_NZ6U>XHPFYUXJ6JT@I4:]7>, M6M6LUFFVU:C79]3*LYL\VZH:7>?TI0[5Z#M?4F?AO?.N\&3%624XBL%J/6H5 MK]9IMM6HUV?4RK.;/-M-+\\I-?JT:%MZ;]U;]1BGFKGVHXQ:^=M30$`]`:+1 M$*K'^F?3WRBHB.CG$U$]'OZ@XK=RFT:YC8K?C8:0BM^*B)X'$=4C?M=ZN7/E M5\4H+->V"/7,'O"T*C371^3FQK3B.[Z4_RI1O+HH_A'$K27DZB.BJ]]>5W/< M/5@(>/Y(JP.YU4-H*YVA=,;:NZ+2&6L%.:4SZA$"GC_2ZD!N]=`9#U'0>]1= M8ZJHUQ`\WWF?`[TC\*/PV'G3[W-0*ENI[.?CN$IEKQ7DZJ.RF[PDKE1V,\BM M'BI;Z0RE,];>%97.6"O(*9U1CQ#P_)%6!W*KA\ZXM9HG#_*1)>@X_#7R7LS`UYCNV+[I!Z8] MP:=!.VY@PA<:F_*Y8+83L)$0=L'RIJU;H2$,^,""J6`ZM_30XG@FXSY^97I, MC,="#YCI,VX'IF%:86#.1;X[8\>C!ESAF8[A,]<3/O1*&*\J\"5/RB$FG=3? M7X?^QH1S]\V0>S8,QO\H/*J\78CKX"W.X1^QY7^/?WID@B$,,[C9,WW=G%\,2@+=28[IR>[P[*2:'VZ?PQI8\HE<\V(JBM<#;W6Y M?2/MN=UI]W_SR35187%\AI7EXIR`$[GPO<%"'YUZ M?S#XR+CK6J:.9,@"AW$V6X^(\X8Q-:)PO.CUML]/7>JT6,F5JK;BQ$`R?)`3KL/?\?<:P/)L3&`%H)%,"7FAVDM]FOA>%=T+G?-`*8N M,@6-:5-K==I:K]_3"`YXOB\1 MXNW)JTSZG7P:Z#IMF)Y8-QH.Q!,8:_QPA*\I"-!/#"<$NFF'`F`$V30G)H^826834.X MPC80V*&+Y#(*N&FGTY-.JP%1'*X!DRY=`C$%CFO.P"L1'W1ZYGI9FBTU%D17 M`29UQB9)R-A[@)`K09!US(5I667D>PAQP"C/093/G-`F+RH-@8`)!"P"43!= MD5W@;$0T]-8(=91T4\>77CH2`6=`X.CV6@G3LYGP,*!$K"Z]%RZ+U\_V1](J M&!'Z;!5:\:`?X#H4B?)$%%'//8V>LI.XACF'Z[UBAWF(+-#%0]L/=1TBQ3BT MB)3MF[R'1[@JF!,;!C$+##T"LRTT,!A06F@9P'H^!`[S"F"2;V@DD")U02;) MS!DP%\2=4`=,>$P7W,^#XY:\:.WI8.`7T&.`[@X!7!1?3V!^6%_+S3DF`QX= M)MDB4QIVCEE,H:F/H:=/<3(&$T^0.F(O8\!U6K_1*14_2G[2AIRVJ%PH,OE( M`*8_Q9?GV%&@8FB&-#ZQ,==E-'D9OX,GVTRF&T-Y^A&7Y#MP#.RQ()?92];F'`XTT26D4P2>HD4 M8Z#][)@2(KJA/V?LYUQ.L@/=@,#N'U,LKK1O"*61"2!?:$'NFKMM17)(0P[^2` M#2U+K%JQ.W+DR*5D"!`Y)/HXC'A.^E;#.+80:'\IL";"!FJP2L@"Z>(Z'LZ@ M&\(GHE>951.<3.2MB,]S5`^7S;,4!"H@I5B4^Y#45UL;D.^'7!(SVBCK0K?Y MT,(,INR8@]O!_[M1KRL5==;;HA.R$)=^/<8P*&S]A@PH08HRF-#KEQT0&!][ M8"X-WB3>/,=:!K$E:1:*"RQN..#:$YI$L,N,7PD,*+(S43C,7#9G^!F7OZ,3 M(F\+W=B\M_M@"5@P/HS@2(>>0//>Z3$Q-4@O361_ZHO8M1D^V$JJB9G%]G8/\JT>>VD+J;2*2M06&UCY M!,TP`W?R`T0XY'YC(5.V+6U39FL5T>J7DHXI37:2:N+WIH]>J%/#76VSOZ/U M^]NY=Z]E&HK?S$:A"XC0]4RP,_.X/2&6P#3W1>M5N[7=[Z+E\?-.!XMIQ5[1 M!0`#8XBFLN!G1(HE[G"G^R\:'R$V.]8BW<0#OV\NI*2/E#Z6[VAETC1N0?M= M\"XJ<6XB-$'O.RC]$;G=5DMK`7:S",00(='7[]+12JSX9?S15U5=2I!9D?04 MH-K:CG':21\!O8SK?%%ND,@L%V6+WA;]@JHW6+IFH4_L7F[K2@@W1Q=448+Y MC]C8$Q#L9%U<1@D4^)()\TY!\72XRX;7$#WM"81/G8BFO;.YE0N+V1]D8V,Y MK(.57`@PD`=C+LH&0-U7 M5@9I?@=H!=V*S(COJ`1F*X7;"J])6XJU9_[:E!M""AB73),:$7PF3RMJ\F+Z M3I#WG9F(&=;G\-FTX4J!XP%^IPZ!M%R^C428$7NB"SFVZ80^UC&X%4P35\Y6 M`NV2`HC1S&,MYTLQ%Z!G93H2J1Q9/K.+"H!#P/(H8DT@)MI2D1>;('D.,(4T M*$CZ7W:XC(WDT*JS914QEJT1Q#7+0NVLNH29J:.5Q&%25G/L8C$T+:^`0.0Z ME:`@^Y54`:*MF/,)D*SF*%T+!+3J,B=UN0?8X^Y48@P+14%(]1-98?=8%-1?E,0=I)VH^2@NIWLD@EYW(QVEU04%7%Y0G(--@H$J*>4XY=' M$=I12`F6I>7?4S(KM[>GQ\>'$,PSYG@Y,]7)N].#S9'Y[L'@[/E59??74V6F&ZQ(T-R+J1 M/`,'-F?16BA?^"%1JF?2\JM99,Q[KW\>2D)U7$A*\RNKF2)$7"O$ZKQIH\L8 M2;T>]!3T68M8(M'A%3(Q7BHA+84;-9+$$+H'!R!MC*(\4BAI:X[?"R_#NDFA M36[\6+[@<@=[)Q'!\2-A*`?@R_TI<6S0J/[.(32-+6=1K24:#FB)T(N_CP"B MJ+%-/=.?'P3Y_3R([+$WW#T]&UPD/'DM;.H)9DLE(?@K4#I!;S'_& MKWA%PCP'!C@&^?3-@53V$!<_;"XELP9_ZJ_8!AM@YC:+ZCC@%MPNK'&/*-E' ME8Y[KV1FQR?`4WZ03W>1M>+J0W5-8Y"7*8U]TNEC*>,4R)5)< M!EV`Z/0T2$V-BF44HC%9K(W66W&`E*K11>*">RQ]432-QVP&,M"HX'0D7H3&9176%C/*+^3QNXT5[:Y.J-?`S$#8AEE/!,)U7[-1FQ]"S M;8W^UC)7FW,=.;1$5P"*)M2;2N;LBNQJK:CW,D M@\HE8W*&"DV/%9YE289'+X;(5Y3EWA;<>"(,+$.5N@7CHD1`U^72!D`*1R!; M<3QS0@69"FA4;5'*8"6!AP90#'WI?%3I0U=\T6EKFZUM+;^GZ)8Z.>&AN!26 M]Q^<+\@2RVMR,ML4D?W3(8RIT<548$Y)^SZCVHG$?:DT%08A%O]4V/XY83O) MN((27H[2]/,>(;WAL_5HFQLJR^75CE4-@E+.X'!S8"$7,4'*]6FY]+!<7B[$3BSSFG*H^!D0X"%#-F0 M#!+)SO'D1%R;KRX\#.+29IK4%`M=^?T0A0)N&M3B965*6%`!8"'7Y::AY0XG M>V?3AM"$B:VYO\S-HL\OJV\&FY[&^]>*8SK"'6**1N\])8?% M>@EHWIU;-X59M`G MM'WAT+:=N:S0?N3>E<;^#/'.F&Q=XY-MTA):@.*)?<"[4`+'KECV/;4#[IF. MQG:!ZPP>;SDGPG(]9XZ+6!Q756>8!<2;DW(CRU3@TS4]W*Z/V6&RN)?97FNB M2G=T2*LP7BRX9Q18J[0AM+BQ=&DU7FY"*FX-E?,"4S6+B0IK0N]#R&S3Q>-1 M&*1J7UP'SIT$*1"M97"Z70\XA+P61+!+3N@=?Q`6O8II%VSEP&1H^ M=5MR"DQNLSW'LOZ_O2MO;MO(\E\%-:6MLJL@A3>ES*RK:$G).A-;7DG>U/RU M!1)-"6L0X."0K'SZ?>_U@49W@P0='Z2,U$S*CL1F]^MW_-[98)PXOB9#435- M_)JF)KE0:=^P[(&LWVWPJ9;I_?7FME;?YS1XX$"!@7%W6*F93V MW:2^N6U(%==7>TLB81?]<'IL5!'V13KU0Y5NQ[)FWKUR#M(!MY%$`9ES@]HB MN90WLB:YTOX8:/3AY.9$L9Q=UH=N9L(>>3XLD>M1E1K]80Y41Z05Q^FCC.%L M%4,"(/S>(QY3L!M,T&_+L&[#6<.5WU-B/,"O-7.0P(-(2B1?I4HD[6R-C-GD M99EAZMF7Z](&YXQR6%5169ZF"84<`H,%1(J;@@X/$98N;`5#;3-9NV6G7BGQ M5>FMFP7P4AFSJR656MZG,6"&G%(VASI;NJM0X6=1T&.):\OAT%'_AU?+EJ02L; MAK5-1+M_UL%]<`OXZLYJTV@ M]`Y%!463T[*_`)/\LH64D+6_$6&(5?W/`$3U7NA?:M[6_91!E M.+VFK,JIU)[1A3H:P`V-!MBW@Y`M$7U/Z#[5K]*.J6*(\2Z)_@3"'TW\X6F/ M3G;4'_K381^_3?1`;JP7ARMCC#[8JG+<63RVQDUC,W8C@3*V$LVPN%-0Y!2C MF%M12NU(LK&]4RQ_4:-OT$NF)C(\\?9J"58V-)%5 M:+Q-,0%,F1,+X'@7+*!:8]K54#&M59-#&1E+-:HF2F]NUCMV#J=)"[50.B;' M-*B>[:H&-,-PTC<[N&W%LT77C/S!>.2.(AZ=^?WQ6-,]+56->497@\ANBL9< M$7?=FTB]LZ.B<>!,4^_\93'6I+8!OW9Z;C<`Y4J*MD90U5WO#J%4J-U8"ME* MC[-K55"->DMLT*ARIT%7N)<9J)O8$_E?]S@:*Q$"/E*3^+1#4V>VX.^DV(P= MM<56FQ2*.)WSL;N<#51AUG;%`LTZ#6MN`FIX_:OF2^$_$&$?^MC)\^ M3\"MUEW5ZCCTQR9,L:1=IN'G:9`Y+."*+E[TJJS6IB,BLK MX'>`Q7CJC&!/FGVL%$)SFZ,A"K7ZQ"91'O1JDEN76OMP+GS"LT&V*^5YR5.\O'^8OE#I.5Q7VX+AA[E3UK>& M?#8H*(=[L45C-2@HIZLR9PMLI>4=BEP_R&:3JMI7J(:MT2BUZB[NV*!'(^_D MM#NSB@Q<$KV(C)/=L@Z?-^&BUTV8V@ELS,H[V-"W\R=D"WK5G%&%9JLB\8)& MZ]3@`;+PG-T'\5(PGYVD)))B>AY/RK=V$0R";Q#! MR=0?3<9JW"3)G!A-2:$!1\,`)SH?A="0INK)D)+XK8SQFE#3&USA7`C\&M4* M@=[%`MDICI9*`_&O[$S]#N*J]P3M*K%VZ.YS)3:RRI9-'Y373R&7HUW7P@%! M?7)68^35=OC[,BK>TDUHZRA,QUL]A6_A)*AQ().V#%K"%>_#N'2M2@`?&1:2(>;$.15WUH0:\`96_)M^_BR3Q(=S M+%@[$-?3$A>)/L%S5_HG^TL=T['KJ8Z=G*)K^0\/G3:Z2!/F.S[U. MY'LGC&ZK)9IZO(\*9F.I#DD]"SZ]%&&P9D6+\;&]8.8?'$F`.(*O)H\]$"=N28N! M18P?4>#V`UR,71>`_U#T;F-I2B=K7U76OH2Y[((/GH&='"S9`*6>(A:''8HZ M'#SQ8YZZTRI[A:)Z)[U>E[\Y5![:!\MT``B*_Y!J`O'G\5[5@7V3,K!9/9*: MERN:OJA*M8*B-/O!:M,?M3DXQK95@5?3=!QZ!8B>ALO-!D5CJ5H]6D2/@^4L M40];=Y5=FJ;,-AKK(FQ0$RWUZVCJ.N[[V<7%FW>_'K^^NKV]>ONS-UA_,X M6Z&"+WREXC_\<EHUJF:'U35_"%J\YO#33-> MM.]=RB:>]S2.J$VLJE-076K?P*0_?.1H'[S^J\HA--O1JG_F["Y*:,`>N(9\ M/-!>!`NZ2&UWZBX^?1#QZ:D_Y8W.SS5(_>P$J#MUEY#XKM#DZ"`Q1F=W]LKN M]$[ZT\[D'+`+^J7+H3KW#D)[=J3NSOE=F?=#L3#HV MT^F-/9"@[M2=/]GYDSLS4&=X]LKPX$,KG3]YP/YDE])\[GK^DK\K^=-YD"Q8 MW.1<=@)[J&CIV9VZ,_%[9>*/.X5Q,*+3G?K'.76G)O=*328_!8[[[[3D@?A! M75[M>?M`O$+;Z?QT,KJ'UNW'/'5GT_?*IG>NS^&(3G?J'^?4G9K<*S79N3X' M[?IT*:#G[OZTZFIC2;BEGZV3Z#VTA3_FJ3L$L%<(X%2^S=W%5PY$@+I3=^6' MWQ63=.6'!\U"^V%WNG:V`_<]N[3;<];QE]JKY8>H[9^'G':G[BS[P5GV8>=1 M'I@`=:?N/,K.H]R9@3J[LU=V!SS*26=R]M&CY#_\D5\[N+UGYN6*1PT\!MM: M!04LA(\0+(,H0\XI&6;T6+"XA_W`J;W@,!G[=QGA2.XZ'7"I,N=?+Z?CSME] M\!"EF1<&14#O)VB_%7A)20\LI$MCJ2#/RY5XC2%*%G&):4SMA7>GRQ+3[Q*8C\D(5`=/[#.TH#Q2(MDP)O@#+*P$Y`G#", M\(A!3`1(^(T>#0;^Z>G$7@MI>308G?G]_MA[#'+@H46:X>,8RS13CVC4G\U0 M#W"8)ZV]QP%_@+_"M>$M1`\L?O(YI]L$,==Q103"M7 M.YI,_=%D[-W#Z>:,)=XB6$<%*)(_D5ERN-N"P<<6:5Y83XP8/"8."/\.Z.D0 MD*`RCY^\%2P`>V"AE$>Q6(:"YA!NV&E6T/>G#^+"%;<"4R[+6&=:\]-\P[F3 M(LX_-=7`W^\6^O]L'2?"-;\^[J]M+ZQFEUP=[-[=7Y M/[W;Z]F[F]GY[9NK=S?>[-V%=_/FUW=O?GES/GMWZYW#XM?PPYO&ZK`&7M@+ M.F\D,Z?;[;]^!\*18"^T_?Q%TK>[5Z+'Q>7YU?4,J?^S5Z(BQY]5*X%-`2UJ M:V"2#-*VYT%^[RF3V8=="17\#E7P6ZZ"+]TJV-+!]6M^=G?^I>[W@EZ+JAN, M7]@\*_'I*J2CK^,9L-EY">0?GP[\'IB4G%Y`036]:+A=#O6*U'L;P"\4]XA> MT'!G#,P6/D&5/`"P@7M^098H*QIT/M>9WN]PUI<^<X;`"D%?ND+16/J4NB`*8#V M!Y_/'M$#"I9+<%D"_,AC5-SKU&O:F7)K#/(M&.#;T"&1_0&1V_>`5"A2`Y0G MOGG-45`K`?1)$"P#W>66\*P!0.3MTF:>M$'X6N+#3N0:18YS,'+UVV"#C1CZ M$W"K3B?32JAL35J7,F4E3&M04_]*^UN"HK/>9'SJ]_J#1E8FKN*\LPI"AE*& M!J&HGQ6VA.*5,]@,*A&)3@:]OU]DP:-WD3XF'B!Y,!NY^AD@%T&#^5-ERTS? MNE2^+D=`[X68>S/06`P]JA,/-[J,,O#\$_H.T^4'*K'EDON7=!O]4U_<"!*I M[X]/A_YTVI=7@)107$>#2=\?@JN,\AJLX3<_42`'/#R4WLFX$E_=:W?H MK!R\:/@NOFMCG[^5@.;Z$WVCB"8F?N]L8JUC[YLV.CR;^).S7L-&SP::W?Y" M1KO3$3OK")]8$N^.KKR=D;9UQ,B?#,:$[+8::A\%MK*%]EIUX]C.&A*+VK;* M,G;#*1D[&TGV3BMV[+CQ.W!C`_O14V^$F)!KO"(+DCP@^.%S)@@<#HW+=]G* M2HT15J&GV_(W`='ZV=RH%#](IZZ%)"L4^EL9/]F;JA2R`\JU8&Y]K8[!OR&# M5T]"-\*QOM\?3?W3T:31:6]RV7.SD>_PL4?3K^1C/S_^Z:)\ MVG(R$=%%^5K=[YO$`,._!0E%^-`JZ.&^GE-W-$`TN=B8!U4:,9EM4(H4&;C* M"U5K'0E;*$,&@V:?HQ8$4:;-3K`^X*XUXY[706*%">MVW&'Z-T1,O#;ZR=C; M1FUU\/KJJ_%N@V^Q"^LJ-0*NQ0`=M26;&?R)K:N;VH[CS=C50.GFJ(GJ1S$>0K8(`H% MO5+P\A&>B`2PM:-$[`3#&QC96.G8\O$^Q0*+*,?MU.[2#A5F021SZ7",)4A9 M?K(YD-Z)4X,I*+$R85;>P;9(H&I@LDFJC'O5H^QC?S"9^).)C30-H6J`C%+" MO*/)<,!MP1:A,F31D+!=!,JL'-K9:F@295YKVRC[9N/A_2CVXS#P[K5RV2T5 M54'>&Y8]$/=JL+<]ZNTP[Y=1="UP+M<]E"H<3JM$H6YWMH=H>,I@`2JCC`NL M#=+CAUJJ"W^,0U"\59!]9/R/J'\?V=S+R_4Z!8\[EYQ#!92PP\+:T='PS)\. M*\!\5JD^68V5L37L%,-=W*[R+[164D6:1:4FX5A4[$=@`[.@5+R68N5F4!;W M:4957(Z$O7#D;MSY&E@[(B\"[!<]874J5K>;!B M8E2-%U)TAC;CO3CJC_W3LS[&XZJB`QZCLQ,FXJ)Y0>+0/QV>X>=$I5Q`25$@ M9<@`8&'0LMJL<3R^\Y?/TRA\->6@Z@C84_SK]35T0Z&Q%B!=`&J6\AYEIVT*']*JDG6=LF MY=9*S5+?+.B;MN,6_$VR;O(M[JA!^#KIV^32-TN?*"/95?J`!^*(EZ#4"N3J?:&[1I`"]$\L>*EU1VL;.#= M69RGOJUI]TJ:L.,G%F14+)[! M3\BYW!IK*61\Q8BNJ&B*X('0$$_1,.#KUJC?JY=V31O,T7E,X2>AM9'QRSLQ%WTL;^<#24#I^S4\R1!E6QU2V]8L\Q@_WU3?!F3:"% M=T:R$KQF@W4CK)EI4R[!(_-2O*AMSF*C%C`X.AW5C.Z@WU(IF`:G+1P-$1;PWE,S^K$B-I8E MZ;M8Y+8FV;%+?G!%AB+7H]ZR?7H[N3!M80WF60=G M'-;TD8M'+7!-AVF^35AAB];L]T\I66!WV;10EH&F*K5XF0F'VD3/.!>=3NOZ MK\XJ+91A@_*S2;.["V.;^`VZL#Y:H6_@Q?862:\S0.N$004*(E>$-QU'3:+Z MVKP%#EEJ2`85(_M4,'XUL'1SFM'AAYI?T_(%6VRI0NHWB&0KQ8=Q'1IA4V)@4ZMP#Q`! MVCQ;2]"N6!@%%;MSWG#)FOG"B1Y`/:W%3T^WBI.QU`X!U$J6'!BG53ZO9:NR M4]U$%8"C@!C"^Q;MSU:OC!O8F.&9,3!$):4[>W3]YPA2#J.4ZD:+LE<'LMMB MN_JGSU.H[\#/:%"HM4ZXPFI)MD5R5OEG6-4H.X5H:A=A$2GQO%?(NE7L'6HT MT4W]T&)YFBL7%`ZT7*Z%YL/:@5PD7^;_!_Z')\Z%SF4DQ[=5)VW!=;XZ9$28 M8!45!8=T8[U,33R0Q]PH)T0H%3$G#G,@[>E7TH]TZA#MU?+M=<60:\K\'M7)!Q_(:5` M9IE@PR:U!BO=(J)-/O$/2VC2H`8<36+@3!9"I;2IRW,1*`S9(@[0=%3S'?`7 M0$HCP-YZ:9NV%K!ZP4190LR+M1RC7U`(@YA5.M.1@<=Y@6J.AM:72H,`1#Y= MR:6FJXVE2'/7%#7J3F=];U,(T1(A/NF4A,VLZ9"["!N'@)C4=YBAQPB4'\[E M%*9-M>14JI=Z)HSR4(I9PD=XWZVNB.+T$0.;.)`0>6$>A:)7MU[G5N>O)=XX MHG&V*/GM9P%IL1!V)N*9+_`779-3C%MX+^9=ON>O/E;C5%[BK,D%"Z7K38Y- MX(6X3H@36/3I*'*UQF\5\UIJZX--#UD,^\^V3&W1VZ(;O^`"Y:>V?"++`W3_ M#3@^DYA&?FOS,!B;_A7_W=11CJZSP;*@GD)M#Q=881B'3_1GIZXJL05Y8#F,(A<4SBD!GU(XW*EL*?K M5O!?5A2%HJ%'2CTZJG2$7E.CJ4V^:'3#\!?-F)S&3B32U/_)!V&+LZE.P#"- M8RQ_J@\EKFU-;45>/ZUIW?Z12`8'?**4(X.KT/;1N++?R(768:T^;92*.G/- M4=&MHH30,K8"C>N$G[/B$<M`40(;,99 MX`71'N$T_@I'.@(QG8E[Q6*,C3 MA,:?!T619@E[RC6'S:P(8B**+"*7N?>"?0()RE$_8(M/E,_++*]RRD9^J"R. MT^7Q&FZ>%6H-Q!B+,LMJWFP=6%L'4T`;U`?-MR-3G[`[8%[Q%_:)<)THFM%4 MB4.:&T,2^%&JG<1+K3IJK?V$Z:)Q]&"+CIG11'S\X5J*C_!%5R_S`@5%U%2VN/=:>1379O7 MO;FZ`"@3&;G&48D<)>4T5#0$"Q+"""GR`)NA_6K`53D=YL::?4T8<0@MG;]1T=;TK.+]G,\;;8AYM`Z\._7C MFT1-]K$'@?%8BZ4C:Y2J(C-8YZKBT8("]1AGN3;"TZG'YS[`_Z>;PMQ&T,/< MD&L0JKO2*1*/DP!KG) MV,Q9$I58S&4&BRJBGQA24Q'E2KOWL:_=?/(*@&;`YK'[:W3O#BNOB*`[80,6Z(_ZY83*T92<6Y[L&O>?F-"OFMDW=&):50K*\(7%-R/$L+"7-%PQ>). MI*S*`E$63H`I&*\PT<(>*LWBN+Q$"/:1EA-6S('EB'ZBKAD,&UE[0&^6@PF+%C?@7(O_/CH=_)TW*2T%D,Z?`%RM\I.Z MYM.L=-4RC7\(HD1:S%K6-="#%W:@@L$'$4SKA%C'0&V:=$\Q$TL#.5[&T[%Z MERS?A?=EV,/W7D=7?P+.`H;)@+D"X4W%^!CD"BM@Y)`TZN0VDQO:]RV!)**+CU&Q/U:4"TZ')Y9X?V+=2=O3; M!2+PS50Z";\&ME4()PH@8/0[=IPO`GIJ,2RQP%75;RCJ<&0L7GK4:]KYR$R1 M8\%^NHSAJ7/<%34D$E'KPH/]SP1FX;?RCZP`S0)_0G;'0JAD`4()?Z=W-&&# M/`#UF&8?[4#.`O22$`Q0+@@8,-F(3W'&2QWMRE+;JN3/#EW"$>8\Y4#)2AY/ ME5%44$%`1.LYSF8'ZE8H`%5U86VA"N=Y^.9D;,-Z+!2/F1S2P%,O-3T)?\]! MHG!WF*VUBIX2T%SK.-!4A[T-'[Z=9T84B'-4'G""3F5E( M!;YD#D1]V$)DT(TM!5KZ6);+63O2&>R"!\10PUL.)EV92!7][+WHOY2AYV/- M8,`?B[1X6C-!*[)A9N=I)944@T'G29XC$'SZ8O!24IL3_J%*;7IUDM/5`MVC M0-I(%(]W(!5@+5?@J"\"W[LLD:-HK0])9#7#_A.,2)BNI*.9BLG*((0LR7DU M-$L63[HC"GLUVW[(E@' M"ZR^$;H.IXC8TYI`R2+_Y)9QW-K4)JM=K,(8)$>N5>=G3)54.!>]J'SDXAX? MU[7XJTV>R.A'$*D7AU60*1XUU-1XK:8_GJCR6?%>(P?)V7IN[12:_WAJ;;I"3\!-3KI[3/8NT`=H!J$ M/BI8Z!=U)QNF*2A7VW$M6_L--T,J[>'7M@^VOE(7KAY[O>;)KO>H=6^U$;(' M_MSK-X%ZSK=>3[6W7B\^7'JW5_S)U_^Z^OWB\IH_]CH[/[_Z\.[VQGL_^]?L M]>^7^K#5^OZO+W^?W5Y>P"]>W[ZY=#T(ZVWCDSVXC>\%O660DYIY0%78TS!P MR%$0/B#*"!W]\I4>H1&K9OVB2CP@A`OT%I^\&;]=5&,W34^8II,?40.G%[/@ M@4^6K@UWK1DY68;-']%13K9XSK$G*U4"S`$DQW(\AKW6',A#0P5**H[,.)3Q M0NS6`FJ!=Y)LLU`6Q=J;)N[];#HKGW"(U.DJZYK;LAV381KZW2U.,2NT372F M,]O18'#F#WIBLM!@<.H/)F?FZ_$$XNP4EQ1`=![2)RPN08Q0)GPLOX0*-.-< ME]P3)E"M@E"*XDP.WS=]('IS6^4RSSN53H#RWP M@4H.W:*2C+B#%O%7ASLK`[(-#MY":1-8.EK#5E4I?L2SX9$9*1&=)XZP+X4^ M*-`Q:'K[=>9J%&^@.9S;IIK2;*X\\S)FU&X.FDZDB[VXTC'2R<$H#)U:;ZO0 M@A)Y&D?'A]<_G?'^#8WN7_P+\[Q^-S"X2Q<(+AX`.2D5QQ*6]#S6F2`@?! MU4!56]'.;LZ]VW0=+;S3\9A4):Z+$6T,48:>G)R`W9+\.1:^O%7U1#,J,8S> M^!1+ZZ!#D\`)V?S'3Y_F6?R*_OS_4$L#!!0````(`(**7S]D_F'XZ0L``.:, M```5`!P`;7IE:2TR,#$Q,#DS,%]C86PN>&UL550)``,#$:].`Q&O3G5X"P`! M!"4.```$.0$``.U=:W/B.!;]OE7[']C,E]WJHH&D.PFI3JIH\B*!0$.2[IZI MJ2EC"U!B2[0D\\BO7\G8"0_+-K:%(3/SH8>`\;DZ1X][KZ[%E__D\[DK@`#1 M&#!RW6D.5O_+K/_E\KDJMH8='>9JB/%/=09'@+^'1H#PO_GG`\:&)X7">#S^ MJ/-+J0X)H-@F.J#BC5P^?Y83__W[7U\$2)4``7&2:V"4:^HL=U#*E+!P7OPKW9 ME2<3\<;"]>,#Y^I2N5PN.)^^7DJAWX7\MJ7"CT:]HP^`I>4AHDQ#N@"@\(0Z M;]:QKC&(402["M?VL\?E#Y.J+%W-F,NE_M"L`G:H)=S3#]A MTR$XW:/0&IK"(N>]`0&]TSWK!<"\X+!8/BB*>_PFWOF+*T:Q"0W!_5?-%"WI M#`!@>SEQXX=V;:$-%C#@"T8`(B8T+(AK"M);%,Y2-[&&."SH,/[:`BBNEN\XY.:+);>__^8/4/!FD!BF"H(KR.'YXI<-1YK)[T@KK*H1 M,H6H_ZB9-E#1A&C`K[(O"E\ABVW4B.[9R%^NJ+XXH[A7%*AM6<[=\I`/`._[ M/8*M$"497IL_3`Q`3O=*>[DQ@/T!$R_=>6%MR5H$##5H7$R&`%&@L)?Y`[V9 MO96"2-AQ!=A?$B#VN&FR`2#GH`?X_8TJIHS>`24B^`-MN0@2=EP1#M(285%K M/@P=W)EU=QCIFQH:4N0DC>,.I8;ZL&L"][:`74QTTS;XK'*%L3&&IJFB:9%P ML^U_Z^D^WS&CD2J9K6-+>0Z&F$*^+&R@9TJQ"F>9KJ3Q-9.S)YW4$WAMZMRU MK9BT_0A>FL[3[OTM@H<\&IZVN&?-N/#"3QJ*@$/1BAF(M]B0[=(AF*AP#V;; M6A-MP*?M%-2AUH4F9!"HC,!\4)(87=%U;//`H:5--;XXJ0P=_9&R#K3DJBW, M5!*:T@ROEC#:P!1Y@99&%/>H2+C9+B&Q1)(0F'9`QE&)#8S-C'XY6.$LXPDY MLD8RMN3S<3S?UP;W>&.#*`!M%X9.$%FN+I]2S6!L9KC(H+)W7Z+)(J7*U>3S MLB;Q4K$V9=@2>9-9O*-0$!G4K@@BIXP`QOPR/Q@,@[6HZG@RX^K MP%$Z,?F<(8J]^.U9'_RH#IA\4HO3J]BR(+.<_0MD5#%B$/4!TA5Q'P2W1=&( M[_03Q)3[?N:^R/40_F(QG3KE< M2[F157ZDXSGV:,9(+?\K&-G.H=&X7R4F]5#4,*`P53-;&C1JJ*H-(=.4;-;( MH+)WY**)(:5*%H7&S0W8ENU$58XK+VJV"!@`1.$(S*I@ZIB*S:!F[UZ;*,H8 MK&5"UBM@1/G6)582Q,;<51L!$SL)\@[3^N!"5.`-":3@'/2@#MF<=>\.;*#Y<+LA,DMT;BEIE/NS<_3LG-WD(ZAB6!!!RH0Y(^":HT*",,AL%[Y(@H2R MEG+XWP84\$:(&M.Y!52A1L&`&4?7D20*H2S=R,)XLJF3"6KVOFN$:(C1*_$O M,"XQZ0`R@KJ:N39UO ML;]2OW,.)O84[CI72@Q]O?<6]915:1873X^-L'3T%C?"9U2LNF7Y)-GU.XSP MHBT*73(Y6(*)]$J#J$D$@TW4T4S0[#DA<@UU["Z%!M2(DI1)%-C,$PRAZBY$ M!%&(3#5PXX!4X`&.>#$11MJ0#F;.TSGH*BE2"`?-?HI;6[80%E,.Y9P,^:J- MR@JN?*!V3",I8RG7*(J^,!O`8B]?/,5_#PB/[I6%`,&`,U?&.0[@C^^-QX,_ M__BA#^W)3_2Y;+PW^T\/]E)I'(_VE:-ZPLCUJTYO[ M'PW0`./Z]+I\??MT6#L<=D?Z^>2I7JGW?K6OT8?]H\^DJ%\4[(=OWQN7Y`$V MJ#ENH%OK7+]Y[E7NKFX'X`[@QAU$+S^?CQ[JS]KQN/GTZ]OUZ'A09D\?JD/X\]V?V"TR?%-RZJ!$9D.S)G((1TL[=+..\#>'*0*8P1V;2:J MM.ZQ>/)"F(!-TS&<`0*HFK*VM8W(.+FTEJ(Q*$YUN\N[K4*W,?*NUB:CF4Q=7!F$_F M--4A@WVG%1W`F`D4[[,%P64]QZZE52!O\K1;"IZML`@5@4HCDKKK?R[D@W]+?][]X# M-]=)@F?:;&HJ7T^0C+_7!YBXB;.+SDWY.GV@HE3S-42LB$-?E3VBN`9Z@NW, MOZ%;M::FZ\_I2[OLI64`G2;J^; M,OID9ZS$G4+_*>E-4;1(M;[+A[/\4V2P(^K&KSHX3F69?*MCF54Z+IQ8^GI< MJ=J*J4#D71^^40EV52TG&SVD?N0]>U,;4A>_MD457)3W^L M<;O=7!S7)LU+#A33B3>6DVXUY)ZSZ_G'ON?M*JHMB6/)3L^_<=GW.D%*:?]5 M,P+/7-V,^L$F[.9HCTVX)[C?V0(IR.V<$^KTL(V=K+J^$>]LI(=R[FF>4F9I MU0+OU,N*,1+Y+NH\X#P[`',SB@<9L.M)Q/78]K3V*=E^/T\@[*B4T8KM2RMU MV"GO#];0B`=@6>T/^J''GXOX*N><=GF/*SH/0@A8_AT=)7F:4-"MC?8"M%]( MUH33*BUS3$='Z4^.;$10.?J6NHMQ=0V@658AF>94=,DG/Z1G-17YH2>8B@C6 M`3#H)=>K#OJ:^19LJ\H6R_&V=@(*4'PI6QQ`9KH_6OF&-']NN&K)%K"VTZV) MH=4B@[+RA<1"S04Z4U4/E@?BO:?QM4JFI!(AL6R.VRMV!D3UF[*CAT,0MS4> MC*&<'Y_21W83J_?F/#0@P@2RJ;,1ZYY=J5K)$/0M]ZK]&"G63DLF9W"U.B'1&4WS0)OP M9`+Q=MV3"29SM<@@C2R%=Y*2.ZZ=WQ%7F9?PQ=MUX8+)7*TC2"*<,%,\;'"!HN;[)NA"XN-WU'S?.2'5 M`X^]YXF5I+3(P,3$P.3,P7V1E M9BYX;6Q55`D``P,1KTX#$:].=7@+``$$)0X```0Y`0``[5WM<]HZUO_^S.S_ MP&:_/,_WP^W"<$ZQ[\CZ;SHG*/W?V\V&Y<``:)9P&B,5PW8_5]K_G^-9J.+YXN1 M#AM]9+&_ZA9<`O896@+"?F=_GUG6XEVK]?3T]+O.ODIU2`#%-M$!Y1\TFLU_ M-OA_?_N?]YQ(EP!.XEWC&J/&0+<:)\>-X[-W?[QY=_*V<7_7;;QJ'Q^[#[$G M3(@>QQH%C>>YB>B'(Q^QYS$Q?\=DVGK5;I^TUE\\.S ML[.6\]?-5RD,^R(;]KCUY_752)^!N=:$B%H:TCD!"M]1Y\,KK&L6Q"@!7XW( M;_#?FNNO-?E'S>-7S9/CWY^IL6&1?<>P-F3\`[QNN7\\<@!K--X3;();,&DX M[_C.6BW`AR,*YPN3L^Y\-B-@\N%H_@)@DX/=/CMI2O/)H!8!TU^,#WM_W`R\Z!`5\P`A!97-@M_IU6Y!"M?RIE\?M0(P!9,V!! M73.I!(YW1U3P`GW$N``CB_T\9Z0$F=X=I:5@-G0U.KLP\9,@BYO'.6]2F+O! M%DC!C/-U21+D8[53TF[+??-V:OH>`S)92,]#6]K<],838&$-A$PN1-AH2YV. MPEQ(GYCBG*B8HAFXD3]9LS`C:=KVL&YS)=%!QCFRH+7JHPDF<\>22<%9[#`^ M1C6B)^4UPD9:FSC<.'KMO((!&67*"#4-,-%LDZE-CXR?]Z3E?:>U M__AZ'2IF%L\UB(1Y=9]6#.V,#4%T>PR:&\KI&`X;P+^HE4#L0-.<@_D8D)3X M!A[=;H0JV-1,,QUS_($M2VRR0@3Y^KIBQ`-L@6<+(`,8:\;XTQD,=7;O$] MJ@5,BZX_<7:M9OO8\X7^$4/%-[_$F;[3QA&2E<6P2V&M4@(2[9`@SVP&K%GQ M)D.RV>(],R%XGD0N%HX&`A,#D`]'3%NY\_B=CI'%)MJYZ7R+K04P73L;V9`? MZ0!I!.+.,U0[8P*$MFS+%4/H#AHKEL#,"Q5)$*&-9#9[0WKLO0'O$5T`'4X@ M,'J>=E*`?R2QK3*3+H9]M1LK@[`Y&!!%-&!^<<@5QO=V[N)0+8NUO:9&&!PP M3QS'P'`M#NJH MJ%3HD\HF[V$$P]^!HQ?WIL%M7&RB\J@:\\#X/^<_;;C43$:(=JRN1L@*HNF# M9MI*C)IDA/T**C>I')Y=_GF=$,&`L(1$-21@H4'C_'G!]D+@\:="-.&$"E@> MZ001@8]_GQ'"?6#-`.F!"6`#&EU,+7H#E.`>3JCTN$?@X^'^2AAWE[+">1XD M$/0!2XKU#B8>QB<9#/DAP?ZLF[;!M/@73#+XLML_/;#`%#)>7"H8Z>I40R2M(M=(0GE$X[2S M/\DP0]D>Z&-+K5`24BY8B2244E(8=W:X#):4.A.JG*[S[ML'C"7A<,,5U,;0 M9&\(A&(.88\7B%Y\Z.;@>P&/[( MH-&[-K7PG(<$73]$H2"B2%5'$)%@>8)XG4$0//)QY;,/57H+BME]3K/L/G@^A];<.8-#1A1[E`^ M%BUQASE$QHKG?WF=Z%`L_&HV?2AB9&']<89--@;E)Q#6JL?>68=6JHC$X5$* MCJ0E"$XD0"*H2,6#GN[YID-065)$&)G"5&GB6;83UMP'*G."&]^F,%*+_1Z- MHGPJ(=SW$0H&^\7"#8;AO+5F#C5H]%%76T!+4W(6%D6J2'M&2!"1F$D).'1T MW9[;C@/MN'"\N)J`&4^.7`*WB/,*4WX$-YC<:<^*PD*I6"@NOBHFO[0(!W,P M1(\VE\#$3B(!4WI3<,YKY1<$4K#F>,M5SR;,1MM]0LTA:&:N*K6'RI""A/C) M/N\JA!M"I7)[;1A24LP]OPN+C'P$^YD@%A:%V&V^*GR'4T:,6[`$R%:3H+89NQ(ZZBT+FO$.TJHAN/M,P833Q!J+#L_@2)/?*/F2-"*"\`A M8>MU[R@P.\CH&'/VMIPVOY+`XT8%Y(=(%I4CD40`!^'*7-)V"RA@'/,62KYL M"H7BB"=86+9E$FD3_!\8%)B-`EE!7HRL3 M4B[[EI440`FM>WI@09@UY'3,9C^;P,&!+=4Y)A9\\1IRRY=4(KIEWM62`9`FY$+`D5,,-%OQR(HBF:VY4B&"? M2''IKTE0#P$E>\1X,^@V758IUCXRI5;?H;@$H\,"OI:3I>R.*.1VQ3U?XM./ MP^\N(S'[DC$Y(%Q2`S323#"8."'E/AK98PH-J!$EN:!)R!;8A"'!E`LX$4E` MS!S'X50H)P(8F?-GOLYL2&>N)=8#8R45N(>)%JEW!>1T`$$9'0YO@+7=`#N6 M1>#8MG@0]@[SQE<86>SE3&>;M``!5$W1>FHF"E,M*:4H`*^4U".'348!![6< M$LT?0:I":RT2+1E::RU9A5&471+5T49[X&3V\_B^Z6HW7D#/Z=X!,H=(F0,> M3[`J&]4!V*1D$NVO,(5K(II8=59'#&!^QU!P6UJKI8]@@@D;F;'!1F4B)RO' MP.<]*-P*.QYCGDR`SBR/[DQ#4]!'7C2`,38D$.DPZAZMS#N;="Y+[$:IE$V@ M%E+D$'&/A73'B9&/E_U@,?J])<3!N"'?1VQ`Y_;%'M`)T"BX8._#Y(J`FEC- M8:+%QB4Q@FJD\.Q@$FQE)QA;#G3`<((*J"_6J3VX!/9".[G(4X*9H8!9?H;._A"(/+H-%BHR M`V->H,CK/Y)I@)P%&JRD$#2L-(*8YTC7560?-0IU)495**'2>H,'\/&@/Q.. MQWQE$V)F`:.S!$2;@AN;,SJ8[-7+*)-'.@;*;"H(0KIV2C:GGD65(?';*R], M_'0D:L34U4=U]9$(\G7U45U]]%>L/G(;IGN[+KU@C&VRPSK,*EL*7#"5=+`R MZ]&4L&0/ZOTU@DA"L^UP7$G@SBF'DZV/0?E],$RYZ-`$C`8?_0ZS'SBO]Y27 M1V==%K)HE=9+D(NHA!HV[S[H;8I]#B4)!VD6=X8A>;*'W+P=@W3VR^%X%PO> M*--+VF04UE4MOG*6`>F:&E1C\Z=CH,#3$86"3BD$*?>\UEE-RL6:+`,J4SV? M>ZNL;T_@F;QNGZWN3"-3164PAZG^BO),`K:,_,ZZ2+,8^::L[)95>HA)1D5R'4"^W:I4I[__>;#;^\_7Z MX>2___E37]C/W]#K,^/E=#G]MD+W/?OI\I2/^;D7-TZ7^TC8_6V?V M\I9^OOOS&ER#IZO5I[-/7WZ\Z;]9C)=Z[_G'5>=J\O/V$_KMU>EKTM;/6_;] MO[Y>7Y![>$W-IVOT9=[3/S]..C>77V9,QOCZ!J*7;X^G]U>/VMNGP8^?__JT M?#L[LW[\UCW]/&^UY_3/T>CSOSM?Z*>3XX?N\Z`#Z-G-Y[>/7QZ>7MO3F7%+ MWGX>SOM@258S\^4'_M$RV^3E]=NA-7]8]O[X^?7R#'S]X^G-SV<\@G/\9G'Y M^.;CW0/6?_:NOG5/C;/%ZZ>++CAY(8J3=YK4]2[3SIXSWT^@HYGH;C-5:*(#Z`LX7:+?9H]FQE4SA0* MDE-XM7=Z)GZ%]7L0:"F%`_MTNTSU,RN:=(PE#[-3I\':`E.8UPX=QT"!1QH2 M11L+<>8+-SSSS(D0&,#XN(HTU!2Y[$FI5W`/3H-MALCG?HY"'RV9RRHI(R9N ML&IEQ,3"(EYSNXFR:2O/"^KHS*4D;.U:;.9`IFS5V:R'B98FR3ILKC!JJ7+8F&10"6IJI>BV%4"PRT"=I,87AN-/(+Y.#NVX=[.5#\_MAE,8C0NE5=4'% M@YB][[M_(FQ=YFN(,('6RLF]FV&345%N>Q^@7A+/-<,Z.P2O/\LGLRPWU0?$ M33OAT0Y+2=_S!%0K;Q%&H9DA:>=`;".$V1Q#1V'4J[D`T\";N3G'NL/F^;/N M'-S<,OMG@#A]WHB3_IY\N(:_:J!MD_9 MKGC@8ZM)4?*-7ZRY%C%3PNYT<-'(E-_ID+W!CFF0]=`NP3`EG[Y)@%C/YBQ= M6'B4G#M&P#A6XIKXQR]N-B>?5L$K&?S@2$E>=E(L1W"*X`3J&K)XL1!CS-<4 MTE'-@PGO$<=\'>)H@%N@`[A4)**L+!49E!.3:V8A9$XUV80!@=&S";^\P3&G M7;*<.R4&TT&BU1-E`B"%R`P"GCT72*B>8\(U[)JCQ, MM'K"2@"D<#ZRPY9O-C"[Y0KJ3A'*E(#D)7,'ABCPI"@=YHGP""8-YZK2+OF5 M'2729QX_E9&O'/3W;[7)LP\NMZ^.LO8QW3.AZ[:W==O;NNUMW?:V;GL;JJW) M5$->DZQM'W*W@^&0`,J#D&X#+4\1:>:&;]J#5#KOO:UPJ^5O"U@J\5?$X*/J`['A@5/A\V5V\C"UJK(?N[ MKB2-+#GQTG;U%L!Q-QRNJSUI^U_JSU9ZT_:_V9A_Z\@C]M:#`G*J>8FNU6ZO=6NW6:K=6NSFHW9$^`X9MKF\&]1J`N#TE^*:\OJ9N M0&[A=&91I1I8G)D*%#-G0'KOFO)"5'.=!%4KYUHYU\JY5LZY*>=019&3.YR< M>.D]X10XEL()KC.A:EU;Z]I:U]:Z-C]=Z^\0["L[S2OXG(9\)6O/6FK?6O'EJ7J?W@^\NP;S*QM9*ME6RM M9&LE6RO97$+)]IB"GS;CXGS),X+4AHXCB55!H<9`5;0:[6'=YOSS*T.=VEU? M?^6_C%8U`/SNOOTMF$+>4PQ9-]H\1J]2H/\^Q4LF*.AR:WA-\WQ,1HY:W@Z[ MT4`(;Q=\R/4DNV/?RXYI8+32GA3MOW>&&Q#Y8%V;$#;6!3/&-?,;T,@Y,GJ, M@^R`1HYPV%]P.>\8J1<]KGE&C2@6U12T,&1%-9NT,LC=*+(`E. M@>L+Q84QM,_^0I=Y*0A`(-BE-C6F'T3,XS0M3DS"7@\.5 M.'LNY-VSW`<8&*X'J$[@PO)Y3Q(0]8]:;MLA'`C_W46B^S`;DVAFGQFXSU]` M3(N>E%OOSK!E=B9BP`C<+22*L*M*;\$"$U[6P9FQ8XSVE$"'CU[R;2(>F>#U M>**X/V#31I9&5A?0C+V',AW@N\-68V;O@1&XV$<086>L+F-@BHFTG2,X:$6L MM!TD`I?^"(+[%9CF%X2?T`AH%"-@.%W58ZYI2`=SU/`5`3P2G<`--<+^M'NG M@S0_,'S8LN\<$6"L$1:YV=X_[-:WO&"?2-B?HP8NN2Z,Q&,-M+AW%QS:E:,2 ML/U#E]N0CH%DC??VGOFH>/'[%A]SK%'@?/'_`5!+`P04````"`""BE\_!(WP M\?,G``#-TP$`%0`<`&UZ96DM,C`Q,3`Y,S!?;&%B+GAM;%54"0`#`Q&O3@,1 MKTYU>`L``00E#@``!#D!``#L77MSVSB2__^J[CM@,U=;F9IH;,=Y.?.H4B3: M5F)+&DG.XZ:FIF@2LIE0I$)2MI5/OP!(2J2$%TD!4.9NJW;7L0ET`_U#H]'= M:/SZKU8+G,$`1G8"77"]!%[G<3+[$;1`)YS-QXX'>D&"_NHDWAU$OPON8(3^ MC?Y^FR3SUP<']_?W/SOHT]CQ(AB'B\B!,?X%:+5^!_@___U?OV(BG0AB$J_! M91B`@9.`XR-P=/+ZV8O7QZ_`U:0#GAX>':6-4`O?"[Y[4/4[='! MQ\N+L7,+9W;+"^+$#AQ,(/9>Q^27%Z%C)UX82/`%F%_@?[7RSUKX5ZVCIZWC MHY\?8O?1[^G,`?!K%/IP!*>`L/XZ6<[A;X]B;S;W,4?D=[<1G-(Y\:/H`+<_ M".`-GGQ,Y013.7J!J?R0_7H"HQA>V-?0?P3PYU>C'G-D)Z4."RT/M+)G^C116'ON=B%M_8/@;;^!;")&Y?QPE>>>59PVU:>+$MJ_.CW8CN0-01IRU\/"('? MR^-H1^79MB,GYP?]*!A(]L6!$R(R\Z3E%X1Q M6$T@X,^\\5]KV?QSI'.8+IM*JWH1MVYL>_YW.XZ9JS@;+QGKU(ZOR8"SA@=X M=1]`/XGSWY#UWCH\RK:''Q@4=HXDYO*F,\!8SNWQV)J,B^C0"@^^.#`<.*-1 MH31IZY/-`FT]IC-*77K?R\R2A55CLUQ$$0P2WM)B;9#4E@4F=&R(-!Y8F^#5 M:&3U)V!S]>C7K+PI7VM3YM!*"E3Q!L=B@KJIE29X;_:Q9K-]6+!O*V]8'3N^ M;0FB0W,*H"Z<0]>9VPCB)^U`)1.B$=$*$R@$#(OEG``DP M7O@)6HY@"HM0,619<^551`M[M`W0DFZ""A5)F8`2-TJ8V+[XG,77(!/<"$E-H?[*A:F%%V=]J(,0RS[(+)=.+.C+\`. M7#"W$WRR>P("F)@]:U21;1%DTE/1P+;LPGD8>PC%*04T&'5F)I.6E@"1B`L& MJ"X@#G*[:2.S.!+)JH@=[B@W=H4&W@UDC!14H5KX2%(VI.>M0>Q,(X8-D,TK)'JCXHQ..&% MQ@J3OF?QL>82:!0I:SM.N$#F\]!>VL@`5>E\I%/2&PNC,\%*]\@^1D<,\K5I MM4(^CC;:&A'&(WZ4$.GJ_/<*L.0))[`OW]X]?3HZ!<0 MI9V@WY->C%J%503-P1Q[7IHIJV@!W8(>5(L\!K&#K0U#->+HC+!AAK_?#L`: M@A-?9!L8XHRTZ#VHYOM8P$FH36-QJ.G44VPV)&&SE]I)+,J2_M!)"4P^2$,1)Z'RY#7T7G:7,.M4$$MMR^G.44,V*$@!G6*3G[.O?$FL\)$>< MS;QD1I)?`[<3!CC;#@8.(J!DZ^&0TYSVS.:$M?<,^I->_XSII#6T_X@%6-J# M!,.NZP`J`%.QFM$?F"D0YT9GZ*@PK$P$6J11L&9<,-]Q,EJR[,*IYWA)I9B- MN!?]-WJ%/#&`,)X,.N_.!Q==:S3^MXW,O%](QN'D$WCA*\23.D!LDICG.8K8@007B M*<;UI2)X"X,8K:5>X(0S>!'&.(MW,)W8#XIBDY58T)YD484[UM4,DB?I%-L" M'S4S'D)V`NC$;@-T9HLI9 M[#N9VP8&P?8!2P7R*52,.-.W^>`ZTXN?DZR`E[^`3#!&P<@66A%9B!JPX8MESU*#&B2%L_G0 MC@814H=(2Y)3TA!&8WP(5._)85+6?WU[5'!1$\LV1-$ M">PNX1Q4Q];6TPAD#R6)L8/I8(X?"O+07_/J):4P'`[`707VPO50N]JOES0F MJ+FBQ0Y9EWD/94T#I[:LJ9!4E33Z6R($,"7P>$7+C/M-&:RHSWGL1`XZ*W3L MF'?A&RZ-062^).'WAZA&%4=&\`X&"S6W"%9]Z][#<\(,O3>RWEO]*\MLB='- MB2_NOR7^:^ZU63FP:O6UQJDCT:CY:?1I MVCN?RCW1N[7FM=G;)&&<#*;9@E-SN"D2T'^:*5!GFH%Q@K?KV/8-UY.@"J-\ M,-D<3OU3;OH\J8_VVK8[\P(/`PKG7V<04X$%$4F=008!+PRL9*V(/6>7VIF] M^"TIS"*69":@D6$50S0`_.I-(3M.(;CX!+5>Z^&RPC+*LC8$6H4L2\,.72DQ MEFTWT=B;W-1INY\7,;E//)A^L*/(1B>',_R_T#T-HS&,[CQ'C3$O25G_/0H9 MMEB&9"H5$`:`O,X;H\,7W@GOLXZ,.^ZJB;M\V4)Z7NIOH5V(CJ>.1PZMZ&)]([]7@44INEK+>TDPQ,PW7S=-M]5"&^,`K"+AC4+H MX^$/N<%[/*GK+;C)SY:"]2H']M9CX11<^Z:U"$=45'QL#+*.,4X\4<1!GW96 MR]7*:Z]`+W#]KAQ>N"]U]?J=P:4%'N=>Q!\-5O&0D,?*BR@:KZ[-7(89]B-> M6[._+[7T=RB*^D][G=E>,(CP.A\$8]N'@RG)9^@%X\5U[+F>'2FY&29#5G-R MIP1++&\?:HD/Q]@S3#S$>0/S]?LJB+?D])./`-2M#"9&W% MM),D\JX7":YE.@GQ>T]AD*#A^<360?L^C-44J*W,Q.XL6_DR`96Y9-:X#5J% MKX&7?8Y^*)?!,%3WMBXB2E5Q:\U5$V\VV?Q1WV'9.%=RU&*0,E*W?9L/;M45 MCWQBW!\P89\\GZ2VS3^YY#8F#V M303A1L#5F,DEE.NFN<6?C"9[U+864ZA^V,04G!F%CD$F-Q(OJFYYCDW!22B_ M\L,`O!'75E5KL^H-1(<;U"F":1BY"*/1LI?`&2D.GI94PADHTRETT%&A!I&R!;PYKZBO6_G7!H(<.Q^%"Q].AB/P1OK=#"R@/5Q,FH/1MU> MOSWZ!'H3Z])T27)UD"MOZ$HFNZK/+TL-W:)=+?69V5QW$C2+$68Z-`=\!E)X M16(H)/-R1ZHU79K'"3UQ>FO2]\7]OC,)-$JLQGZN7H`Z6V"CL@N="-HQ/%V[ M]M0D!HF([O2\7S[1341O;PFYJ^H4-9,1)"G7_CA9>`>/6]V01N"0F6R_CQ!UPW:KBE$%76C683 M,W':8W(CR!`JM`)D"S%^Y!,*L8@D_K!K'_E*SG3E\1V^9@T$% MR93S4OBCUI%@+LD+.TEH6P1[2%+NJ%&+JYP:LLL*F#=ZT!#EVC8JBOQQA_".MD;D;@5Y=,%-G)?E?&/'GJ-B2=()Z;QS M2.6`=?6K/>YU4NMOB(S"\7E[9$G4:#5R>.=)L'1P9XZ_@=?Z`\+T+:ZO=``X@>K=W8^L;J@_=X:M<\LT+^Z?(,P M.3C%RO=RT$_1.0:#J\EXTNYW>_TS`M64BG%\UD)($;?5)['RN89;9JQCQ[>G M?GB_XY**G&ZUNRRJ\UB]0B+N"Y#.]KL(HECIQU_%HH5TN>Z) MT\28D&LX5U)J>:^G:!"K.YAM_-!M^@93)=4CVYE^A2/)&4O-M,?GX/1B\&$, M3D>#2S!`1EI[@C>^=F?2>T^>Y7IM-*>@JAS7<*LR,_HT206NJ/I#1F`TG?'/ M%-RA7N?@5K2&)B+TT<;-G.\C\E0KZ89(;'W2CB?A"&+N/!\B`KCK28A^P#*] MBJ';"YJJXEW1TIM:MR.NF8]TKWH'20BBO'\09%#$O\4_.]C$6"`J^/;8*M\8 MV"M"KTW:&#N&T4JA['+R-:8&[I!MFIK:(6@8^8?_CR#FCM4DGE"L<*6AY)F0 MIL::(;(\-:IX9LS9+B'8+?^X:!+JIJ/AYUQLQ'96I@!UG=?R*Q3Q&T0=W_9F M2K*,JC&@\]Q5BT,&(DG+[/D?'.P%<=;.>"I;+0"4;FA4GAY5U_2%Z='">WRT M_7-+=-"._.7F)4?[_\(UQ_JU.$3.VT*R]K$V/8F)>:M#4X\+4HR4$4J0[[*+?4.CZ#\ M+T"TPGLPLZ,OR``G#UL:WQ!T5`1N9!SGL5B$CG"&YU>921;E(IF/54\>56!!)GR#KS'VJ5JZ%Z"J5K^QCW(&HM[=.L M]EZQQMHPP@Z+9#E$\YY87Q<>J8FO0B=(4C91#DW,EJ!PA^O%\S"V?:Q`8-[& M\+,;E01-MV:%,U+S*@8I]5>X'I:67D,'H.SJV_HO4A[O"MWM?@=R0X??7R%R0ZDEWV62&E%PPC.+<]-_># M9(Z$_-G6E!,E[OAZG&AUH]7CD:%FLJ9YB<,,O;A;M*\A:]@S_3Y8,VQLU%*J M.V]-;DQLD\W?5!G:2WQ$'$$?N^^'=H17E!Y4\UG0Z^&IR!W+1YRU`?.T41KX MW/AE*TJ[0O\F?6WHXU__U6J!/S]WEW\VD97'47 M]V`GO+Y;G)^?O/K_HO9A? MWSG=A\\7[8OIU]%Y\-/3E\^C0\'R-+KR+F/__C)X-^LZ;[],V_VS M=[>P#\/+OA=\^_3EY=7%%_O5_>#SUS_.[U[=GB2??^J\?#L[.)S%'\?CM__; M?A>?'Q^][SP,VC`^Z;]]]>7=^_OGBYM;=Q2]>CN<]>!=M+SUOWT./Q_XA]&W MYZ^&R>S]7??9UP]G)_##L_L77Q_"L3<+7\RMM^?'T^7U[6+^X6;R4VS==-N3 M-R_^`IWQJ-4R=.ZMN6CXRUT,J]UM8-T%G(1$C93)I->YE+AFJC-A>-L2L,=> MZ!&.199V+'OCE^R%OA]HEH0''\\R\[?;G:NSB)-PAK9&]P['O&/R!B>Q$C3M M6SP&--_5JL0="]\V2F9:F`ID5 MJ!LHT2K/':NH$$S2>SI763[DJBE8MS4=;:^.@(V(394YJN??*J;X]X([&._J M<@ZO,[.71+-NZ[7Q=>!':,!,TTQXZG:CS<8F)*JSARMNVA(RQ*HM$M@MQ$A$Y M"LP1F2`!3A@7S"D3^Y.T<$MO\$K-0?U"KEO]E^+"R#I3FCU0@;J1,J_R_+'< MJ8BI6^P\#:=@GK4EJ*3D$^P'*(7RYZ*3/S]UW2D,VXRBAS7:]C3J^V/;4[B3 MM>U73???MN<@0,*V9\U1<]O^U`O0Z79'MCVO,[.V/8A`Z%+J%P@T\-?I\RH,>MY]'3G M8_*884:BTR8`RYB7#V=J3Y(1:,E8$LU!?2M^!.>9)3:8]L,$YB$M%;ABTC+Q MW"R+&2:FR*M'M@_R9CA]+\`-\Y"PT2.B2(Y%.'&'WB3,4\2I:C`Q:6D-1;*X M8!DQV%J.H`.].WP'$JNG_8&02'HLC:0,0H58Y%+5>^Q<>B;WNDUFF)5,TFA8 M"B9R6>DV]%UDB9L^>,E(D@4IZN!WL\GI`!67GB&7*(\GUIZ7-B!YZFM@`3N# MW-[L=S+H$@Z_@2.T`%QRWQO?V()NQYY[B>VK5EH4BIK3%_C<,'="\E?@Y`WP M]6V(#HY%J/2G4^D9CN+0>!*6!\%?;H1NC.V$ M$K*D^<:9X]Z-KEJ[X"^]((R\9$FN"V?F@VJ]):"N-W%8GC$&[O)T)>P%#QB7 ME$W':RJ+GJ7K)&:H;KRF2&95#R=*[YWBB%"R5(U+!E5CITHZ/RP8YHHOG"+= M-YOEEAL)',:+Z]A!>U16?0=7J3.;)"@O;!82.9/3Y!#*B/I0/+P:HX8TZOL3 M-:1P)XH:YEV`ZR58-:='#O[WTU_L/ZXZKUO7UC]B>E'B>H`I/1T2]5I;*)WZ=WJ M>Z"O$GW];V]588_SQFNOWQE9[;$%'G>M]*\(<(T?E>H@H`C7RE.DPL4[ M)^3&B1TEU<791OM&%"W1%D%*4'&CZ^T)>&.=]?I]'%4?G.('HWJ#KE$OBM2@ MY"5'G8V=K[Q48%;`]49(,WC$$9>%=HAM0>W36MNEJ([J^[_&B_D\C7#;?IYF MT0O0N6665NZEYD3MJ%B=).G=;P"B&HJ2G+%\8U?#X85UB8P2_'IBGIV#5/_I M8'39GO0&?<.`K"CS4J&["C.C.ZI7@3=JV5RAV/:A+(A>&=:M$H1/9+:'BVA6 M3JK<;*=O];-8X"5*#MN]+D``>6VX3@Q[PDM)=+21:8IB\7A@&EZKZ:4NO>]I MF@\;'=CR&I2X8Q5;<:E_W;5$UJ293O\MQ[ZIV];;8BA?IMX82RWMV0_)N;]I MAKI$-YIUJY@CUFEZT&^E.S(EM]FLYI47UDI#2$Z#3KTLQQ*U4C!/-/NAM96) MJ)E.)^E\/?)*PY&2\$:Q?P-/X13I,];U.AH13H$7Q(N(!-7FH>\Y2Z/N%9IP M2F&'S<$U>F=B[-T$WM1S["#!M:<1\@IOQY-3_F"*'RGU7%+J(`Q&66JK$N`T M9>%=]C/V-A[!6+YB#:>N*BX7S63Y]9Y>-`M[N(T"RGGN64 M).9,B3]*2%2[1T/$D?3C3>GC"M,IQ+V0="W3:YI$YZ@BX4'"2$Q??Y+,G"9V]>**L@J=490F(*M-TQ M%O,B]9`<1Q[?OS0:7!RN9RR=(4LIV",+/N-'\ZV&)KQ*6^VT`D/?E:U>QDIS M0[TP?Y513];3(+JQ@^SU.]PS.K*[^5NO0X21?',83+-#ONV/T6_2N]3_:>[( MEMS&<;^"IZVDRK,[>^_6/JEE.7'%L;V6.ZFI/*EMMJ,=M^21Y)[.WR\/48=% M4J(.TB\YN@D0("@0`$%@'J:'Y$3O/)Y>=%B^DC>RDX@B8=+W[GQTC4S7)>3(VC:;/F)'IEWQA MU6EF4)N(/@RH3D7\H6(R*&>#VIDJ63Y0 M%7X&'`-P%,!PS(!A@6_YWT(E;R=157=3U))5M9:OQ]:EWXT7)%$8G4BF.7T+ MV4_UMF,QZ@BTDJ/2GW^E%KT+JXWODWQG\#\Z.\]B8*:SB`IEV(W_WA:V%/T4 MNDT^F6&;5TJ([!%6/AXP`%`(L?UIY7%5FP1K+ZF4C/-*F)DS;\Y2,U7OCMKJHM8JWJK=25Z7C"Z\_HX5V^?/RSUY)^*SA\B;->FDX:W=6C*J!1]UB)PKGFGO M)1ODC^K,.HU3JD6!6<]4AS2I>UH@H<'(&IKVJ*,MC[3/MJB[I=IKU]K,'?;]Q/\-79[1RNI#=;$E:TJ9['W1UE7L-XR]HWA5F;A"G5>']BS#Y[ MZDVG+.5"$E3=5Y/[RPWJY6+I8LU/+ M>X=_:56M]Y5S/3-->]T&V-J=)YQ$/W>>W*2%W9DJ5<:95.-VL:[MY>#K[(1& M+G[G->MK5%=K2%=RV@:'+OK@-9:NVX,XE3+]%\P?/=AOF$[]N%G-O1W3IH[K M;AZ)C;QU?G$>5A[\!#MOY>R].?[)[N9UK7'=.D#VA7;MNY1#BN!WGG$*!:LS MO>E@KP9MDOV<8P"*`JHX.BA9._7SM7=#O9R^WHKUC!'3).)5&#R%9_K*>7"" MK@8^LSFWW0E3:=1_@_N(E>EG;P=S;[OQE[7ZDQ9R:/7E5Z;%:B[)L%<2ZHDF M25[M,*V--P]JDF0II@02*J"M:L_:&X=NDFX\9>BP+/WN\/WK4XI^NZ(H\UYI M5?5^'G@K%J/ZK)454>D]=UJ``>41 M)>@G\8VEDQG63U)"9.YO,1X8P)VYN6U"K%?'4_'>?R,=4!0D8?P8I1=T")]# M=)S'+T$83;*1I).9WD@R0J11;#9^!A4(^,9@[F`CM0FQ'G16\=Y_(_$W#QR_ M\Q9.4G)>/)'9J)R``FD$+A\[`SX:OI'QEE_.*,55#Z?)F.T;.IOGC_2=Z,CR MKUOK^DILGDZ(C`7'NE`CV20E&SFR%'7VQ3)(=LL]8ZGJ*52@ M;>T>/7&2[:2Q&D9[NNAV=Q#6[R6MAVBB&?E'!KF]X[C>VWX`9;@K MQL]&S:FRG9QSP-0E:)O$%Y1D/[98HNF+9-7_G^,9(D."^C(WK[A!2O+C5U_@U:0^Z?E(`6Q+B5(&:K4&XTMX!#HU\UJTCIO5UH1:/H2*.HS$`AM6#4AE<.#3DX_7A9 MC)F;9"4.V]]R)T:%W['&$AD.D+2URQ;)K(0AR7[U&]%YM<2>G?O.ZC?5REHG`UV\'H;5FF0+%0IA\%=7JL.[ M_^H$3&M\==(E,ZM%;VK]"R5&Q@`;9/V:2K=Y04_/E0>3$]-YUC2^,4>7!!U"7D+1>8F3+"^O*/6S:.2G"D@#0E70>^ATHN!,Z(EU M6@VC)@4ER8U?,$W?L7,8OF++]1"_H$6YK="R9/>8EI M+VBMUM,;*IN(W;TW)&!:PQN2+MD@ZWV/QXUGM%-L)K;7[:1M]CD98]THKZ[U MK2U>,&$C/4>=EV/YS)?'?YI!G@'F\QREAR2\5*V($:SH*E8C)H9L]E:3NC+6 MCCO5)HV&?7W+G>$XGXN/77Q.$],R3L/6'#<^'/AXX:61G;P7,2>B3T[)M.E` M:QS%/$+(;*;\KD4>I2L!"E,WAWEO70I2=L0Q/"7O9@\1[RU+@C@Y8@,E^;', MT`NW1&6"J`$`@9C!AR","L>CZC]@]LY7D@@G]23()7X<99C.,Y-LHU^XE:JU MLE41R;-E"4WW9"<;BHCB`3UC-Z1!'*VE=GVY$@_D%7G/S^B`J76_8QEC[\4Y M'$A;/-*>,0FQQ7J1Q_1J_B:0]>.W&^1)]Q.='9J[Q;J!/_X*B3;%5'(8Y#`L MPO00G%GH>(%_IGA\HNL]-%$;,YFD)+0Y%@R`Q_\IB,T$Y%8IW?H=8H9[9K/G MU@##^0L*DM%NA:2836:NRXB0E=QDP_D6(0#-"R+S6Z1-2'R'*+DU&BZMY"MA MA=:!BR.]/1FZ MWH/>[GV)S]C(Q@;Y(CQC=3S%B->AHD M5S3`7+FD@7IKCCFO0`X<#-Q:XW6;Z>4BAD0?7/L"#+(9Z&GC8E_Z%">C/?:L M(S7_HK\VO_I3I$.!C[7\S%,HC/K7V&1MA!`J":E,$D`M$9M+WY10T#%Z2D-C MC=BIY>!I0S[BT&F=5].IGMV#8?(:Y6V)>?=1FERDIE5QL-[*^2LZGS]%\>^1 MCX(TCM"1/I5(QE+3,O3F%;:$$K7J)D`__4J@@(.Q=R^)Q9!V)\'55;J*>:-A M5&Y;Y*:&$QUY.Y)%G/@H>0T/*-TD[CD(7Z3&5V%J%<87B7<7C5Z>XP0X*M+U MA2&S'0[2XESH9>HOG5D[>HY>T3FF)4+\+#@AC[C%ER0D96">PT.8.8<#N[Y% MQ_DU":/3+80\AEZ,`SH02MPDH$ZQ0P4],/S0`+1JEP]?('$[0A:0N M12=2Y7$,@U^)W9S5KR*CI=9/?C=>``&#NH/`L5IF-]5_Y*R;[Z242!$J863/(;"DD*N5''")M87]XQ=U]]5'G)*5VV0Q&S<_ZW&W5 M=?-&@7;;"X@%(BRF6S(UI$-[@6X51HCFW4VZ"\I9S$<3;DEHWQ!D*$O*O(," MW5)!"7='GF5I+3(P,3$P.3,P7W!R92YX;6Q55`D``P,1KTX# M$:].=7@+``$$)0X```0Y`0``[5U;<]LXLGX_5?L?M-Z7S6UA1%0A(2"E0`4K;\ZP_`BT5))$6``$%Z.0^9Q);0C:\;C0\- MH/'Q[_O[K5.``#9<8+5&RQ;L_:\[^[_6?JOGS.8W)FR=(9?^UG3A`M"?H07` M]-_T]U/7G7]HMQ\>'EZ9]*/$A!@0Q\,F(.P'K?W]WUOLO[_]STF@UL!T6X<'K8.C#[^]_7#XOG5WVVN][AP MM+]?7MR84S`S]B$BKH%,)H#`#\3_X85C&BYT4`Z]6JF?8/_:CSZVSWZT?_!Z M__#@U2.Q]GX/D&NU/F+'!M=@W/)5_^`NY^#3'H&SN0O:C'BV-!BV'\V;-:3FRD`[EZ+-7QW?;;6AQFPX).#`$0N MLV&;?::=VD3[=Z4J_C4T,$#N%+C0-&PB0>/-%A5TX`Q1+<"-2_\^HZ($E=YL MI?V[?&_H&61Z8CL/@BH^?YWI)D6Y*\<%',KX'Y=D0=96AU-V1V[/.]SR0P5D MJL"O0T>:;X;M":@0`2%3"Q$U.E+=45@+Z8XIKHD*%RV@C7QG+:*,)+?M.Z;' M)HDNLHZ1"]WE&1H[>.83%`[-,IN)*3JG+(]^S/_Y!=5K36/PZ`)D`2O2F;5< M@&!$;DS%VHZY)LEF%,S!D2#;&`'[TUY:2Z0[(BXCL84(R:J5F%?GULTC^Q/# MF/_U/*O?&J--ZX9(^41Q;)"1SQ;#+[:9HFU@NR3ZB:_Z?N<@)(W_2)$0^;RX MIM3.X(S^E2C5=B5E'=ZXQW7Q>@<,;$8ZT;]NN=LZXPX_T9[[+'#?G$+[V5/' MV)EQ^(_KI!O4P1;`G_8.7G7D^,F-"9"!H=-]A&H-L"8HG,K*Q3][C"2"OH[. M.O9BN(<-WB$R!R8<0V#UG9D!D1+L4X6M0JYF$R2YWYHETO$*K=%YU8D'H6K[ M4RS6A>J_?A5C5-SNU"4D=?Z1XT,;$BJ"]-:<$4=[$Y28H[2HTF.`,;`N`B!3 ME?(U<@$FP/\D]X#O>9CU)LM`:00A\9M:(V9R+QCF*=W4`GFD+4L>4*+)_G?\ MRX,+PZ8:DJ[;,S!>0C2Y-VQ/"37*)S@^VLMD'UD.&1\^.>$3-[$=65I,G(B9-`4_?:DOJA_VJ*Q5;]0:-468KMT^;F.F@24C'2:V M+/#`K5/:L,R05H/!F(65.%>1DGTN9P"FB=*=X\QIOU2D0N/]5FR"%-S+\XCK MS%B*/%AU*C1?FJB:F"\5J=!\;[314W8LL01NFB1&3T:%SW")\(1&>UMV7KJ< M2%G?()D1']]IVQ+J.;,9=&?^-CVR>@YR(9H`9%(EE03*#'&:5H)\!X0R\9*R M]5IX\"D>=55.M22B(2_9Q669&]X(X MVR0Y8!`GB3(VZ(:11%]390>\DL3HH1BY'7,CO;^-DI3TE_"TY2"U%MN2H27P M"5EK&QXIB2S15)9E08:480\-:)VAGC&'-+`J262EB-(6)(7,EPJ8MF16US2] MF>?G9_RU/KN#C\$4(`(7(+@4?.$0MC<_&-\:CXIRE%PJ:**38@;GA5="4DSP MK,,"V(Y_!HI.^Q-PS&HPS#$D(.KEJB=]#U-NO/D--:9=/E;CAEWRJQ%XF`WB(ZNF)=X4WJSL$ES<;JY.-U!WER<;BY.5_GB]'HJC$YP M`^S+LOQ4RQ#@FRE57WT.,55RQ3/"O#C*.60GP]:^0J3KN5,'PZ<51U)GXRV) ME0DB'*;=ADWG,Z3-+7"WR1)EXB:>("A\P MV=)+W;29)JHFO#85*0D'\^293_&\=:7JA$7 M$V'>[J#V0@*L`-U@'-I=S8HB+D#;.$CSK?6%PQH6.C4;,IZNM8,(LB4 M9B\FA=U08:A=(K6,JSQFVXF5OFH`UQ0HVDE67#5VFD^A$;,%ZIGC\]AP!U`2 M]BT$C\#_\(A_;6PP_F9@;-!5R2G[$U@G#KX!>`%--`2Y'S2)NJ'"<-M"-.TVY;%5`B+B M>Q/%*L)MJ;2Z[:+43#$QU24SB:#(*AG`928_91IH(;2XSOI^I;=E,SLNJ[*P MV,K.@&B`F4\,T(UA@\'8WZDZ0S?>B$`+&EC);8P\8G5E-'-XZ=IZ+P^"^NXX M,_4(TPY0_8X?61SP()D&-+@/1DK*J^P6JHV%"%AW!WRZ*KA?`7<5T;NNB^'( M`:1 MLOQ,ML!:A-0=F,E8VPL6!]R,`@K'8+JPFHS&#+3D+?X%(V@T7W\&8P=3O6@G MJ$[4P_#27Y&Q4FM!30.V'3,>`Y-RN-[40!-PAL(L$^W6$$-DPJVGJ64%8>E: M5GKEJ](ZNMX?2-"=[XA`ZM!B8%!P`F5 M17T)`359P-U"-:;:=WGH^O;)3O0$\A?KG.M60HV]"^C"B0_?#7!=&RC>O,X2 MIRTMSV/73+P$LA8I+%K(EEL]45GT*UV8+M;%9\@,L&0]A"0A!:4\O5278XL; MJ$BLR".PW;)U0IU_QR6]B"92!D8034AT MH_VS0:"IA'$F"JKP\GX'0J'5WI>_?_V-.N&4W:=;`&Q,P)4W&P$\&&]=I55F M2CX%JLV(!$$-K7]4-#>O[89RSR#3$]MYV!-X;#3E+FC4I.0[R!G-%F":S67C M^ETVWNU@'%>*FQO%S8WBYD9Q%3I3WHWBYP!R0C5Y/@3;5Q.$I#4[M%]G]K$K\7EH)E_AVRM2T:REYD&PEKS)AUAW' M6=DV5B\^O!9`]8ONGL8NG0YPSS:@FK4.GP*ZIF^%/L)I`6FAHSE96D%GR'<* M5?P0_\8YEP*31SR,L:LF@2Z]J8$GBBZ?[I;ZXMPA#]*ZK@0TU1XT.`1GD0A] M1QZCW1GJJ,Z,G>E2-D.D2'IY9#(-4HWUDIO*$8IMGJO@A)9:R\WUSFIXB/A5 MT")%G0LN'H*+Z-2Y:5_=Y="F$QA[(-`O8Z5V%9$I^25&D+R@2SE"P1E+_-H$ ML=/?P95UN@*^,!Z(!]W5;W)E(#F:>SGL@`=#"04I`7%--$S MO7/Y^<:U0R&\96PE27*0B(T.C25C'=?`?Y-[:]W(\(UL%34%!HD_L@%A* MP58&T<>_[^^W_OWM\O[P/__^;LZ]QS_1FR/KZ=UB\N<2W?6]A]-W^.C=^>L? M=[=+8K];F$\=^ZM[Y"VNR=?;[Y?@$CQ<++\X,[YG';N_OCV^4)OH.7Q'ZX1.>SOOGUY[A[=7H^I1.A96M?X_=?A[`PL\')J/_UP?K3M#GYZ\W[HSNX7_=]^?3L] M`M]^>WC[Z]&Y@3/G[?ST]?W[/^Q'TYIUT/F]MTF3AY@"^3'BUUZ M7#M/=(86@,@Z]9;56(U.O65B4J"DAI33$I2!A8OWKOG+@YA&&9=Z*Z2L3-U2 M:+?0:IR.R^'-:ZGMW5@6+NM0;#6\I>%:[HP&)J4Y2P[INB*U3.MG8"NO%D21 MW8ZDN26ATR5.VDG2:^@*/-A*JR=18-8^@8CR24FS=E9C-9JU,S&1>!A!=)?: M!,#R%;V@$<%>Y<15[5*GRZO&7)W#AS>VH3,0U'"P/5+L&LS#B60POG)<$.7( M5)@U59:FK$D!>Z;#)G&N+3Q651LT55;]#)H.FXR$EXS`&\O'+575=<^45_O` MNXV@G*>@"@?>,DR;*:^6ILU&4%X5Z<(CUS^)SDX5L4(%8WH*9#P`@I[T%-I`BM17BW';C:"`L.C954?GB9X?T*N0J"@SI7=A*.&8I@7<]7R_#P?D_EE=SE3R:E$-JO8EU M&I0ZCD[N2)XE]++$Q&22]!H.=AYLQ8]62GE=("I(?_QH^MNGUW0:&2"F/:M; M3__'?'5!O591RHM+?D5*G21F-<4`U<7DDO4IK\PJE_PZF)T/4%E/BDBT?9>& M+(R7-#K=&[97HM$W!5?Z+#8GAN),;NY[#E4&N\4W(7-I^U='L\U?B-49CN+$ M+K#[,9*P]7SCS>?!5HMA1VSF#(T=/`N03=QZE'2U-J?H.D3VW#`68'+B%S!\ MGFE`=HF;>R]Y\WM5MD9B/Z,])WU%<,*KD4PS-4=O8^UK7`BE>%C2S6OFV2!WKQNTKQN4L7739XYAN1( MI(3RR=:Q,LZ;N2,DWS2RTN6E\\%.H9?G?**,(1M;T?;!,7*ANQS2WYOAGV+, MK["0XJ2IH7>5HW>R7"\_C6LH7$/A&@I7A^I,N])#2DJ MW"E=6&7<*9/:9(!5WZR03V6X?.<"_O*@17G<*C]6)/W#T5R1`TX-K:DJK>'W M)RY^T]";AMXT]*8*G2F?WB2$%J4,)U->36[.96,FIPZ@-J[CYVTXM\!F,Q@\ MY\3N$SJ(E2L%R(2@\)$GP::;[:X72(**N5FSR56%V:MA0PT;JC(;XHLQ:G:Z MN#2HQL#/9$N\F-9YSRND3YR74\PIL#Q62LN_GA%63@O*:K%FHQ?.!_@:3J8N M\8>%&)^2)$I&VJ!A6)5C6'(=D2,%U5"NAG(UE*L*G2F?GTB[A2>]ABA5CB@5\"^>4U`- M66K(4D.6JM"9\LD21XA1X6`\XFMR1(H+T;J?F.H('!'WJVY=0&,$;;]"5^'B M4!SM-;??7B93$O"IYAY<5>:TAB,U'*G*'"E'<%'A6'G$5L;%,BE1+@#K?$MN ME4+BVV7S1@3\\JA.QPMV2$QP5VUG*PWK>9FL)[?_-%RG*G-3PW4:KE-EKI,: M4I2X4ZJPRKA3)J_)`*N6;*;OF![K=!=9QWXQIMC[:-SD)JLQ+GZ3JR'>\&FQ M8DE^:]=@`EDCR+TR9AD$AP#SU<19M.DW`P^W0FUCCIW:JIYXPF,"YM?IH!0D M"5;,C+?T<\517FM-R^0O`NXZ!AL!FQO1GH>9!B5SQ#Q)FL3<1+0B+U;(A1VNE0'B^EQ8AL2O'R] M.4V'R46@W<`A]A8X/_U>:Z\/B(GAW&==\N"-MUH?.I(,2NP];E$Z$@8CVC(V M[#/*E1_/048!5\Z8O=&LKN5,@2B]"4SL*6QQKAW.R-=@[F!V%Y8ML[R,+!$G MZLFMURBD9*,4>YA:+,($S=\[MD$X<+"W$K#=:0QZX@4K\.>-B,?T;L.USY#R@&V`0!P'+?_4OXY52/N#3 MFJ^A"5*1BHSQ6L)Z/WCG5-K2-+G9.@6;%&`BS`]%@TW4[FJ]>T)_(B&^IS5< MHXDU%9L(]0(+SO6V`ZLJ03[>='T8?`8\$?AO5J0R)=_]L'-D M550)``,#$:].`Q&O3G5X"P`!!"4.```$.0$``.U;:W/B.!;]OE7S'[1\FJDI MVA#R(M5)E0,..`%,VR;IWJFI+F,+4&++1))YY->O9//&-DY/ILNS2W_HPI*N M=,X]5P_K.I__72R"!L206`PZH#\'J/8K\WX#15#SO;%A(Z!BQFMMAB:0E^$) M)/R9UX\8&U])TG0Z_63SIM1&!%(_(#:DH@`4BS=`_/OE7Y_%(#4"Q1!7H.UC MH-D,5,J@7+TZ/;^J7(*>60,GI7(Y,N(6,WI%[1'T+##S7$RO9GWBHNO"QIBB MY)-/AM))J521$*;,PC8L+-KCP(MO[3`BL?D82KP%),A>&GAO<+M_#SKHS<<0 M82;H2`)>J5HI%0"SR!"RCN5!.K9LF-%JP8-N-9]6EA3*TM=VRP@IKSCX.`,- M'Q=WJ`2T**K6(PTLV@^MEC4AK&*I7*R45\!*J!<+?'H<`!"'E?"!]<%BKRQ*P(F+!L1 M.+@NB"@H+C7[[EK]3QSDLHE%;.*[,-U)TICX8SY%$/?RVA-1!WO6VXX3U1(? M$[JM->2"=/-A?,8$_G0^?$S*8R#4:X?6QPGEP,%/)\;'1!C%T/HH4K;E_G12 M?$P[<&/%VJ8E6IN<"!`_>KJ:N@B&7?.M@_HN)2%"TZX>:V[`HN^0-@9_2SMFL?U'E#H:/@F_+T; MPXL>%DW2;;?#9-?RP,`[(N=LJGMR6@I4T!5<5%/@#H(W%R9.; M46!A!VA<2A*>/`D<04S%F;/E4RYT#UN!@W@'<1H?)W":SC6+CNY M"L!_ZJ#1TF[E%F@JFZ'$+U%&$6!%B5`AE2-6@ M&JO!&?=^NZV:;;Y-&$#NU(4:)E=%Z=14Q3B^,647)4Z5TN%=O%R*%>8\%(;O M&H:IU1[`DZSK\E(BK2OVDWAQ_M>T"6^0_WAJ/U;^_..K/0YFW_!9U7F[F`R_ MS7&O'DP;%Z1Z\7#RW#/GU+V8V&\E]YY5@XE.[\VO;=B&T]:\66T^/)^KY^/^ MQ*[/GEMR:_"J-_'O)Q=GI&0K4M#[\M2^(SW4INZTC1^\NGW_,I`[C8<1[$"_ MW4'X[=O+1:_U8EU.M>?7+\W)Y:C*GG^O7=Q[4LFC7PWC_C_R`VU6RH^UF29# M6NW<7[X\/$[/@N'(T0YY^/F_6)(@?S]N3IJUNU84V;/LR:C3]!S=`7]^0?%+.Q07OHU"-N MZV-"]F(1JR:/5$.NA3$:QJNA-CKJG)T.'X3*)[%2 M78)Z3P&F%BG6U%IU18^TDFLU?F+E"TU7_B;?MA1NH2LMV53JO$0WD_:$HVX) MNB4(E^785*[$:E<%M1Z7K_G55=H5>6.?,(!CT]Y)R?@HA]_R[;"_ M%!/Q5%S:%451L7Q2K)0_S:BS2C^]$X8@'B7`W@=C:?=#,-)S[0E`0A";ED/+ M&H>&$G097?557/>U0O1.S^Q__Y#%.;M6PC55X9KR^5\'LOD%P_O`^+B3@B<# MHMBO#;*&R])`#'ZV[X;%UP_AJ->%I/P8E?N4B<]K"B!*#(=?NESQ,H2'*H.> MF+4%8"U:71<8"41*-VPUYMQ]QPSMG(`L%DV,7-?JBV1OU)8&W!BQ0-0VB!^, MEX,@WGV&%-X:XHY;=Q@&1.3B9$KSQ2H6UB)/G\BBA:P^.2ARV1#X& M\^V7D>\ZD%#E->#;79UO.C9B^:%U&&)ZW&V$[3H-I0W6J46^U8>)Q:V\HD@K MKG)3^7'&A[))C`IE-N9V>8KM/42)V$/R458Z?S32P*7L#LJ,-_&)@[!%Y@)Q MCBBE8$O7:"]`\\/I`#[IYOW+S3*-_D]:5%(PI[I@:79'?&^Q,.&A+#X1SMN. MF15I&EW9>0XH"UUF^CJT?6PC%W8@$S%C^OR'&*9'Q;'+S7!XI,\%,X[DYPU0\@32OT9\9:>:E[XYOB7P* M_0/HIB$]1+=K(>?.)_EBM@MJ\VYFFT+'QZ$K\JQ5!HS)!,/7)Y72``J/M)`M M3IWRD,"\+[0'@*?%I4:&%D9O(:SUX88_\`6LNW$AJPT6/K7<];EG?1]LPAF[ M=3F*_(3"W\8LXSLT[_K1(DA`#__PBZ^2T2UYE]?;B_]SZ+>_S"!Y@BD6P9P/ M[4)BC*Q<1LUAB*GRM]!K@!QQ\;(*H-P*_0ZLJ=>QGH>BHS"?6#QXQ%D`\ND$ M\[T\_"#NE-W#'D$G<*$VV+^&$VG1)XL02[PL$AT-1_S%0:#.H6,^B$?:IA/? M<:[#Y?V0DR-%AZZX/^A:A,U-[DLJ_B:8K[JY=L"/@$Z_U=IX/\HU\_>`3=T< M##X@?`UX@3()KP[RQ_4PQ%2&:5\8Y(=D)I1A[(9I_"B)&>V`_P502P$"'@,4 M````"`""BE\_HVD1M(14``"&9@,`$0`8```````!````I($`````;7IE:2TR M,#$Q,#DS,"YX;6Q55`4``P,1KTYU>`L``00E#@``!#D!``!02P$"'@,4```` M"`""BE\_9/YA^.D+``#FC```%0`8```````!````I('/5```;7IE:2TR,#$Q M,#DS,%]C86PN>&UL550%``,#$:].=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`@HI?/U!;CX:Y%```$D,!`!4`&````````0```*2!!V$``&UZ96DM,C`Q M,3`Y,S!?9&5F+GAM;%54!0`#`Q&O3G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`(**7S\$C?#Q\R<``,W3`0`5`!@```````$```"D@0]V``!M>F5I+3(P M,3$P.3,P7VQA8BYX;6Q55`4``P,1KTYU>`L``00E#@``!#D!``!02P$"'@,4 M````"`""BE\_D)N6G3\6```X<0$`%0`8```````!````I(%1G@``;7IE:2TR M,#$Q,#DS,%]P&UL550%``,#$:].=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`@HI?/Z_D;2'4"```YC\``!$`&````````0```*2!W[0``&UZ96DM M,C`Q,3`Y,S`N>'-D550%``,#$:].=7@+``$$)0X```0Y`0``4$L%!@`````& -``8`&@(``/Z]```````` ` end XML 29 R2.htm IDEA: XBRL DOCUMENT v2.3.0.15
Consolidated Balance Sheets (USD $)
Sep. 30, 2011
Dec. 31, 2010
CURRENT ASSETS  
Cash$ 357,432$ 435,894
Prepaid expenses78,7368,800
Deferred consulting fees4,50063,923
Total Current Assets440,668508,617
PROPERTY AND EQUIPMENT (NET)4,4281,344
OTHER ASSETS  
Trademark and patents, net151,733117,771
Lease deposit1,1221,122
Total Other Assets152,855118,893
TOTAL ASSETS597,951628,854
CURRENT LIABILITIES  
Accounts payable497,440451,412
Accounts payable – related parties229,204228,269
Accrued expenses445,270427,529
Accrued expenses – related parties1,963,0001,964,316
Due to stockholders 6,000
Customer deposits40,000 
Notes payable287,430283,266
Total Current Liabilities3,462,3443,360,792
CONTINGENT LIABILITIES224,852224,852
TOTAL LIABILITIES3,687,1963,585,644
STOCKHOLDERS' EQUITY (DEFICIT)  
Preferred stock, 50,000,000 shares authorized of $0.00001par value, no shares issued or outstanding00
Common stock, 395,000,000 shares authorized of $0.001par value, 270,491,949 and 259,362,171 shares issued and outstanding, respectively270,492259,362
Additional paid-in capital22,991,80921,593,448
Other comprehensive loss(23,946)(8,519)
Deficit accumulated during the development stage(26,327,600)(24,801,081)
Total Stockholders’ Deficit(3,089,245)(2,956,790)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)$ 597,951$ 628,854
 XML 30 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.15 Html 10 115 1 false 0 0 false 3 true false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.medizoneint.com/role/DocumentAndEntityInformation Document And Entity Information false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.medizoneint.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.medizoneint.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) false false R4.htm 003 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) Sheet http://www.medizoneint.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) false false R5.htm 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.medizoneint.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 005 - Disclosure - NOTE 1 BASIS OF PRESENTATION Sheet http://www.medizoneint.com/role/Note NOTE 1 BASIS OF PRESENTATION false false R7.htm 006 - Disclosure - NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH Sheet http://www.medizoneint.com/role/Note0 NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH false false R8.htm 007 - Disclosure - NOTE 3 BASIC LOSS PER SHARE Sheet http://www.medizoneint.com/role/Note00 NOTE 3 BASIC LOSS PER SHARE false false R9.htm 008 - Disclosure - NOTE 4 GOING CONCERN Sheet http://www.medizoneint.com/role/Note000 NOTE 4 GOING CONCERN false false R10.htm 009 - Disclosure - NOTE 5 COMMITMENTS AND CONTINGENCIES Sheet http://www.medizoneint.com/role/Note0000 NOTE 5 COMMITMENTS AND CONTINGENCIES false false R11.htm 010 - Disclosure - NOTE 6 COMMON STOCK WARRANTS AND OPTIONS Sheet http://www.medizoneint.com/role/Note00000 NOTE 6 COMMON STOCK WARRANTS AND OPTIONS false false R12.htm 011 - Disclosure - NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS Sheet http://www.medizoneint.com/role/Note000000 NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS false false R13.htm 012 - Disclosure - NOTE 8 DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE - RELATED PARTIES Sheet http://www.medizoneint.com/role/Note0000000 NOTE 8 DUE TO STOCKHOLDERS AND ACCOUNTS PAYABLE - RELATED PARTIES false false R14.htm 013 - Disclosure - NOTE 9 CUSTOMER DEPOSITS Sheet http://www.medizoneint.com/role/Note00000000 NOTE 9 CUSTOMER DEPOSITS false false R15.htm 014 - Disclosure - NOTE 10 SUBSEQUENT EVENTS Sheet http://www.medizoneint.com/role/Note000000000 NOTE 10 SUBSEQUENT EVENTS false false All Reports Book All Reports Process Flow-Through: 001 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Parentheticals) Process Flow-Through: 003 - Statement - Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) Process Flow-Through: 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) mzei-20110930.xml mzei-20110930.xsd mzei-20110930_cal.xml mzei-20110930_def.xml mzei-20110930_lab.xml mzei-20110930_pre.xml true true EXCEL 31 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Y,V$W,V5C9%]E8SAD7S1D83%?.3(V,%]F-39E M.39B9#-F,V,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?,E]#04Y!1$E!3E]&3U5.1$%424].7T9/4CPO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DY/5$5?-%]'3TE.1U]#3TY#15)./"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O6QE#I!8W1I M=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0 M&UL/CPA M6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G M92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7SDS83'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^365D:7IO;F4@26YT97)N M871I;VYA;"!);F,\2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!6;VQU;G1A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y M,V$W,V5C9%]E8SAD7S1D83%?.3(V,%]F-39E.39B9#-F,V,-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-A-S-E8V1?96,X9%\T9&$Q7SDR-C!? M9C4V93DV8F0S9C-C+U=O'0O:'1M;#L@8VAA'!E;G-E M6%B;&4@XH"3(')E;&%T960@<&%R=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XU+#,Y,#QS<&%N/CPO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'1R86]R9&EN87)Y($ET96US/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%SF%T:6]N(&]F(&1E9F5R'1E;G-I;VX@ M;V8@=V%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&%C8V]U;G1S('!A>6%B;&4M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S6UE;G1S(&]N(&YO M=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!& M:6YA;F-I;F<@06-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J M=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY4:&4-"B`@(`T*("`@("`@9FEN86YC:6%L(&EN9F]R;6%T:6]N M(&EN8VQU9&5D(&AE65A2!O9B!N M;W)M86P@'!E8W1E9"!F M;W(@=&AE(&9U;&P@>65A6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-4 M64Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE M)SY296-E;G0-"B`@("`@#0H@("`@("!!8V-O=6YT:6YG(%!R;VYO=6YC96UE M;G1S/"]F;VYT/CPO9F]N=#X-"B`@(`T*("`@(#PO9&EV/CQB3X-"B`@(`T*("`@("`@/&9O;G0@6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE M)SY&86ER(%9A;'5E#0H@(`T*("`@("`@365A&ES=&EN9R!D:7-C;&]S=7)E M&-E<'0@9F]R('1H92!D:7-C M;&]S=7)E28C.#(Q M-SMS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY.3U1%#0H@("`@#0H@("`@("`R)B,Q-C`[ M($-!3D%$24%.($9/54Y$051)3TX@1D]2($=,3T)!3"!(14%,5$@\+V9O;G0^ M#0H@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!4:6UE2!F;W(@3X- M"B`@(`T*("`@("`@/&9O;G0@0T*(`T*("`@("`@*"8C.#(R,#M6 M244F(S@R,C$[*2!T;R!B92!C;VYS;VQI9&%T960@8GD@82!C;VUP86YY(&EF M('1H870-"B`@("`-"B`@("`@(&-O;7!A;GD@86)S;W)B'!E8W1E9"!L;W-S97,-"B`@#0H@("`@ M("!A;F0O;W(@2!O9B!T:&4@96YT:71Y)B,X M,C$W.W,@97AP96-T960-"B`@(`T*("`@("`@2!D971E2`Q,BP@,C`P.2XF(S$V,#LF(S$V,#M!8V-O2P@=&AE(&9I;F%N8VEA;`T*(`T*("`@("`@8V]N9&ET:6]N(&%N9"!O M<&5R871I;VYS(&]F($-&1T@@87)E(&)E:6YG(&-O;G-O;&ED871E9"!W:71H M#0H@(`T*("`@("`@=&AE($-O;7!A;GD@87,@;V8@4V5P=&5M8F5R(#,P+"`R M,#$Q(&%N9"!$96-E;6)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY.3U1%#0H@("`@#0H@("`@("`S)B,Q-C`[($)!4TE#($Q/4U,@4$52 M(%-(05)%/"]F;VYT/@T*("`-"B`@("`\+V1I=CX\8G(O/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY4:&4-"B`@(`T*("`@("`@8V]M<'5T871I;VYS(&]F(&)A6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X M)SX-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#(V)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^1F]R#0H@("`@(`T*("`@("`@ M("`@("`@("!T:&4\+V9O;G0^(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^5&AR964-"B`@("`-"B`@("`@ M("`@("`@("`@36]N=&AS($5N9&5D/"]F;VYT/@T*("`@("`-"B`@("`@("`@ M("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4V5P=&5M8F5R#0H@#0H@("`@("`@ M("`@("`@(#,P+#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@ M("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@86QI9VX] M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!! M1$1)3D"<^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1C96YT97(^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,G!X)SX-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q,#PO M9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@ M("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY.=6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X-"B`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#LM#0H@#0H@("`@("`@("`@("`@("`@3&]S2!I=&5M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@ M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@ M("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@ M("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#LM#0H@#0H@("`@("`@("`@("`@("`@17AT M2!I=&5M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H M=#X-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXR-CDL-C,R+#8W,CPO9F]N=#X-"B`@("`-"B`@("`@ M("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@ M(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-3`L,30S+#,T M-SPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@ M("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T* M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@ M(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"87-I M8PT*("`@("`-"B`@("`@("`@("`@("`@("!L;W-S('!E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@ M#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X- M"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)V)A8VMG6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE'1R86]R9&EN87)Y M(&ET96US/"]F;VYT/@T*(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T* M("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\ M9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXH,"XP,3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T* M("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)V)A8VMG6QE M/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LM#0H@#0H@ M("`@("`@("`@("`@("`@17AT2!I=&5M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G/@T*("`-"B`@("`@("`@("`@("`@/&1I M=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9"<^#0H@("`-"B`@("`@("`@("`@(#QD:78@"<^#0H@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L M969T/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9"<^#0H@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SY"87-I8PT*("`@("`-"B`@("`@("`@("`@("`@ M("!,;W-S(%!E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@ M("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M("`-"B`@("`@("`@("`@(#QD:78@"<^#0H@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@/&1I=B!S='EL M93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*("`-"B`@("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`-"B`@("`@("`@("`@(#QD M:78@"<^#0H@#0H@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@("`@(`T*("`@("`@("`@("`@/&9O;G0@ M6QE/3-$)U!! M1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4V5P=&5M M8F5R#0H@#0H@("`@("`@("`@("`@(#,P+#PO9F]N=#X-"B`-"B`@("`@("`@ M("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@ M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D"<^#0H@("`@#0H@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@("`-"B`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^,C`Q,#PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO9&EV M/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@ M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1L969T/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D(&%L:6=N M/3-$;&5F="!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M,B4^#0H@("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LM#0H@#0H@("`@("`@("`@ M("`@("`@3&]S2!I=&5M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@ M("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@ M("`-"B`@("`@("`@("`@(#QD:78@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@ M("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,BPS-SDL M-S@W/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@ M("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`- M"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@ M("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXI/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#LM#0H@#0H@("`@("`@("`@("`@("`@17AT2!I=&5M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@ M("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T* M("`@("`@("`\='(@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY$96YO;6EN871O<@T*(`T*("`@("`@("`@("`@("`@ M("AW96EG:'1E9"!A=F5R86=E(&YU;6)E6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@ M(`T*("`@("`@("`\='(@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)V)A8VMG6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#LM#0H@#0H@("`@("`@ M("`@("`@("`@0F5F;W)E(&5X=')A;W)D:6YA6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1% M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T* M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXH,"XP,3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`@#0H@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@ M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@ M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT M/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S M<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@ M("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@ M#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1% M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@ M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T* M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXH,"XP,#PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX- M"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U!!1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX- M"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@ M("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,"XP,#PO9F]N=#X- M"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\ M+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE"<^#0H@#0H@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/@T*("`@ M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I M=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T* M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,"XP,3PO9F]N M=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@ M("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!! M1$1)3D"<^#0H@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\ M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@ M6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R M:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXH,"XP,3PO9F]N=#X-"B`@(`T*("`@("`@("`@ M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY#;VUM;VX-"B`-"B`@("`@('-T;V-K(&5Q=6EV86QE M;G1S+"!C;VYS:7-T:6YG(&]F(&]P=&EO;G,L(&AA=F4@;F]T(&)E96X-"B`@ M#0H@("`@("!I;F-L=61E9"!I;B!T:&4@8V%L8W5L871I;VX@87,@=&AE:7(@ M969F96-T(&ES(&%N=&ED:6QU=&EV90T*(`T*("`@("`@9F]R('1H92!P97)I M;V1S('!R97-E;G1E9"X\+V9O;G0^#0H@#0H@("`@/"]D:78^/&)R+SX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!497AT($)L;V-K73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@ M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE. M+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`-"B`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.3U1%#0H@("`@#0H@("`@ M("`T)B,Q-C`[($=/24Y'($-/3D-%4DX\+V9O;G0^#0H@("`@(`T*("`@(#PO M9&EV/CQB3X-"B`@(`T*("`@("`@/&9O;G0@2!H87,@:6YC=7)R960@2!H87,@9G5N9',@6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4 M:6UE2!W:6QL#0H@("`@(`T* M("`@("`@F%T:6]N+"!A;F0@=&\@9G5N9"!A9&1I M=&EO;F%L(&QO'!E;G-E0T*(`T*("`@("`@8F4@9F]R8V5D('1O('-U8G-T86YT:6%L;'D@3X-"B`@(`T*("`@("`@/&9O;G0@2!,:6YE)B,X,C(Q M.RDN("8C,38P.TUA;F%G96UE;G0@9&]E2!,:6YE#0H@("`-"B`@("`@('1O(&EM<&QE;65N="!O=7(@8G5S M:6YE2`F;F)S<#LD,R!M:6QL:6]N(&1U65A<@T*("`@("`-"B`@("`@(&5N9&EN9R!$96-E;6)E0T*(`T*("`@("`@;6%Y(&1R87<@86YY(&%M;W5N="!U<"!T M;R!T:&4@9G5L;"!A;6]U;G0@;V8@=&AE($5Q=6ET>2!,:6YE+`T*("`@#0H@ M("`@("!I;B!I=',@9&ES8W)E=&EO;BXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N M>2!D;V5S(&YO="!P;&%N('1O#0H@("`-"B`@("`@(&1R87<@;6]R92!F=6YD M2!P=70@;6]R92!S:&%R97,@=&\-"B`@ M#0H@("`@("!-86UM;W1H*2!U;F1E2!D2!,:6YE('1H3X-"B`@(`T*("`@("`@/&9O;G0@2!C=7)R96YT(&EN(&ET&-H86YG92!!8W0F(S@R,C$[*2!A;F0-"B`- M"B`@("`@('1O('!A>2!C97)T86EN(&]T:&5R(&-O2P@86QT:&]U9V@@=&AE($-O;7!A;GD@:&%S(&YO#0H@ M("`-"B`@("`@(&-U6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE M2!T;R!S=6-C97-S9G5L;'D@86-C;VUP;&ES:"!T:&4@<&QA;@T*("`- M"B`@("`@(&1E2!A9&IU6EN9R!A;6]U;G1S#0H@#0H@("`@("!O3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Y,V$W,V5C9%]E8SAD7S1D83%?.3(V,%]F-39E.39B M9#-F,V,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO.3-A-S-E8V1? M96,X9%\T9&$Q7SDR-C!?9C4V93DV8F0S9C-C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/&1I=B!S='EL93TS1"=415A4+4E. M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@ M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@("`-"B`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY.3U1%#0H@ M("`@#0H@("`@("`U)B,Q-C`[($-/34U)5$U%3E13($%.1"!#3TY424Y'14Y# M2453/"]F;VYT/@T*(`T*("`@(#PO9&EV/CQB3X-"B`@ M(`T*("`@("`@/&9O;G0@3X- M"B`@(`T*("`@("`@/&9O;G0@3X-"B`@(`T*("`@("`@/&9O;G0@2!C;VYS=6QT:6YG(&9E97,@=6YD97(@82!C;VYS=6QT:6YG#0H@("`@#0H@ M("`@("!A9W)E96UE;G0N("8C,38P.TEN(%-E<'1E;6)E2`X+"`R,#`R+"!T:&4@8V]U2!H87,@8F5E;B!U;F%B;&4@=&\-"B`@(`T*("`@ M("`@<&]S="!T:&4@6%B;&4L('1H92!O2!I;G1E;F1S#0H@ M("`-"B`@("`@('1O(&-O;G1E3X-"B`@(`T*("`@ M("`@/&9O;G0@3X-"B`@(`T*("`@("`@/&9O;G0@2!E>&ES=',@86YD('5N=&EL('1H90T*("`@ M#0H@("`@("!S=&%T=71E(&]F(&QI;6ET871I;VYS(&AA'!I6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T* M("`@#0H@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[ M($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SY/<&5R871I;F<- M"B`@(`T*("`@("`@3&5A6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@("`@(#(P,#DL('1H M92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&QE87-E(&%G2!I;B!+:6YGF%T:6]N(&]F(&ET6UE;G0@:6YC2!A;'-O(&5N=&5R960@:6YT;R!A(&QE87-E M(&%G6UE;G0@;V8@)FYB2!S;V]N97(@=&AA;@T*(`T*("`@("`@8W5R M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!.;W1E+"!787)R86YT'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J M=7-T:69Y/@T*("`@("`-"B`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SY.3U1%#0H@("`@#0H@("`@("`V)B,Q-C`[($-/34U/3B!3 M5$]#2R!705)204Y44R!!3D0@3U!424].4SPO9F]N=#X-"B`@("`@#0H@("`@ M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/ M3CH@=6YD97)L:6YE)SY787)R86YT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!;&P-"B`@(`T*("`@("`@;W5T M3X-"B`@(`T*("`@ M("`@/&9O;G0@3X-"B`@(`T*("`@ M("`@/&9O;G0@F5D(&)E='=E96X@3V-T M;V)E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P="<^26X@36%R8V@@,C`Q,2P@ M=&AE#0H@#0H@("`@("!#;VUP86YY(&=R86YT960@;W!T:6]N65AF5D(&)E='=E M96X@3V-T;V)E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^)B,Q-C`[/"]F;VYT/CPO9F]N M=#X-"B`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!4:6UE65A2!R96-O9VYI>F5D#0H@(`T*("`@("`@)FYB'!E;G-E(&1U6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4 M:6UE65A2!H87,-"B`-"B`@("`@(&%C:&EE=F5D(&-O;6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J M=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE&5R8VES92!P3X-"B`@(`T*("`@("`@/&9O;G0@2XF(S$V M,#LF(S$V,#M4:&5S92!O<'1I;VYS(&AA=F4@86X@97AEF5D('1O M#0H@("`-"B`@("`@('!A=&5N="!C;W-T'!E8W1E9"!L:69E(&]F('1H92!P871E;G0N/"]F M;VYT/@T*("`-"B`@("`\+V1I=CX\8G(O/CQD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`- M"B`@("`@(%-E<'1E;6)E2!G&5R8VES86)L M90T*(`T*("`@("`@9F]R('5P('1O(&9I=F4@>65A2!H87,-"B`-"B`@("`@(&%C:&EE=F5D M(&-O;6UEF%T:6]N(&%N9"!S86QE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY&;W(-"B`@(`T*("`@("`@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E M;6)E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2:7-K+69R964-"B`@ M("`-"B`@("`@("`@("`@("`@("!I;G1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^ M#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+C0S M/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@ M("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@ M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T* M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU M#0H@#0H@("`@("`@("`@("`@("`@>65A6QE/3-$)V)A8VMG6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+C`P/"]F;VYT/@T*("`- M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^ M#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@ M/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*("`- M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@("`@("`@("`@ M/&9O;G0@3X-"B`@ M#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!4:6UE2!O9B!T:&4@"<^#0H@("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1C96YT97(^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U!! M1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@ M("`@("`@/&1I=B!S='EL93TS1"=415A4+4E.1$5.5#H@,'!T.R!$25-03$%9 M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G M(&%L:6=N/3-$8V5N=&5R/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@&5R8VES M92!06QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@ M(`T*("`@("`@("`\='(@6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1L969T/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM M4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+#6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF;F)S<#LD/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I M=CX-"B`@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@ M/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)V)A8VMG6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@ M("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-3`L,#`P/"]F;VYT/@T* M("`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@ M/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^#0H@(`T*("`@("`@("`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@ M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@ M("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`-"B`@("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X- M"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXP+C$T/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D M:78^#0H@(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@ M(#PO=&0^#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY%>'!I6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\ M+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R:6=H=#X-"B`@(`T*("`@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SYN M+V$\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@ M("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@("`@("`\+W1D/@T*("`-"B`@ M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`- M"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>&5R8VES960\ M+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@ M("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T M.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!- M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1R M:6=H=#X-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SYN+V$\+V9O;G0^#0H@#0H@("`@("`@("`@("`@ M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO9&EV/@T*("`@("`-"B`@("`@ M("`@("`\+W1D/@T*("`-"B`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@/"]T9#X-"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@ M("`\='(@6QE/3-$)U1%6%0M24Y$ M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!- M05)'24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T M/@T*("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@ M("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@("`\='(@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>&5R M8VES86)L93PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@ M(`T*("`@("`@("`@("`@/"]D:78^#0H@("`@(`T*("`@("`@("`@(#PO=&0^ M#0H@(`T*("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X-"B`@(`T*("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T M9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$Q)3X-"B`@("`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@("`@#0H@("`@("`@("`@/"]T9#X-"B`@#0H@ M("`@("`@(#PO='(^#0H@("`@(`T*("`@("`@/"]T86)L93X\8G(O/CQD:78@ M2!D;V5S(&YO="!P87D@9&EV:61E;F1S+"!T:&4@ M9&EV:61E;F0@'!E;G-E(&]F("9N8G-P.R0R,BPX.#8-"B`@ M("`@#0H@("`@("!A;F0@)FYBF5D(&%S('!A=&5N M="!C;W-T2!M96YT:6]N960L('=H:6-H(&-O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T9/3E0M4U193$4Z(&ET M86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@5$585"U$14-/4D%424]..B!U;F1E6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY$=7)I;F<-"B`-"B`@("`@($9E8G)U87)Y(#(P,3$L('1H92!# M;VUP86YY(&ES6QE/3-$)U1%6%0M24Y$14Y4 M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)' M24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4 M:6UE2!S;VQD(&%N(&%G9W)E9V%T M92!O9B`Q+#`P,"PP,#`-"B`-"B`@("`@(')E6QE/3-$ M)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5& M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T* M("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!4:6UE2!,:6YE*2!F;W(@8V%S:`T*("`@#0H@("`@("!P2`Q M."P@,C`Q,2P@9F]R(#$L-3@S+#3X-"B`@(`T*("`@("`@/&9O;G0@2!A;F0@2G5N92`R,#$Q+"!T:&4@0V]M<&%N>2!S;VQD(&%N(&%G M9W)E9V%T92!O9@T*("`@("`-"B`@("`@(#0L-C(U+#`P,"!R97-T6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE0T*("`@("`- M"B`@("`@(#(P,3$L(&9O3X-"B`@(`T*("`@("`@/&9O;G0@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=& M3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD M97)L:6YE)SY#;VUM;VX-"B`@("`@#0H@("`@("!3=&]C:R!F;W(@0V%S:"`F M(S@R,3$[($9O6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE2`R,#$P+"!T:&4@0V]M<&%N>2!I2X@)B,Q-C`[5&AE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE2X@)B,Q M-C`[5&AE($-O;7!A;GD@86QS;R!P86ED('-T;V-K(&]F9F5R:6YG(&-O6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@("`@($IU;'DL($%U M9W5S="!A;F0@4V5P=&5M8F5R(#(P,3`L('1H92!#;VUP86YY(&ES6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1) M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z M(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/ M3CH@=6YD97)L:6YE)SY297-T3X-"B`@(`T*("`@("`@/&9O M;G0@3X-"B`@(`T*("`@("`@/&9O;G0@3X-"B`@(`T*("`@("`@/&9O;G0@3X-"B`@(`T*("`@("`@/&9O;G0@65A3X-"B`@(`T*("`@("`@/&9O;G0@2`R,#$P+"!T M:&4@0V]M<&%N>2!I2!P=7)S=6%N="!T;R!A#0H@#0H@("`@("!O;F4M M>65A6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI M9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UEF5D('1H92!I'!E;G-E(&9O3X-"B`@(`T*("`@("`@/&9O;G0@F5D('1H90T*("`@#0H@("`@("!I'!E;G-E M(&ES(')E8V]G;FEZ960@;W9E2!R96-O9VYI M>F5D(&-O;G-U;'1I;F<-"B`@("`@#0H@("`@("!E>'!E;G-E(&]F("9N8G-P M.R0S,BPP,CD@86YD("9N8G-P.R0Q,"PW-30@9'5R:6YG('1H92!N:6YE(&UO M;G1H6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY!;'-O+`T*("`@("`-"B`@("`@(&EN($%U9W5S="`R M,#$P+"!T:&4@0V]M<&%N>2!IF5D('1H92!I6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@("`@($1E M8V5M8F5R(#(P,3`L('1H92!#;VUP86YY(&ES2!R96-O9VYI>F5D(&-O;G-U;'1I;F<@97AP96YS92!O9B`F;F)S M<#LD,3,L-3`P(&1U3X-"B`@(`T*("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y M/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!4:6UE2!E M;G1E2!O=VYE M9"!B>2!-86UM;W1H+"!W;W5L9"!R97-U;'0-"B`@(`T*("`@("`@:6X@=&AE M(&)E;F5F:6-I86P@;W=N97)S:&EP(&)Y($UA;6UO=&@@;V8@;6]R92!T:&%N M(#0N.0T*("`-"B`@("`@('!E2!N;W0@8F4@=V%I=F5D(&)Y('1H90T*("`@#0H@("`@("!P87)T M:65S+CPO9F]N=#X-"B`@(`T*("`@(#PO9&EV/CQB3X- M"B`@(`T*("`@("`@/&9O;G0@2!F;W(@82`R-"UM;VYT:"!P97)I;V0L(&-O M;6UE;F-I;F<@;VX@=&AE(&1A=&4-"B`@(`T*("`@("`@;VX@=VAI8V@@=&AE M(%-%0R!F:7)S="!D96-L87)E9"!E9F9E8W1I=F4@=&AE(')E9VES=')A=&EO M;@T*("`@("`-"B`@("`@('-T871E;65N="!F:6QE9"!I;B!C;VYN96-T:6]N M('=I=&@@=&AE(')E2!,:6YE+"!T;R!R97%U:7)E($UA;6UO=&@@=&\@ M<'5R8VAA2!T:&4@4W1O8VL@4'5R M8VAA0T*(`T*("`@("`@;6%Y+"!A="!I=',@6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE2!M=6QT:7!L>6EN9R!B>2!F:79E('1H92!A=F5R86=E(&1A M:6QY#0H@("`@(`T*("`@("`@=')A9&EN9R!V;VQU;64@9F]R('1H92`S,"!T M7,@:6UM961I871E;'D@<')E8V5D:6YG#0H@(`T*("`@("`@ M=&AE(&1E;&EV97)Y(&]F('1H92!$6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY4:&4-"B`@(`T*("`@("`@0V]M<&%N>2!A9W)E960@=&\@<&%Y('5P M('1O("9N8G-P.R0U+#`P,"`H;V8@=VAI8V@@=&AE($-O;7!A;GD@<&%I9`T* M("`@#0H@("`@("`F;F)S<#LD-"PS,#`@9'5R:6YG('1H92!N:6YE(&UO;G1H M'!E;G-E2!O9@T*("`-"B`@ M("`@('1H92!3=&]C:R!0=7)C:&%S92!!9W)E96UE;G0@86YD(')E;&%T960@ M=')A;G-A8W1I;VX-"B`@("`-"B`@("`@(&1O8W5M96YT871I;VXN)B,Q-C`[ M)B,Q-C`[1G5R=&AE2!-86UM;W1H+"!I;@T*("`@("`-"B`@("`@(&%D M9&ET:6]N('1O(&%L;"!O=&AE7,-"B`@("`-"B`@ M("`@('-U8V@@9&5L:79E2!B97EO;F0@,3`@=')A9&EN M9R!D87ES('1H870-"B`@#0H@("`@("!S=6-H(&1E;&EV97)Y(&ES(&QA=&4N M("8C,38P.SPO9F]N=#X-"B`@(`T*("`@(#PO9&EV/CQB3X-"B`@(`T*("`@("`@/&9O;G0@2`R-2P@,C`Q,2P@=&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0@=V%S#0H@ M("`-"B`@("`@(&1E8VQA2!T:&4@4T5#+B`F(S$V M,#M4:&4@0V]M<&%N>2!H87,@86=R965D#0H@("`@(`T*("`@("`@=&\@9FEL M92!A;&P@;F5C97-S87)Y('!O6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE0T*("`-"B`@("`@(&YO="!B92!E>'1E;F1E9"!B>2!T:&4@ M<&%R=&EE6QE/3-$)T9/3E0M4U193$4Z(&ET M86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@5$585"U$14-/4D%424]..B!U;F1E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@("`@($1E8V5M M8F5R(#(P,3`L('1H92!#;VUP86YY(')E86-H960@86X@86=R965M96YT('=I M=&@@041!#0H@("`-"B`@("`@($EN;F]V871I;VYS("@F(S@R,C`[041!)B,X M,C(Q.RD@9F]R(&9I;F%L(&1E=F5L;W!M96YT(&%N9`T*("`-"B`@("`@('!R M;V1U8W1I;VX@;6%N=69A8W1U2!T:&4@<&%R=&EE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX] M,T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UEF]N92!# M;W)P;W)A=&EO;B!W:6QL(')E;6%I;B!I;G9O;'9E9"!A2!I;B!A M8V-O2!I;F-U&EM871E;'D@ M)FYB0T*("`@#0H@("`@("`F;F)S M<#LD,3,X+#`P,"!A;F0@)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!46QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[ M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE' M2%0Z(#!P="<@86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE2!T;R!C;W9E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SY!65A65E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\9&EV('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@ M86QI9VX],T1J=7-T:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY!2!A;G1I8VEP M871E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I% M.B`Q,'!T)SY.3U1%#0H@("`@#0H@("`@("`Q,"8C,38P.R!354)315%514Y4 M($5614Y44SPO9F]N=#X-"B`@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T M>6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)' M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1J=7-T M:69Y/@T*("`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!4:6UE3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Y,V$W,V5C9%]E8SAD7S1D83%? M.3(V,%]F-39E.39B9#-F,V,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO.3-A-S-E8V1?96,X9%\T9&$Q7SDR-C!?9C4V93DV8F0S9C-C+U=O'0O:'1M;#L@ M8VAA&UL;G,Z;STS1")U'1087)T7SDS83